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Family Functioning as a Moderator of Neurocognitive Outcomes 
Among Survivors of Pediatric Acute Lymphoblastic Leukemia 
 
Thea Loraine Norris, Ph.D. 
The University of Texas at Austin, 2016 
 
Supervisors:  Kevin Stark and Emily Greenspahn 
 
Chemotherapy treatment for pediatric Acute Lymphoblastic Leukemia (ALL) can 
affect neurocognitive functioning across many areas, including attention and executive 
functioning. Some variables that may moderate or protect against neurocognitive deficits 
following chemotherapy treatment have been identified, including gender, age at 
diagnosis, time since treatment, and socioeconomic status. Evidence from pediatric 
traumatic brain injury and pediatric brain tumor populations suggests that positive family 
functioning serves as a protective factor for neurocognitive outcomes of children who 
survive these conditions. However, no research was found that examines whether positive 
family functioning similarly moderates the effects of chemotherapy on the neurocognitive 
functioning of survivors of pediatric ALL. The purpose of this study was to examine the 
effect of family functioning upon neurocognitive outcome among survivors of pediatric 
ALL treated with chemotherapy, specifically in the domains of attention and executive 
functioning. 
Participants were 20 children and adolescents who completed chemotherapy-only 
treatment for ALL and 20 healthy comparison participants, all within the ages of 8 and 
15. Participants were administered measures of attention and executive functioning. In 
addition, one caregiver for each child completed a measure of family functioning and 
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rating forms of their child’s attention and executive functioning. Multiple regression 
analyses were conducted to examine the relationship between family functioning and 
neurocognitive functioning.  
Tests of the interaction between family functioning and group membership in 
accounting for variance in neurocognitive functioning indicated that family functioning 
did not have a differential effect on neurocognitive functioning for the survivors as 
compared to the healthy children. Family functioning accounted for a significant amount 
of variance in caregiver ratings of attention and executive functioning for all participants, 
even after controlling for demographic variables in the sample as a whole and 
demographic and treatment related variables in the clinical group. That is, caregivers who 
rated their family as having more difficulties with family functioning also rated their 
child as having more difficulties with attention and executive functioning. Additionally, 
survivors performed significantly worse than healthy controls on measures of sustained 
attention, working memory, and processing speed, providing additional evidence that this 
population is at risk for neurocognitive late effects in these areas.  
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Chapter 1: Introduction 
A diagnosis of cancer in a child is perhaps one of the most difficult situations a 
family can experience. It is estimated that more than 15,000 youth ages 0-19 are 
diagnosed with cancer each year in the United States alone (American Cancer Society 
[ACS], 2014). Worldwide, almost 1 out of every 285 children are diagnosed with cancer 
before the age of 20 and roughly 1 out of every 530 young adults between the ages of 20 
and 39 is a survivor of childhood cancer (Ward, DeSantis, Robbins, Kohler, & Jemal, 
2014).  The most common form of cancer among children and adolescents is Acute 
Lymphoblastic Leukemia (ALL), which accounts for nearly 30% of childhood cancers 
(Ward et al., 2014). ALL occurs across all ethnic groups and in both genders, but is 
slightly more prevalent among Hispanic and Caucasian children and male children 
(Hunger & Mullighan, 2015). It is most often diagnosed in children between ages 3 
through 5 (Hunger & Mullighan, 2015). 
ALL occurs when stem cells develop into a type of white blood cell known as 
lymphocytes or leukemic cells (Bisen-Hersh, Hineline, & Walker, 2011). These cells, 
unlike typical white blood cells, are unable to fight infection and their proliferation leaves 
less room for the formation of healthy blood cells and platelets (Bisen-Hersh et al., 2011). 
Lymphocytes originate in bone marrow but can be carried through the bloodstream to 
nearly every organ system in the body, including the Central Nervous System (CNS; 
Bisen-Hersh et al., 2011; Mulhern & Butler, 2006). Although some potential genetic, 
environmental, and viral contributions to the development of ALL have been identified, 
the exact cause of the majority of cases of ALL is unknown (Bisen-Hersh et al., 2011; 
Hunger & Mullighan, 2015).  
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Diagnosis of ALL is most commonly made through a bone marrow aspiration 
(Mulhern & Butler, 2006). Once diagnosed, the child with ALL is classified into one of 
four categories (low-risk, standard-risk, high-risk, and very high-risk) based upon the 
degree of progression of lymphocytes beyond the bone marrow and blood into other 
organ systems in the body (Riccio, Sullivan, & Cohen, 2010). This classification helps to 
determine the type and degree of treatment that the child receives. Due to improvements 
in treatment regimens over the past forty years, approximately 90% of children diagnosed 
with ALL now survive (Hunger & Mullighan, 2015). This decrease in mortality rates is 
largely attributed to the introduction of prophylactic CNS treatment, which prevents the 
spread of leukemia into the CNS and thus prevents the occurrence of CNS relapse, one of 
the leading causes of death in ALL (Buizer, de Sonneville, & Veerman, 2009). 
The first form of CNS prophylaxis was cranial irradiation or cranial radiation 
therapy (CRT; Buizer et al., 2009). While CRT greatly improved survival rates in ALL, it 
was also found to contribute to the development of long-term and progressive 
impairments in cognitive functioning (Montour-Proulx et al., 2005). These deficits in 
intellectual, academic, and neuropsychological functioning caused by CNS prophylactic 
treatment came to be known as “neurocognitive late effects” and pediatric oncologists 
sought ways to decrease the occurrence of such deficits while still ensuring survival 
(Daly et al., 2008; Espy et al., 2001). This led to the development of treatment protocols 
consisting of intrathecal chemotherapy, which is administered directly into the spinal 
fluid via a lumbar puncture (Brown et al., 1998; Buizer et al., 2009; Mulhern & Palmer, 
2003). Currently, chemotherapy-only treatment protocols are utilized for majority of 
patients with ALL (Kingma et al., 2002; Espy et al., 2001; Moleski, 2000).  
While the use of chemotherapy-only instead of radiation therapy has helped to 
decrease the neurocognitive late effects experienced by survivors of ALL, research has 
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found that chemotherapy-only treatment can still cause subtle neurocognitive late effects 
(Anderson & Kunin-Batson, 2009; Iyer, Balsamo, Bracken, & Kadan-Lottick, 2015). 
Survivors of pediatric ALL treated with only chemotherapy have been shown to 
experience declines in intellectual and academic functioning following treatment 
(Moleski, 2000; Mulhern & Palmer, 2003; Iyer et al., 2015; Peterson et al., 2008). These 
declines in intellectual and academic functioning are thought to be secondary to deficits 
in core neuropsychological domains (Butler & Haser, 2006; Moleski, 2000; Mulhern & 
Palmer, 2003). 
The specific neuropsychological domains most often found to be impaired among 
survivors of pediatric ALL treated according to chemotherapy-only protocols are 
attention and executive functioning (Anderson & Kunin-Batson, 2009; Bisen-Hersh et al., 
2011; Buizer et al., 2009; Campbell et al., 2007; Peterson et al., 2008; Riccio et al., 2010; 
Schatz, Kramer, Ablin, & Matthay, 2000; Winick, 2011). Among this population, deficits 
in attention have been found across the subdomains of selective attention, divided 
attention, sustained attention, and shifting attention (Ashford et al., 2010; Baron, 2004; 
Buizer, de Sonneville, van den Heuvel-Eibrink, & Veerman, 2005; Carey et al., 2008; 
Harila, Winqvist, Lanning, Bloigu, & Harila-Saari, 2009; Kingma et al., 2002; Lesnik, 
Ciesielski, Hart, Benzel, & Sanders, 1998; Reddick et al., 2006). Subdomains of 
executive functioning that have found to be impaired among this population include 
cognitive flexibility/working memory, goal setting/planning, information 
processing/processing speed, and attentional control/inhibition (Ashford et al., 2010; 
Carey et al., 2008; Harila et al., 2009; Jansen, 2008; Kingma et al., 2002; Lesnik et al., 
1998; Waber et al., 1995). While these weaknesses in attention and executive functioning 
may be less pronounced than the weaknesses observed among survivors of ALL treated 
with radiation therapy, they still have important consequences for the survivors’ lives 
 4 
after cancer (Anderson & Kunin-Batson, 2009). Neurocognitive late effects among this 
population have been found to be associated with difficulties in social, emotional, and 
behavioral functioning; concerns about school performance; and lower levels of quality 
of life than healthy population norms (Kanellopoulos, Hamre, Dahl, Fossa, & Ruud, 
2013; Kunin-Batson, Kadan-Lottick, & Neglia, 2014; Iyer et al., 2015; Moyer et al., 
2012; Patel, Wong, Cuevas, & Van Horn, 2013). 
As researchers gain a better understanding of the neurocognitive late effects 
associated with chemotherapy-only protocols for the treatment of childhood ALL, 
emphasis in research is now shifting towards the identification of variables that may 
serve to moderate or protect against the development of neurocognitive late effects (Daly 
et al., 2008; Mulhern & Palmer, 2003). Moderators and mediators have been identified 
for medical, treatment-related, child-related, and demographic factors, such as disease 
classification, treatment intensity, age at diagnosis, gender, and socioeconomic status 
(Brouwers, 2005; Buizer et al., 2005; Buizer et al., 2009; Moleski, 2000; Mulhern & 
Palmer, 2003; Peterson et al., 2008; Stehbens et al., 1994; Waber et al., 2012; Winick, 
2011). In addition, some researchers have suggested that psychosocial variables such as 
family functioning may moderate neurocognitive outcome among survivors of pediatric 
ALL, as there is evidence from the literature on pediatric traumatic brain injury and 
pediatric brain tumors that the level of functioning in a family influences how well a 
child or adolescent recovers from neurocognitive insult (Anderson & Kunin-Batson, 
2009; Max et al., 1999; Nadebaum, Anderson, & Catroppa, 2007; Taylor et al., 1999; 
Yeates et al., 1997). 
Family functioning refers to the extent to which a family is able to engage in the 
interactional patterns necessary for the achievement of family goals (Walsh, 2011). A 
model of family functioning that has been used in research with the pediatric cancer 
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population is the McMaster Model of Family Functioning (MMFF; Carlson, 2003; 
Epstein, Ryan, Bishop, Miller, & Keitner, 2003). The MMFF consists of six dimensions 
(problem solving, communication, role functioning, affective responsiveness, affective 
involvement, and behavior control) that are thought to be important for the health of the 
members of the family and the successful achievement of family tasks (Epstein et al., 
2003; Lebow & Stroud, 2011). Within each dimension, researchers have identified 
behaviors and interaction patterns that range from “most ineffective” to “most effective” 
(Epstein et al., 2003). Those deemed “most ineffective” tend to lead to the development 
of clinically significant difficulties for the family, while those deemed “most effective” 
lead to physical and emotional health for the members of the family (Epstein et al., 2003). 
Families of survivors of pediatric ALL have been found to demonstrate lower rates of 
functioning across the dimensions of the MMFF (Alderfer, Navsaria, & Kazak, 2009). 
Evidence from the pediatric traumatic brain injury and pediatric brain tumor 
populations suggests that positive family functioning serves as a protective factor for 
neurocognitive outcomes of children who survive these conditions. In the field of 
traumatic brain injury, research suggests that the level of functioning in a family 
influences how well a child or adolescent within that family recovers from 
neurocognitive insult (Max et al., 1999; Nadebaum et al., 2007; Taylor et al., 1999; 
Yeates et al., 1997). Two studies have investigated this phenomenon among survivors of 
pediatric brain tumors and found similar results (Ach et al., 2013; Carlson-Green, Morris, 
& Krawiecki, 1995). However, no known research has examined whether positive family 
functioning similarly moderates the effects of CNS-directed chemotherapy on the 
neurocognitive functioning of survivors of pediatric ALL. 
The purpose of this study was to investigate whether family functioning 
moderates neurocognitive functioning following chemotherapy treatment for ALL. Based 
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upon a multidimensional model of attention and Anderson’s model of executive function 
(EF), four subcomponents of attention and four subcomponents of EF were examined 
(Anderson, 2002). The attention subcomponents were: selective, divided, sustained, and 
shifting. The EF subcomponents were: cognitive flexibility (working memory), goal 
setting (planning), attentional control (inhibition), and information processing (processing 
speed).  Caregiver ratings of survivors’ attentional and executive functioning were 
examined as well. It was hypothesized that survivors of ALL from poorer functioning 
families would experience more severe neurocognitive late effects than those from higher 
functioning families. Moreover, it was hypothesized that such a relationship between 
family functioning and neurocognitive functioning would not be found among healthy 
control children.  
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Chapter 2: Literature Review 
Acute Lymphoblastic Leukemia 
Prevalence.   
Childhood cancer, although relatively rare, is more common than many people 
realize and is a significant health problem around the world (Moore, 2005; Riccio et al., 
2010). Approximately 1 out of every 300 children under the age of 16 has a diagnosis of 
cancer (Riccio et al., 2010). On average, one to two out of every 10,000 children is 
diagnosed with cancer each year in the United States (Butler & Haser, 2006; Moore, 
2005). Cancer is the leading cause of death by disease among children under the age of 
15 and the second leading cause of death among children and adolescents overall, with 
accidents being the first leading cause (American Cancer Society, 2015). In 2015 alone, 
approximately 10,380 children under the age of 15 were expected to be diagnosed with 
cancer in the United States and 1,250 cancer deaths were expected to occur among that 
age group in that year (American Cancer Society, 2015). 
The incidence of childhood cancer varies by age and by type of cancer, with some 
cancers more common at certain ages than others (Riccio et al., 2010). In general, the 
types of cancer most often seen in children are quite different from those common among 
adults (Riccio et al., 2010). Types of cancer commonly seen in children and adolescents 
are “leukemias, brain and other nervous system tumors, lymphomas (lymph node 
cancers), bone cancers, soft tissue sarcomas, kidney cancers, eye cancers, and adrenal 
gland cancers (ACS, 2006)” (Riccio et al., 2010, p. 207), with leukemias and solid tumors 
most prevalent in this age group (Riccio et al., 2010). 
Leukemias are the most common form of cancer among children and adolescents, 
accounting for approximately one-third of cancers in children under the age of 15 and 
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one-fourth of cancers in people under the age of 20 (Bisen-Hersh et al., 2011; Butler & 
Haser, 2006; Riccio et al., 2010). Leukemia refers to a diverse set of diseases of the blood 
forming tissues (Brown et al., 1992; Daly et al., 2008; Riccio et al., 2010). Leukemia is 
characterized by the production of large amounts of abnormal early-stage white blood 
cells called leukocytes (Daly et al., 2008; Riccio et al., 2010). The leukocytes block 
production of normal white blood cells and therefore impede the child’s ability to fight 
off infection (Daly et al., 2008; Riccio et al., 2010). There are two types of normal white 
blood cells in which leukemia may develop: lymphoid cells and myeloid cells (U.S. 
Department of Health and Human Services, 2008). Leukemias that begin in lymphoid 
cells are referred to as lymphocytic, or lymphoblastic, leukemias; leukemias that begin in 
myeloid cells are referred to as myelogenous, or myeloblastic, leukemias (U.S. 
Department of Health and Human Services, 2008). Leukemia can also be classified as 
either acute or chronic, depending on the speed with which the disease develops and 
progresses (U.S. Department of Health and Human Services, 2008). Acute leukemias are 
those that progress quickly, whereas chronic leukemias progress more slowly (U.S. 
Department of Health and Human Services, 2008).  Altogether, then, there are four main 
types of leukemia: acute lymphocytic leukemia, acute myelogenous leukemia, chronic 
lymphocytic leukemia, and chronic myelogenous leukemia (Riccio et al., 2010; U.S. 
Department of Health and Human Services, 2008). 
The most common form of leukemia among children is acute lymphocytic 
leukemia (ALL), which is also known as acute lymphoblastic leukemia (Butler & Haser, 
2006). ALL is the most common cancer among children and adolescents ages 1 to 16 and 
accounts for approximately 76% of all cases of pediatric leukemia (Leukemia & 
Lymphoma Society, 2014). Of the approximately 6,000 cases of ALL diagnosed annually 
in the United States, roughly 76% percent of these are among children, adolescents, and 
 9 
young adults less than 20 years of age (American Cancer Society, 2015). ALL occurs 
across ethnic groups but is slightly more prevalent among Caucasian  and Hispanic 
children than among African American or Asian American children (Hunger & 
Mullighan, 2015). The yearly incidence of ALL among white children is about 3 or 4 per 
100,000 (Mennes et al., 2005; Mulhern & Palmer, 2003). It is more common among boys 
than girls, with 1.3 males diagnosed for every 1 female diagnosed (McNeil, Cote, Clegg, 
& Mauer, 2002; Mulhern & Butler, 2006). The majority of cases of ALL are diagnosed in 
children between the ages of 3 to 5 years (Hunger & Mullighan, 2015). 
Characteristics of ALL. 
ALL is a “malignant disorder of lymphoid cells” that “results when a surplus of 
stem cells develop into lymphocytes, a type of white blood cell also referred to as 
leukemic cells” (Bisen-Hersh et al., 2011, p. 293). Lymphocytes are unable to fight 
infection and the proliferation of them leaves less room for healthy blood cells and 
platelets to form (Bisen-Hersh et al., 2011). The lymphocytes are originally found in the 
bone marrow (Mulhern & Butler, 2006). From there they enter the bloodstream and are 
transported, via the circulatory system, to nearly every organ system in the body (Bisen-
Hersh et al., 2011; Mulhern & Butler, 2006). This includes the central nervous system 
(CNS), which consists of the brain and the spinal cord (Carlson, 2010).  Possible genetic, 
environmental, and viral influences on the development of ALL have been identified 
(Bisen-Hersh et al., 2011; Mulhern & Butler, 2006). For example, children with the 
genetic disorder Down syndrome have been found to be at an increased risk for the 
development of leukemia (Riccio et al., 2010). However, the genetic and environmental 
influences that have been identified as implicated in the development of ALL so far do 
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not account for the majority of cases of the disease and the exact causes of most cases of 
ALL remain unknown (Bisen-Hersh et al., 2011; Daly et al., 2008; Riccio et al., 2010). 
Presenting symptoms of ALL can include fever, fatigue, paleness of the skin, 
bone pain, easy bleeding or bruising, infection, swelling of the abdomen, swollen lymph 
nodes, enlargement of the thymus gland, headache, seizures, vomiting, rashes, gum 
problems, and/or weakness (Mulhern & Butler, 2006; Riccio et al., 2010). Since many of 
these symptoms resemble those of a number of nonmalignant conditions, definitive 
diagnosis is based upon a combination of laboratory tests and imaging results and is 
sometimes delayed (Mulhern & Butler, 2006; Riccio et al., 2010). The specific laboratory 
tests used to diagnosis ALL include blood smear, bone marrow aspiration, bone marrow 
biopsy, spinal tap, and lymph node biopsy, with bone marrow aspiration being the most 
commonly used diagnostic test for this condition (Mulhern & Butler, 2006; Riccio et al., 
2010). Once a child is diagnosed with ALL they are classified into one of four categories 
based upon the progression of the disease: low-risk, standard-risk, high-risk, and very 
high-risk (Riccio et al., 2010). This classification is made based upon the presence of 
cancer cells beyond the bone marrow and blood, in organs such as the liver, spleen, or 
lymph nodes (Riccio et al., 2010). 
Treatment for ALL. 
Treatment for ALL generally lasts for two to three years and consists of multiple 
phases (Bisen-Hersh et al., 2011; Butler & Haser, 2006; Moleski, 2000). Prior to the early 
1960s, survival rates for ALL were very low (Moleski, 2000; Moore, 2005). However, 
survival rates have improved dramatically since that time due to marked improvements in 
the treatment (Butler & Haser, 2006; Winick, 2011). The factor most commonly credited 
as responsible for decreased mortality rates of ALL over the past several decades has 
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been the introduction of prophylactic CNS treatment, which prevents leukemia from 
spreading into the CNS (Buizer et al., 2009; Hill, Ciesielski, Sethre-Hofstad, Duncan, & 
Lorenzi, 1997; Von der Weid et al., 2003). CNS prophylaxis is necessary because the 
blood-brain barrier prevents chemotherapeutic agents delivered to the rest of the body 
from reaching the CNS (Buizer et al., 2009; Moleski, 2000). Without CNS prophylaxis 
the CNS is a sanctuary for leukemic cells and the chance of CNS relapse is high (Butler 
& Haser, 2006; Mennes et al., 2005; Mulhern & Palmer, 2003). CNS relapse, also known 
as CNS leukemia, occurs when leukemic cells invade and proliferate within the CNS 
(Brown et al., 1992; Moleski, 2000). Without CNS prophylaxis up to 80% of children and 
adolescents with ALL experience CNS relapse (Buizer et al., 2009). CNS relapse is a 
major cause of mortality in ALL (Buizer et al., 2009). The best way to treat CNS relapse 
is to prevent it from occurring, so CNS prophylaxis has become a standard part of 
treatment for children with ALL (Brown et al., 1992; Iuvone et al., 2002). 
These new treatment protocols have served to nearly eliminate the occurrence of 
CNS relapse, which now occurs in less than 10% of cases of ALL (Buizer et al., 2009; 
Moleski, 2000). Currently, approximately 90% of children and adolescents ages 0-19 
years diagnosed with ALL reach long-term event-free survivorship (American Cancer 
Society, 2014; Hunger & Mullighan, 2015). As of January 1, 2010, there were 60,489 
survivors of childhood ALL living in the United States (American Cancer Society, 2014). 
Late effects of treatment. 
With the increased survival rates that have accompanied improvements in the 
treatment of childhood ALL in the past several decades, interest has grown in the study of 
the “late effects” of CNS prophylactic treatment (Bisen-Hersh et al., 2011; Brouwers, 
2005). Late effects are impairments in functioning that occur after the successful 
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completion of cancer therapy (Mulhern & Butler, 2006). They are generally defined as 
occurring two or more years after the time of diagnosis and are thus different from “acute 
effects”, the “effects of disease and treatment that are acute or subacute and time limited, 
such as chemotherapy-induced nausea and vomiting or temporary cognitive changes 
induced by cancer therapy” (Mulhern & Butler, 2006, p. 262). Late effects are generally 
considered to be chronic and progressive (Mulhern & Butler, 2006).  
Among survivors of childhood cancer overall, approximately two-thirds 
experience at least one long-term consequence, or late effect, from their cancer and its 
treatment (Nathan et al., 2007). Survivors of childhood ALL are especially at risk for 
long-term and progressive impairment in the area of cognitive functioning because CNS 
prophylaxis treatment can be toxic to the developing brain (Kesler et al., 2010; Nathan et 
al., 2007). The intellectual, academic, and neuropsychological deficits caused by CNS 
prophylactic treatment are known collectively as “neurocognitive late effects” (Daly et 
al., 2008; Espy et al., 2001).  
The first form of CNS prophylactic treatment for ALL, introduced in the late 
1960s and early 1970s, was cranial irradiation or cranial radiation therapy (CRT; Buizer 
et al., 2009; Montour-Proulx et al., 2005). At first, CRT consisted of 24 Gy of radiation 
delivered to the spinal cord (Buizer et al., 2009; Von der Weid et al., 2003). Although it 
served to significantly decrease the incidence of CNS relapse, and thus increased survival 
rates among children with ALL, research found a high incidence of neurocognitive 
deficits among survivors of ALL treated with CRT (Brown et al., 1992; Montour-Proulx 
et al., 2005). These included significant declines in overall intellectual functioning as 
well as impairments in short-term memory, attention, information processing, motor 
speed, and perception (Brown et al., 1992; Moleski, 2000). Furthermore, survivors of 
ALL treated with CRT were found to have an increased incidence of special education 
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placements for learning disabilities and to have decreased rates of secondary school 
completion (Mennes et al., 2005). 
Based upon this research into the late effects of CRT, pediatric oncologists began 
to explore ways to decrease the amount of CRT administered to children with ALL, while 
still ensuring survival. They began reducing the dosage of CRT (to 18 or even 12 Gy) and 
adding chemotherapy to the treatment protocols for childhood ALL (Buizer et al., 2009; 
Montour-Proulx et al., 2005). The chemotherapy was delivered intrathecally (directly into 
the spinal fluid) and typically consisted of the drug methotrexate (MTX), alone or in 
combination with other drugs (Brown et al., 1998; Buizer et al., 2009; Mulhern & 
Palmer, 2003). It was found that the level of radiation could be reduced without 
negatively impacting CNS relapse-free survival rates, and a combination of CRT and 
intrathecal (IT) chemotherapy was the primary form of CNS prophylaxis for childhood 
ALL in the 1970s and early 1980s (Buizer et al., 2009; Kingma et al., 2002; Von der 
Weid et al., 2003). However, a high incidence of neurocognitive late effects persisted 
among survivors treated with combined modality (chemotherapy plus CRT) therapy, 
despite the decreased levels of radiation that were involved (Buizer et al., 2009; Kingma 
et al., 2002; Montour-Proulx et al., 2005). 
In the mid-1980s, CRT was eliminated and chemotherapy-only treatment 
protocols began to be used as CNS prophylaxis for non-high-risk childhood ALL (Hill et 
al., 1997; Jansen et al., 2008; Kingma et al., 2002). It was found that similar, or even 
better, survival rates could be generated with chemotherapy-only treatment among 
children with standard-risk ALL (Buizer et al., 2005; Moleski, 2000; Von der Weid et al., 
2003). Currently, CRT is only used with a small percentage of children who are deemed 
to be at the highest risk for CNS relapse (American Cancer Society, 2014; Hunger & 
Mullighan, 2015). Typical CNS prophylaxis for non-high risk ALL now consists of 
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systemic and IT chemotherapy (Iyer et al., 2015; Montour-Proulx et al., 2005). The 
specific chemotherapeutic agents used vary across medical institutions, but IT 
chemotherapy typically consists of MTX, alone or in combination with other drugs such 
as cytosine arabinoside (bytarabine), anthracyclines (such as doxorubicin), asparaginase, 
mercapclines, vincristine, and corticosteroids (Bisen-Hersh et al., 2011; Moleski, 2000). 
Neurocognitive Late Effects of Chemotherapy 
Given that chemotherapy-only protocols are now the standard form of CNS 
prophylaxis for the majority of children and adolescents with ALL, research interest in 
the potential neurocognitive late effects of this form of treatment has grown immensely 
over the past few decades (Buizer et al., 2009; Butler & Haser, 2006; Iyer et al., 2015). 
Although there has been some inconsistency among the results of studies in this area, 
methodologically sound studies on the intellectual, academic, and neuropsychological 
functioning of ALL survivors treated with chemotherapy for CNS prophylaxis have 
shown that a significant amount of survivors show evidence of deficits in at least one area 
of functioning (Moleski, 2000; Iyer et al., 2015; Peterson et al., 2008; van der Plas et al., 
2015). 
Intellectual functioning. 
In terms of intellectual functioning, studies have found that survivors of childhood 
ALL treated with chemotherapy demonstrate impaired performance on measures of Full 
Scale IQ (FSIQ; Giralt et al., 1992; Hill et al., 1997; Raymond-Speden, Tripp, Lawrence, 
& Holdaway, 2000), Verbal IQ (VIQ; Giralt et al., 1992; Harila et al., 2009; Hill et al., 
1997; Kingma et al., 2002; Raymond-Speden et al., 2000), Performance IQ (PIQ; Brown 
et al., 1998; Giralt et al., 1992; Harila et al., 2009; Hill et al., 1997; Raymond-Speden et 
al., 2000), and Simultaneous Processing (Brown et al., 1992). Furthermore, some studies 
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have found that children and adolescents receiving chemotherapy for CNS prophylaxis in 
ALL show evidence of declines in various areas of intellectual functioning over time 
after their treatment has ended. These areas include FSIQ (Mulhern, Fairclough, & Ochs, 
1991; Ochs et al., 1991), VIQ (Harila et al., 2009; Mulhern et al., 1991; Ochs et al., 
1991), and PIQ (Jansen et al., 2006; Montour-Proulx et al., 2005; Mulhern et al., 1991). 
However, other studies have found ALL survivors treated with chemotherapy-only to 
perform similarly to controls on measures of intellectual functioning (Anderson, Godber, 
Smibert, Weiskop, & Ekert, 2000; Ashford et al., 2010; Kingma et al., 2001; Rowland et 
al., 1984; Stehbens et al., 1994; Tamaroff et al., 1982; Ueberall et al., 1996; Von der 
Weid et al., 2003; Waber et al., 1995). Other studies found deficits in intellectual 
functioning relative to controls that approached, but did not reach, statistical significance 
(Carey et al., 2008; Kaemingk, Carey, Moore, Herzer, & Hutter, 2004; Reddick et al, 
2006; Schatz et al., 2000). 
In order to resolve these contradictions as to the presence or absence of deficits in 
intellectual functioning among ALL survivors treated with chemotherapy-only protocols, 
Moleski conducted an extensive review of the literature in 2000. Reviewing 33 studies 
published between 1981 and 1997, Moleski found that roughly two-thirds of the studies 
reported deficits in at least one area of intellectual functioning. Many of the studies that 
did not report finding evidence of impaired intellectual functioning among this 
population had significant methodological weaknesses (Moleski, 2000). In some of the 
studies, researchers reported that chemotherapy alone was not neurotoxic because the 
patients’ mean IQ was in the average range. However, this conclusion is problematic 
because research has found that healthy siblings of ALL survivors tend to function in the 
above average range of intellectual functioning, with an average IQ value of 
approximately 112 to 113 (Moleski, 2000). Therefore, it is reasonable to assume that the 
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survivors themselves may have been functioning in the above average range as well if not 
for their treatment, and IQ scores in the lower end of the average range may in fact 
represent a decline in functioning for this population. Because of this, scholars have 
argued that is important to use matched controls, as opposed to normative data, for 
comparison when investigating neurocognitive late effects in this population (Moleski, 
2000). 
Some studies included in Moleski’s seminal review of the literature enlisted a 
non-CNS treated cancer group in order to control for school absences due to treatment as 
well as for the psychological experience of having cancer (Moleski, 2000). All but one of 
these studies found evidence of impaired intellectual functioning among ALL patients 
receiving IT chemotherapy for CNS prophylaxis. Other studies used a healthy non-sibling 
control group for comparative purposes (Moleski, 2000).  Two of these studies did not 
find evidence of declines in intellectual functioning among the subjects who had received 
chemotherapy. However, these two articles, which report on results from the same larger 
study, included both CNS- and non-CNS-treated cancer patients in their “chemotherapy-
only” group. Therefore, no conclusions about the effects of chemotherapy used for CNS 
prophylaxis can be made, as the CNS-treated subjects were mixed with what should have 
been a non-CNS cancer control group. Another study that reported finding no evidence of 
declines in intellectual functioning among ALL survivors treated with chemotherapy had 
only 3 such subjects in its study (Moleski, 2000), a sample size that makes rendering 
conclusions for the larger population rather difficult. Overall, Moleski found that studies 
which had included a control group of either siblings or non-CNS-treated cancer patients 
consistently found significant differences in intellectual functioning between the control 
groups and ALL survivors treated with chemotherapy.  
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Peterson and colleagues followed up Moleski’s review of the literature with a 
meta-analysis in 2008. Criteria used for inclusion in the meta-analysis were: inclusion of 
participants who had competed chemotherapy-only treatment for pediatric ALL as well 
as a comparison group that did not receive CNS-directed treatment, publication in 
English, inclusion of enough original data to allow for calculation of effect sizes, and 
publication after 1990 (Peterson et al., 2008). Of the 160 relevant articles originally 
found, the majority failed to meet criteria for inclusion in the study and only 13 were 
included in the meta-analysis. The results of the analysis indicated that survivors of 
pediatric ALL treated with chemotherapy alone had significantly lower FSIQ scores as 
compared to control groups (Mean effect size = 0.55, 95% Confidence Interval = 0.27 – 
0.83, n = 10). After eliminating from analysis the three studies that had used test norms as 
the control group and the three that utilized foreign translations of intelligence tests, the 
recalculated mean effect size for FSIQ from the remaining seven studies was still 
significantly different from zero (M = 0.76, 95% CI = 0.42 – 1.12, n = 7). Similar results 
were found for the index scores VIQ and PIQ and for subtests measuring working 
memory and processing speed as well. These results provide empirical support to the 
assertion that survivors of pediatric ALL treated according to chemotherapy-only 
protocols do experience deficits in intellectual functioning following their treatment. 
A more recent meta-analysis conducted by Iyer and colleagues confirmed the 
findings of these earlier reviews through examination of ten studies meeting more 
stringent inclusion criteria (age < 21 years at time of ALL diagnosis, ≥ 5 years 
postdiagnosis or ≥ 2 years off treatment and in continuous first remission, no history of 
CRT, cancer-free at the time of assessment, and comparison with a healthy control group 
(Iyer et al., 2015). 8 of the 10 studies included in the analysis assessed intellectual 
functioning. For FSIQ, 432 pediatric ALL survivors were compared with 465 healthy 
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control subjects. For VIQ and PIQ, 452 ALL survivors met criteria for inclusion and were 
compared with 510 healthy control subjects. In regards to FSIQ, the ALL survivor group 
performed 0.52 standard deviations lower than the healthy control group, which equated 
to approximately 7.8 IQ points and was a statistically significant difference (95% CI = -
0.68 to -0.37, p < .001). For VIQ, the survivor group performed 0.54 standard deviations 
lower than the healthy control group, equating to 8.1 IQ points and representing a 
statistically significant difference (95% CI = -0.69 to -0.40, p < .001). Significant 
differences were also found for PIQ, with the survivor group performing 0.41 standard 
deviations lower than the control group (6.15 IQ points, 95% CI = -0.56 to -0.27, p < 
.001). In sum, results of this meta-analysis indicated that survivors of pediatric ALL 
performed significantly worse than healthy peers on measures of FSIQ, VIQ, and PIQ.  
Neuropsychological functioning.  
Deficits in intellectual and academic functioning among this population have been 
well established in much of the literature (Mulhern & Palmer, 2003). Originally, it was 
thought that these deficits could be due to the general effects of chronic illness and school 
absenteeism (Mulhern & Palmer, 2003). However, studies involving control groups 
comprised of pediatric cancer patients whose treatment did not include CNS directed 
chemotherapy have disproved this notion (Mulhern & Palmer, 2003). It is now believed 
that deficits in intellectual and academic functioning are “secondary” late effects 
resulting from deficits in what are called “core” areas of neuropsychological functioning, 
such as attention, working memory, processing speed, and memory (Bisen-Hersh et al., 
2011; Schatz et al., 2000). It is thought that these deficits in core mental processes impair 
the development of higher-level abilities, leading to the declines in IQ level found among 
this population (Bisen-Hersh et al., 2011; Schatz et al., 2000). Research has shown that 
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decreases in Verbal, Performance, and Full Scale IQ scores among this population are 
largely the result of domain specific weaknesses in processing speed and working 
memory (Kahalley et al., 2013; Patel et al., 2013).  
The focus of research on neurocognitive late effects of chemotherapy among 
survivors of childhood ALL has shifted from the study of global intellectual functioning 
to the identification of patterns of specific neuropsychological deficits in this population 
(Butler & Haser, 2006; Moleski, 2000; Mulhern & Palmer, 2003). Evidence from these 
studies has shown that survivors of childhood ALL treated with chemotherapy alone 
consistently show declines in at least one area of “core” neuropsychological functioning 
(Moleski, 2000). The specific core neuropsychological domains most commonly affected 
in this population are attention and executive functioning (Anderson & Kunin-Batson, 
2009; Buizer et al., 2009; Peterson et al., 2008). These basic neuropsychological 
processes are crucial for the acquisition of new information and skills, and deficits in 
these areas are thought to underlie poor performance of ALL survivors in the classroom 
and beyond (Buizer et al., 2009; Mulhern & Palmer, 2003). 
Attention. 
The domain of attention consists of a number of subdomains, including selective 
attention, divided attention, sustained attention, and shifting attention (Baron, 2004; 
Ginstfeldt & Emanuelson, 2010; Mirsky, Anthony, Duncan, Ahearn, & Kellam, 1991). 
Selective attention is the ability to maintain focus on a particular cognitive set or stimuli 
“in the presence of background ‘noise’ or distraction” (Baron, 2004, p. 222). Commonly 
used tests of selective attention include digit span tasks, where participants are asked to 
repeat a sequence of numbers read to them by the examiner. Divided attention is the 
ability to “respond to more than one task or event simultaneously” (Baron, 2004, p. 222). 
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Commonly administered tests of divided attention include trail making tests, in which the 
participant has to draw a line between circles while alternating between numbers and 
letters in sequence. Sustained attention is defined as the “ability to maintain vigilance and 
respond consistently during continuous or repetitive activity” (Baron, 2004, p. 223). 
Commonly administered tests of sustained attention include continuous performance 
tests, which require the subject to attend to a visual or auditory presentation of a series of 
random letters or numbers and to respond to a target stimulus. Finally, shifting attention 
is the ability to flexibly shift ones attention from one focus or stimuli to another (Baron, 
2004). Commonly administered tests of shifting attention include verbal and design 
fluency tests, which detect difficulties with the ability to shift in terms of perseverative 
errors (Baron, 2004). 
Survivors of ALL treated with chemotherapy alone have been found to 
demonstrate impairments in a variety of subdomains of attention. In fact, attention is one 
of the domains most commonly found to be effected in studies of this population, with 
approximately one-fourth of survivors of ALL showing evidence of deficits in attention 
(Bisen-Hersh et al., 2011; Butler & Copeland, 2002). Specifically, studies have found 
evidence of impaired performance, relative to controls, on tests of selective (Ashford et 
al., 2010; Carey et al., 2008; Harila et al., 2009), divided (Carey et al., 2008; Kingma et 
al., 2002; Lesnik et al., 1998), sustained (Reddick et al., 2006), and shifting (Buizer et al., 
2005) attention. These deficits may impact survivors’ ability to maintain concentration 
and ignore distractions, which in turn may negatively impact their academic achievement 
and quality of life (Anderson & Kunin-Batson, 2009; Butler & Copeland, 2002). 
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Executive functioning.  
Executive functioning (EF) is a somewhat nebulous concept within the field of 
neuropsychology, as several differing definitions and models of EF have been proposed 
but none have received universal acceptance (Baron, 2004). Various subcomponents of 
EF that have been proposed include planning, reasoning, cognitive flexibility, inhibition, 
initiation, and working memory (Anderson, 2002; Baron, 2004). Further complicating the 
conceptualization and assessment of EF is the fact that various aspects of EF overlap 
considerably with other domains of neurocognitive functioning such as attention and 
memory (Baron, 2004). However, the abilities that fall under the domain of EF are 
crucial to successful daily living and consideration of their intactness among survivors of 
pediatric ALL is critical (Anderson, 2002; Baron, 2004). 
Researchers have proposed a developmental model of executive functioning 
based upon factor analysis and clinical neuropsychological knowledge (Figure 1; 
Anderson, 2002). In this model, EF is comprised of four distinct domains, referred to as: 
(a) attentional control, (b) information processing, (c) cognitive flexibility, and (d) goal 
setting. Although these domains are thought to be separate within this model, they are 
also thought to operate in an integrative manner in order to execute tasks. Thus, they can 
be conceptualized of as an overall control system (Anderson, 2002). Each of these 
domains subsumes a number of highly integrated cognitive processes. 
Within this model of EF, the attentional control domain relates to the ability to 
selectively attend to certain stimuli, to inhibit certain responses, and to focus attention for 
a prolonged period of time (Anderson, 2002). Therefore, it consists of processes such as 
selective attention, self-regulation, self-monitoring, and inhibition. Deficits in attentional 
control are thought to be reflected by impulsive behavior, lack of self-control, failure to 
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complete tasks, the inability to self-correct procedural mistakes, and inappropriate 
responses to stimuli or situation. 
 
 
 
  Figure 1: Anderson’s developmental model of executive functioning. 
The information processing domain refers to the ability to quickly and accurately 
process information (Anderson, 2002). It is thought to include processes such as 
efficiency, fluency, and processing speed. Deficits in this domain are reflected by 
reduced output, delayed responses, hesitancy, and slow reaction times. 
The goal setting domain refers to the ability to develop new initiatives and 
concepts, to plan actions in advance, and to approach tasks in an efficient and strategic 
manner (Anderson, 2002). Aspects of this domain include initiative, conceptual 
reasoning, planning, and strategic organization. Deficits in this domain are thought to be 
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reflected by poor problem solving abilities, disorganization, poor planning, development 
of inefficient strategies, continued reliance on previously learned strategies even when 
they are no longer effective, and poor conceptual reasoning.  
The cognitive flexibility domain refers to the ability to shift between cognitive 
sets, to learn from mistakes, to divide attention, to devise alternative strategies, and to 
simultaneously process multiple sources of information (Anderson, 2002). Components 
of this domain are divided attention, working memory, conceptual transfer, and feedback 
utilization. Deficits in this domain are reflected in rigidity and ritualistic behavior, 
difficulty with new activities or procedures, failure to adapt to new demands, and 
perseverative behavior such as continuing to make the same mistake or break the same 
rule regardless of feedback. 
Studies have found that survivors of pediatric ALL treated with chemotherapy-
only show evidence of deficits, relative to controls, in various aspects of executive 
functioning. These include cognitive flexibility/working memory (Ashford et al., 2010; 
Carey et al., 2008; Iver et al., 2015; Kingma et al., 2002; Lesnik et al., 1998; Waber et al., 
1995), information processing/processing speed (Iver et al., 2015; Jansen, 2008), and 
attentional control/inhibition (Harila et al., 2009). These deficits have been found to 
underlie problems with behavior and school performance among survivors of ALL 
treated with chemotherapy-only protocols (Buizer et al., 2009). Furthermore, deficits in 
executive functioning have implications for survivors’ long-term occupational and social 
functioning and their overall quality of life, as intact executive functioning is crucial to 
optimal academic, adaptive, and social functioning (Campbell et al., 2007; Winter et al., 
2014). 
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Summary. 
Overall, research shows that chemotherapy-only treatment for ALL, while 
perhaps less neurotoxic than CRT, is still associated with neurocognitive late effects (Iver 
et al., 2015; Riccio et al., 2010; Winick, 2011). Deficits in the areas of attention and 
executive functioning are particularly prevalent among this population (Anderson & 
Kunin-Batson, 2009; Campbell et al., 2007; Peterson et al., 2008; Riccio et al., 2010; 
Winick, 2011). These deficits may lead to real and significant impairments in the 
classroom setting (Nathan et al., 2007). Impairments in attention and executive functions 
such as working memory, cognitive flexibility, and inhibition have also been found to be 
associated with increased stress and problem behavior and decreased ability to use 
effective coping strategies among survivors of pediatric ALL, all of which impact the 
survivors’ quality of life (Riccio et al., 2010). Survivors of pediatric ALL treated with 
chemotherapy alone who have neurocognitive deficits following their treatment have 
been found to be at risk for poor quality of life (Kunin-Batson, Kadan-Lottick, & Negila, 
2014).  
Risk and protective factors. 
As understanding of the neurocognitive late effects of chemotherapy-only 
treatment for ALL improves, a prominent focus of research has become the risk and 
protective factors that serve to mediate and moderate the effects of the treatment. 
Traditionally the focus of this research has been on biologic moderators and mediators, 
including disease and treatment-related factors such as the intensity of the treatment 
regimen (Brouwers, 2005; Buizer et al., 2009). Children who have received intensified 
treatment, such as higher doses of systemic methotrexate, have been found to perform 
significantly worse than survivors treated on lower intensity protocols in a few studies 
(Buizer et al., 2005; Buizer et al., 2009). However, some studies examining differences in 
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outcome based on risk-group and treatment intensity have found that these differences are 
less pronounced than those related to child characteristics such as age at diagnosis and 
maternal education level (Waber et al., 2012). Such findings suggest that a focus on 
child-related and psychosocial risk factors is increasingly important for this population.  
Child-related moderators of neurocognitive outcome include age at diagnosis, 
gender, time since diagnosis, and age at testing (Brouwers, 2008). Specifically, young 
age at diagnosis and female gender have been found to be risk factors for neurocognitive 
late effects following chemotherapy-only treatment for ALL (Buizer et al., 2009; 
Moleski, 2000; Peterson et al., 2008). Particularly, children younger than 5 years of age 
at the time of diagnosis have been found to be particularly vulnerable to cognitive 
dysfunction as a result of their treatment (Buizer et al., 2009). This is believed to be due 
to the fact that their brains, being less mature than those of older children, may be more 
vulnerable to the neurotoxicity of the treatments used for CNS prophylaxis (Buizer et al., 
2009). In this case, age at treatment is seen as a proxy for the level of 
“neurodevelopmental maturity” of the child’s brain (Mulhern & Palmer, 2003). Several 
studies have found that male survivors of pediatric ALL outperform female survivors on 
tests of neurocognitive functioning (Buizer et al., 2009). Effect-size statistics used in a 
meta-analysis on this literature confirmed the significance of the differential 
performances between male and female survivors (Peterson et al., 2008). Thus, girls 
appear to exhibit more late effects. 
In addition to these child-related moderators, social and demographic moderators 
of neurocognitive outcome in this population have also been identified. Socioeconomic 
status (SES) has been identified as one such moderator in that differences in SES have 
been found to account for a significant amount of variability in neurocognitive outcome 
among this population (Stehbens et al., 1994; Winick, 2011). Specifically, survivors of 
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pediatric cancer from families with higher levels of SES have been found to have higher 
levels of neurocognitive functioning after treatment (Mulhern & Palmer, 2003). This is 
thought to be due to survivors from higher SES families being exposed to more enriched 
environments, which may help them overcome deficits more easily (Mulhern & Palmer, 
2003). 
Research has helped to clarify our understanding of the medical, treatment-
related, child-related, and demographic factors that mediate and moderate neurocognitive 
outcome in survivors of pediatric ALL (Patel & Carlson-Green, 2005). However, much 
less is known about potential psychosocial moderators of neurocognitive outcome in this 
population (Anderson & Kunin-Batson, 2009). One specific potential psychosocial 
moderator of neurocognitive outcome that has not yet been explored among survivors of 
pediatric ALL is family functioning. Given evidence from the pediatric traumatic brain 
injury and pediatric brain tumor fields as to the effect that family variables have on 
neurocognitive outcome, it is worth exploring whether positive family functioning serves 
as a protective factor against neurocognitive late effects for survivors of pediatric ALL 
(Anderson & Kunin-Batson, 2009; Hocking et al., 2011; Nathan et al., 2007). 
Family Functioning 
From a family systems perspective, family functioning refers to a family’s ability 
to engage in basic interactional patterns that enable them to achieve family goals (Walsh, 
2011). There are several models of family functioning, but most include dimensions such 
as “family structure or organization, communication, cohesion, problem solving, and 
emotional expression” (Hocking et al., 2011, p. 945). One model of family functioning 
that is used quite often in research and clinical practice is the McMaster Model of Family 
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Functioning (MMFF), which was first described by Epstein, Bishop, and Levin in 1978 
(Carlson, 2003; Epstein et al., 2003). 
The McMaster Model of Family Functioning. 
Grounded in systems theory, the MMFF views families as open systems that are 
comprised of various subsystems (i.e., parents, children) that relate to other, larger 
systems such as schools and extended family (Carlson, 2001; Epstein et al., 2003; Lebow 
& Stroud, 2011). Underlying the MMFF is the assumption that the primary purpose of the 
family unit is to facilitate the social, psychological, and biological growth and 
maintenance of its members (Epstein et al., 2003). According to this model, this purpose 
is achieved through the accomplishment of a variety of tasks, which the developers of the 
MMFF divide into three types: Basic Tasks, Developmental Tasks, and Hazardous Tasks 
(Epstein et al., 2003; Lebow & Stroud, 2011). Basic Tasks are the most fundamental and 
involve instrumental issues such as the provision of food, money, transportation, and 
shelter (Epstein et al., 2003). Developmental Tasks are the various stages that the family 
and its members face over time. These occur on both an individual level (i.e., infancy, 
childhood, adolescence, middle age, and old age) and a family level (i.e., the beginning of 
a marriage, a first pregnancy, or the “empty nest” after the last child leaves home; Epstein 
et al., 2003). Hazardous Tasks are crises that arise due to unexpected circumstances, such 
as accidents or job loss (Epstein et al., 2003). Inability for a family to effectively 
accomplish these three task areas has been found to be associated with the development 
of clinically significant problems and maladaptive family functioning (Epstein et al., 
2003). 
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Dimensions of family functioning in the MMFF. 
The MMFF identifies six dimensions of family functioning as being most 
important for the emotional and physical health of family members and the effective 
accomplishment of the tasks required of the family (Epstein et al., 2003; Lebow & 
Stroud, 2011). The six dimensions, which will be defined in greater detail, are: problem 
solving, communication, role functioning, affective responsiveness, affective 
involvement, and behavior control (Epstein et al., 2003; Lebow & Stroud, 2011). Within 
each dimension, the authors of the MMFF have identified practices and patterns of 
interaction that they deem to range from “most ineffective” to “most effective” (Epstein 
et al., 2003). “Most ineffective” functioning in a dimension is thought to lead to the 
development of clinically significant difficulties for the family, while “most effective” 
functioning in all dimensions is thought to contribute to “optimal physical and emotional 
health” among family members (Epstein et al., 2003, p. 582). Research on the MMFF has 
not found one dimension that serves to predict good or poor overall family functioning on 
its own; rather, all dimensions are thought to be important to understanding the overall 
function of a family (Epstein et al., 2003). 
Problem solving. 
Problem solving is defined within this model as the ability of a family to 
efficiently and easily resolve problems so as to maintain effective family functioning 
(Epstein et al., 2003; Lebow & Stroud, 2011; Miller, Ryan, Keitner, Bishop, & Epstein, 
2000). The MMFF identifies two types of problems that families face: instrumental and 
affective (Epstein et al., 2003). Instrumental problems are those that relate to the 
provision of basic necessities of living, whereas affective problems are those relating to 
emotions and feelings (Epstein et al., 2003). 
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In the MMFF, effective problem solving can be broken down into seven 
sequential steps: (1) problem identification, (2) communication about the problem with 
appropriate people, (3) development of a set of possible solutions, (4) deciding which 
solution to pursue, (5) putting the solution into place, (6) monitoring the progress of 
solution implementation, and (7) evaluation of the effectiveness of the problem-solving 
process (Epstein et al., 2003). According to this theory, the process that a family engages 
in when faced with problems in need of solutions is more important than the content of 
those problems in determining the level of functioning of the family (Epstein et al., 
2003). Highly functioning families tend to engage in these steps (discussing the issues, 
communicating with each other, deciding on and implementing an appropriate solution, 
etc.) whether the problem is relatively minor or is rather major, such as a job loss or 
terminal illness (Epstein et al., 2003). 
The developers of the MMFF hypothesize that most effective functioning in this 
domain occurs when (a) both instrumental and affective problems are solved and (b) 
when all seven steps of the problem-solving process are preformed (Epstein et al., 2003). 
Least effective functioning is thought to occur when families are unable to complete even 
step one of the process, the identification of problems (Epstein et al., 2003). 
Communication. 
The second dimension of family functioning included in the MMFF is 
communication, which is defined within the model as the patterns of verbal information 
exchange that occur within the family (Epstein et al., 2003; Lebow & Stroud, 2011; 
Miller et al., 2000). The MMFF focuses on verbal, as opposed to nonverbal or behavioral, 
communication because it is more easily observed and measured (Epstein et al., 2003). 
Furthermore, it focuses on the overall family pattern of communication as opposed to 
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examining the individual communication styles of members of the family, as this has 
been found to be most helpful to families and family therapists in the clinical experience 
of the authors of the MMFF (Epstein et al., 2003).  
As with problem solving, the MMFF divides communication into two areas, 
instrumental and affective (Epstein et al., 2003). In addition, the MMFF considers the 
style of communication in which the family engages. It does so along two independent 
continua, with one ranging from clear to masked and the other ranging from direct to 
indirect (Epstein et al., 2003). The clear vs. masked continuum refers to whether the 
message is expressed clearly or is vague and muddy. The direct vs. indirect distinction 
refers to whether the message is expressed to the intended recipient or to another member 
of the family (Miller et al., 2000). 
Therefore, within the MMFF there are considered to be four possible styles of 
communication: clear and direct, clear and indirect, masked and direct, and masked and 
indirect (Epstein et al., 2003). To illustrate each of these four possible styles, imagine a 
situation in which a wife is angry with her husband for coming home late from work 
without calling. An example of clear and direct communication in this circumstance 
would be if she told him “I am upset that you are late and I wish you would have called to 
tell me you would be late.” An example of clear and indirect communication would be if 
the wife told their daughter, in the presence of the husband, “I am upset with your father 
because he was late and did not call to tell me that he would be.” An example of masked 
and direct communication would be if the wife said to her husband “Traffic must have 
been really bad for you to be getting home at this time.” Finally, an example of masked 
and indirect communication would be if the wife told the daughter, in the presence of her 
husband, “It’s really annoying when I don’t know what time people are planning to be 
home for dinner.” Although the model focuses on verbal communication, it does take into 
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account nonverbal behavior, especially in so far as it contradicts the information that is 
being verbally exchanged, as this is thought to reflect masking or indirectness or both 
(Epstein et al., 2003). 
According to the MMFF, most effective functioning in this domain occurs when 
(a) the family is able to communicate well about both instrumental and affective matters 
and (b) when the communication is clear and direct (Epstein et al., 2003). Least effective 
functioning is thought to occur when the communication in the family is masked and 
indirect (Epstein et al., 2003). 
Role functioning. 
Within the MMFF, roles are defined as the patterns of behavior family members 
engage in so as to fulfill the family’s functions (Epstein et al., 2003; Lebow & Stroud, 
2011; Miller et al, 2000). According to the MMFF, there are five basic types of family 
functions that are necessary for the maintenance of an effective and healthy family 
system: provision of resources, nurturance and support, adult sexual gratification, 
personal development, and maintenance and management of the family system (Epstein 
et al., 2003). Each of these areas includes a number of tasks and functions. The ‘provision 
of resources’ area includes tasks and functions related to the attainment of food, clothing, 
shelter, and other basic human needs. The ‘nurturance and support’ area includes tasks 
related to providing members of the family with warmth, comfort, and reassurance. The 
‘adult sexual gratification’ area involves ensuring that each adult partner is satisfied with 
the level of sexual intimacy present in the relationship. ‘Personal development’ tasks and 
functions include those related to the physical, emotional, educational, social, and 
professional development of each family member. Finally, the ‘maintenance and 
management of the family system’ area includes a variety of functions and tasks related 
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to decision making/leadership, boundaries, finances, discipline, and health (Epstein et al., 
2003). 
The MMFF identifies two aspects of role functioning that are deemed to be vital 
to effective family functioning: role allocation and role accountability (Epstein et al., 
2003). Role allocation involves the family’s patterns for the assignment of roles and role 
accountability refers to the ways in which the family ensures that roles are fulfilled 
(Epstein et al., 2003). An example is the task of taking out the trash, a part of the 
provision of resources area of family role functioning. The parents discussing amongst 
themselves who will be responsible for taking out the trash and deciding together that it 
will be their oldest son’s job to do so would be an example of role allocation. The use of 
a sticker chart to monitor whether or not the son has accomplished this task would be an 
example of role accountability. 
Most effective functioning occurs when all of the family functions have been 
clearly allocated to the appropriate family member(s) and when accountability is 
maintained (Epstein et al., 2003). Least effective functioning occurs when necessary 
family functions are unaddressed and when either allocation or accountability is not 
maintained (Epstein et al., 2003). 
Affective responsiveness. 
Affective responsiveness within the MMFF relates to the family’s range of 
emotional responses to stimuli, both in terms of quality and quantity (Epstein et al., 2003; 
Lebow & Stroud, 2011; Miller et al., 2000). The qualitative aspect refers to the ability of 
the family to respond with a spectrum of human emotions, as well as whether or not the 
emotion experienced matches the stimuli and/or context (Epstein et al., 2003). The 
quantitative aspect refers to the degree of affective response expressed, and ranges from 
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absence of response to over-responsiveness, with reasonable or expected responsiveness 
in the middle (Epstein et al., 2003). The MMFF identifies two groups of affect: welfare 
emotions (such as love, joy, and concern) and emergency emotions (such as sadness, fear, 
and anger; Epstein et al., 2003). 
Most effective functioning is defined as occurring when the family experiences a 
full range of qualitatively and quantitatively appropriate responses to stimuli. Least 
effective functioning occurs when only a narrow range of affect is experienced or when 
the amount and quality of affective responses are inappropriate for the context in which 
they occur (Epstein et al., 2003). 
Affective involvement. 
The MMFF defines affective involvement as the degree to which the family 
demonstrates interest in and values the activities and interests of individual family 
members (Epstein et al., 2003; Lebow & Stroud, 2011; Miller et al., 2000). This 
dimension focuses both on the amount of interest the family shows as well as the way(s) 
in which they demonstrate that interest (Epstein et al., 2003). The model identifies six 
types of affective involvement: lack of involvement, involvement devoid of feelings, 
narcissistic involvement, empathic involvement, overinvolvement, and symbiotic 
involvement (Epstein et al., 2003). These types exist on a continuum, with ‘lack of 
involvement’ at one extreme and ‘symbiotic involvement’ at the other. 
‘Lack of involvement’ occurs when family members have no interest or 
investment in one another’s lives. ‘Involvement devoid of feelings’ is when family 
members have a purely intellectual interest in one another. ‘Narcissistic involvement’ 
occurs when a family member is only interested in another family member to the extent 
that the other member’s behavior reflects upon himself or herself. ‘Empathic 
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involvement’ takes place when family members’ interest in each other is for the sake of 
the other person. ‘Overinvolvement’ happens when family members show an excessive 
amount of interest in one another. Finally, ‘symbiotic involvement’ occurs when family 
members are invested in one another to such an extreme and pathological extent that it is 
difficult to differentiate between the individual members of the family. Empathic 
involvement is thought to contribute to most effective functioning in this dimension, with 
symbiotic involvement and absence of involvement leading to least effective functioning 
(Epstein et al., 2003). 
Behavior control. 
The final dimension of family functioning within the MMFF, behavior control, is 
the pattern of standards and rules set by the family in order to handle the behavior of its 
members in a variety of situations (Epstein et al., 2003; Lebow & Stroud, 2011; Miller et 
al., 2000). These situations are grouped into three types: physically dangerous situations, 
situations involving psychobiological needs, and situations that involve interpersonal 
socialization, both within and outside of the family (Epstein et al., 2003). Each of these 
types of situations may require different sets of standards and rules from the family. 
In addition to the standards and rules set by the family in these areas, the MMFF 
is also interested in the amount of latitude that the family allows relative to these 
standards and rules (Epstein et al., 2003). Included in the model are four styles of 
behavior control that vary in terms of standards and latitude: rigid behavior control, 
flexible behavior control, laissez-faire behavior control, and chaotic behavior control 
(Epstein et al., 2003). Rigid behavior control occurs when the family’s standards for 
behavior are quite narrow and specific and the family allows for very little variation or 
negotiation between situations. In flexible behavior control, the standards set by the 
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family are reasonable and may vary or be negotiable depending on the context or 
situation. With laissez-faire behavior control, the family holds no standards for the 
behavior of its members, allowing members complete latitude regardless of the situation. 
Finally, a chaotic behavior control style consists of a random and unpredictable 
vacillation between the three previous styles of behavior control, such that members of 
the family never know what to expect. Most effective functioning is associated with a 
flexible behavior control style and least effective functioning is associated with a chaotic 
behavior control style (Epstein et al., 2003). 
Family functioning in families of pediatric cancer survivors. 
Consideration of family functioning is crucial to a comprehensive understanding 
of the experience of survivors of pediatric ALL because childhood cancer is in many 
ways a family affair (Alderfer et al., 2009; Butler & Copeland, 2006). Although most 
parents of children diagnosed with cancer are resilient and demonstrate good coping after 
a period of significant, but transient, distress, a substantial portion (approximately 25-
30%) will experience increased or prolonged distress or psychopathology (Kearney, 
Salley, & Muriel, 2015). While rates of divorce do not appear to be any higher among 
parents of children with cancer than among the general population, parents of pediatric 
cancer patients are actually at greater risk for psychological difficulties than their children 
with cancer (Kazak et al., 2012; Syse, Loge, & Lyngstad, 2010). Siblings of pediatric 
cancer patients have been found to be at an increased risk for difficulties in emotional, 
social, and behavioral functioning (Gilleland et al., 2013). While severe psychopathology 
among siblings is rare and some siblings display no difficulties with psychosocial 
functioning, some siblings of pediatric cancer patients experience symptoms of anxiety 
and depression, poorer quality of life, and difficulties with academic and social 
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functioning (Gerhardt, Lehmann, Long, & Alderfer, 2015). Parents and siblings of 
pediatric cancer patients have also been found to demonstrate symptoms of post-
traumatic stress (Alderfer et al., 2010; Kaplan, Kaal, Bradley, & Alderfer, 2013). 
In addition to the challenges faced by each individual family member, a diagnosis 
of a potentially terminal illness such as ALL in a child poses a significant challenge to the 
functioning of that child’s family as a whole (Alderfer et al., 2009). Many families 
demonstrate resiliency following pediatric cancer; however, a subset of families 
experience significant and long term difficulties with family functioning (Van Schoors, 
Caes, Verhofstadt, Goubert, & Alderfer, 2015). Families of children receiving cancer 
treatment have been found to demonstrate lower levels of functioning than families of 
children who have completed treatment, but even “off-treatment” families have been 
found to show evidence of long-term disruptions in family functioning (Alderfer et al., 
2009). In addition, the presence of neurocognitive late effects among pediatric cancer 
survivors has been found to be associated with increased levels of stress among parents of 
the survivors and decreased levels of family functioning (Hocking, Hobbie, Deatrick, 
Hardie, & Barakat, 2015; Patel et al., 2013). 
Research examining family functioning among adolescent survivors of childhood 
cancer and their families has found higher levels of self-reported difficulties in family 
functioning among this population (Alderfer et al., 2009). One study that used a self-
report measure of family functioning based on the MMFF found that 35-62% of 
adolescent survivors and 17-44% of their parents reported poor levels of family 
functioning in at least one of the six dimensions of the MMFF (Alderfer et al., 2009). In 
that study, almost half of the adolescent survivors, one fourth of their mothers, and one 
third of their fathers reported poor family functioning on four or more of the dimensions 
of family functioning included in the MMFF (Alderfer et al., 2009). These levels of self-
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reported difficulties with family functioning are much higher than are typically found 
among community samples, in which less than 10% report poor functioning on that many 
dimensions (Alderfer et al., 2009). This indicates that the six dimensions of family 
functioning included in the MMFF are very relevant areas to consider when working with 
survivors of childhood ALL and their families.  
Family functioning and neurocognitive late effects in TBI. 
Although the relationship between family functioning and neurocognitive 
functioning has not been studied among survivors of pediatric ALL, there is evidence 
from research on pediatric TBI that family variables, such as family functioning, may 
predict child neurocognitive outcomes following TBI (Hocking et al., 2011). Studies have 
found better family functioning to be positively associated with neurocognitive outcomes 
following pediatric TBI (Nadebaum et al., 2007). Researchers began investigating family 
influences on neurocognitive sequelae in pediatric TBI after it had been found that 
pediatric TBI has a negative impact on families (Taylor et al., 1999). It was thought that 
the negative impacts of TBI upon the family might in turn make it difficult for the family 
to adequately support the child’s recovery from TBI (Taylor et al., 1999). Supporting this 
notion, there has been evidence linking family stress and ineffective parenting practices 
within the clinical literature (Taylor et al., 1999). Furthermore, studies performed on 
animals showed that environmental influences affected recovery of function (Taylor et 
al., 1999). Therefore, researchers in the field of pediatric TBI hypothesized that the long-
term sequelae of pediatric TBI may be partially related to environmental factors such as 
family functioning (Taylor et al., 1999). As there have been no reviews or meta-analyses 
conducted on this literature to date, each study investigating the relationship between 
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family functioning and neurocognitive outcome following pediatric TBI will be examined 
individually. 
Yeates and colleagues (1997) examined the influence of injury severity and 
preinjury social environment on neurocognitive outcomes among children with severe 
TBI, moderate TBI, and a comparison group of children with orthopedic injuries (OI). 
They assessed premorbid child and family characteristics during a baseline assessment 
shortly after the children’s injuries and child neurocognitive functioning was assessed at 
baseline and approximately 6 and 12 months postinjury (Yeates et al., 1997). They used 
growth curve analysis to test three hypotheses regarding the influence of injury severity 
and pre-injury social environment on neurocognitive outcome (Yeates et al., 1997). The 
measures of pre-injury family environment, which were used a predictors of 
neurocognitive outcomes, included the Family Assessment Device (FAD), a measure of 
family functioning based upon the MMFF (Yeates et al., 1997). There were three 
measures of cognitive functioning chosen as dependent variables. The first was a prorated 
Performance Scale IQ (PIQ) derived from a short form of the Wechsler Intelligence Scale 
for Children – Third Edition (WISC-III), which was used as a measure of nonverbal skills 
that has been found to be sensitive to the acute effects of TBI in children. The second 
measure of cognitive functioning was the total raw score from the Developmental Test of 
Visual–Motor Integration (VMI), a drawing task that requires visuoperceptual, 
constructional, and graphomotor skills and has been shown to be sensitive to TBI in 
children. The final measure of cognitive functioning used was the total number of words 
recalled across five learning trials on a shortened, preliminary version of the children’s 
California Verbal Learning Test (CVLT), a word-list learning task that measures verbal 
memory skills. Total recall on the CVLT has been shown to discriminate between 
children with TBI and matched controls. 
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Yeates and colleagues (1997) found that the four family variables included in 
their analysis accounted for significant amounts of variance in each of their outcome 
measures, even after controlling for injury severity (group membership). In fact, the 
preinjury family environment accounted for a larger amount of variance in outcome at 12 
months post-injury than did injury severity. After controlling for injury severity and 
demographics, family environment accounted for as much as 25% of the variance in 
cognitive outcome following TBI.  
Furthermore, they found that family functioning moderated the effect of TBI in 
that children from families with above-average family functioning tended to experience a 
more rapid and complete recovery from TBI, while children from families with below-
average family functioning tended to experience a slower and less complete recovery. 
Specifically, below average family functioning was associated with lower amounts of 
cognitive improvement over the course of the first year postinjury and worse cognitive 
outcomes at 12-months post injury. For example, the difference between the severe TBI 
and the OI groups in total recall scores on the CVLT at 12-months postinjury was directly 
proportional to measured family functioning. For children whose FAD scores reflected 
above-average family functioning (i.e., scores were 1 standard deviation below the mean, 
as lower scores on the FAD reflect better family functioning), the group difference was 
only 2.69 words. However, for children whose FAD scores were reflective of below-
average family functioning (i.e., 1 standard deviation above the mean), the difference 
between the severe TBI and the OI groups was 9.23 words. Therefore, a difference of 2 
standard deviations on the FAD resulted in a more “than 1 standard deviation increase in 
the discrepancy between the OI and severe TBI groups” in memory functioning (Yeates 
et al., 1997, p. 626). 
 40 
The results of this study support the notion that family variables help to determine 
children’s neurocognitive functioning following TBI and that the child’s family 
environment moderates the impact of TBI (Yeates et al., 1997). Specifically, this study 
found that the deficits in memory functioning that are associated with severe TBI were 
cushioned by above-average family functioning and made worse by below-average 
family functioning (Yeates et al., 1997). Furthermore, their finding that environmental 
measures such as family functioning accounted for at least as much, or more, variance in 
level of neurocognitive outcome than did measures of injury severity suggests that the 
child’s eventual neurocognitive functioning following a TBI depends as much, if not 
more, on environmental influences than on injury-related variables (Yeates et al., 1997). 
In a later report on findings extending this research by Yeates and colleagues, 
Taylor et al. (1999) examined whether postinjury family environment was related to 
concurrent child outcomes in TBI. They looked at three aspects of the family 
environment: family dysfunction, parental psychological distress, and injury-related 
family burden (Taylor et al., 1999). They assessed patients at baseline (shortly after 
injury), at 6 months postbaseline, and at 12 months postbaseline (Taylor et al., 1999). 
There were three groups of children included in the study: children with severe TBI, 
children with moderate TBI, and children with an orthopedic injury not involving insult 
to the CNS (Taylor et al., 1999). The orthopedic group was included in order to control 
for possible confounding variables such as proneness to accidents, the experience of 
hospitalization, and practice effects from repeated testing, as well as to examine possible 
differential consequences of TBI as opposed to non-CNS related injury (Taylor et al., 
1999). As with the previous report, the measure of family functioning used in this study 
was the General Functioning scale of the FAD (Taylor et al., 1999). However, a much 
more comprehensive neurocognitive test battery was administered to the patients in this 
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aspect of the study. The specific domains examined included global cognitive ability, 
language skills, perceptual-motor skills, memory, attention, academic achievement, 
school performance, behavior problems, child competence, and adaptive behavior. 
They examined the influence of post-injury family status at the 6- and 12-month 
follow-ups on concurrent child outcomes via hierarchical linear regression (Taylor et al., 
1999). This study found that these post-injury measures of family function were 
associated with concurrent child outcomes at both the 6- and 12-month follow-ups 
(Taylor et al., 1999). Higher levels of concurrent family functioning were associated with 
better child functioning, even after controlling for injury severity and pre-injury family 
functioning (Taylor et al., 1999). Furthermore, they found an interaction between group 
contrasts and family functioning, such that the group effect of severe TBI vs. orthopedic 
group interacted with the FAD-GF in predicting verbal memory, math skills, and teacher 
ratings of academic performance (Taylor et al., 1999). Specifically, this study found that 
the differences in outcomes between severe TBI and orthopedic injury in these domains 
were more pronounced in children from families with higher levels of dysfunction at both 
6- and 12-months post baseline (Taylor et al., 1999).  
Other studies have also found support for a link between family functioning and 
memory functioning among pediatric TBI patients. Max and colleagues used the 
McMaster Structured Interview of Family Functioning (Mc-SIFF), a clinical research 
interview based upon the MMFF, to assess family functioning (Max et al., 1999). The 
Mc-SIFF is used in order to obtain scores on a rating scale named the Clinical Rating 
Scale (CRS), which contains seven items corresponding to the seven domains of family 
functioning included in the MMFF (Max et al., 1999). They utilized the global score from 
the CRS in their analyses (Max et al., 1999). Max and colleagues (1999) assessed 
intellectual and memory functioning among children with severe traumatic brain injuries, 
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mild traumatic brain injuries, and orthopedic injuries using the WISC-R and the 
WRAML. Specifically, they used a prorated PIQ score, a prorated VIQ score, and a FIQ 
score from a short form of the WISC-R and a Verbal Memory Index and Visual Memory 
Index from the WRAML in their analyses. Max and colleagues began with eight 
independent variables: family psychiatric history, duration of impaired consciousness, 
family functioning, lowest post-resuscitation score on the Glasgow Coma Scale (a 
measure of responsiveness to stimuli following a TBI), neurological exam, “novel” post-
injury psychiatric disorder, pre-injury psychiatric disorder, and socioeconomic status 
(Max et al., 1999). 
The researchers found that intellectual and memory function outcome in pediatric 
brain injury was significantly related to a Psychosocial Disadvantage Factor that included 
family dysfunction (Max et al., 1999). Notably, this study found that family functioning, 
together with family psychiatric history, added significantly to SES in explaining 
cognitive outcomes two years after injury. While causation certainly could not be inferred 
from this cross-sectional study, the results do suggest that psychosocial disadvantage 
factors such as poor family functioning influence children’s cognitive outcomes from 
TBI (Max et al., 1999). This study supported the findings of Yeates et al. and Taylor et 
al., and added findings related to family functioning having an effect on general 
intellectual functioning after pediatric brain injury as well. 
A more recent study found similar results in the domains of attention/executive 
functioning. Nadebaum and colleagues investigated long-term attention/executive 
functioning among survivors of pediatric TBI (Nadebaum et al., 2007). Their study 
consisted of 54 children who had sustained a TBI and 17 healthy control subjects who 
were selected to match the TBI group as closely as possible in terms of age, gender, SES, 
and pre-injury abilities (Nadebaum et al., 2007). Family functioning was assessed using 
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the Family Functioning Questionnaire (FFQ), which parents completed at baseline and 
five years post-injury (Nadebaum et al., 2007). They used four cognitive measures to 
assess the various subcomponents of EF included in Anderson’s model (Anderson, 2002). 
These included Sky Search from the Test of Everyday Attention for Children (TEA-Ch) 
for attentional control (sustained attention), Score DT from the TEA-Ch for cognitive 
flexibility (divided attention), Block Design from the Wechsler Intelligence Scales for 
Children-III (WISC-III) for goal setting (organization and perceptual reasoning), and the 
Processing Speed Index from the WISC-III (a composite of the Coding and Symbol 
Search subtests) for information processing (efficiency and speed of information 
processing). They also administered the Parent Form of the Behavior Rating Inventory of 
Executive Function (BRIEF), a rating scale that measures behavioral manifestations of 
executive dysfunction. The BRIEF was administered at baseline and five years post-
injury, whereas the cognitive measures were only administered five years post-injury. 
As with Taylor et al. (1999), Nadebaum and colleagues (2007) utilized 
hierarchical linear multiple regression analyses to identify factors that predicted EF 
outcome. They found that pre-injury family functioning was a significant predictor of 
Processing Speed Index scores, with higher scores associated with higher levels of family 
functioning. Family functioning also significantly predicted overall EF outcome 
(performance on the composite measure of EF), with better pre-injury family functioning 
again associated with better outcomes. 
Summary.  
Using different measures of family functioning, researchers have identified a 
protective influence on children’s immediate and longer-term recovery from traumatic 
brain injury. Pre-injury family functioning, as reported at the time of injury, explained 
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significant amounts of variance in executive functioning, memory, and intellectual 
outcomes at 6- and 12-months as well as 2- and 5-years postinjury (Max et al., 1999; 
Nadebaum et al., 2007; Yeates et al., 1997). Concurrent family functioning was also 
found to explain significant amounts of variance in memory and academic achievement at 
6- and 12-months postinjury (Taylor et al., 1999). One interpretation of the findings of 
these studies is that the neurocognitive effects of TBI make these children more 
vulnerable to family influences than their peers who have not sustained a head injury 
(Taylor et al., 1999). Also, it could be that families with higher levels of dysfunction lack 
the ability to adequately support the child’s recovery from TBI, such that the child does 
not have enough opportunity or motivation necessary to perform the practice of cognitive 
skills that is necessary for a more complete neurocognitive recovery from TBI (Taylor et 
al., 1999). Another interpretation is that a positive family environment actually facilitates 
neural recovery (Taylor et al., 1999). This hypothesis has been supported in studies with 
animals, but has little empirical support to date from studies of human recovery of 
function (Taylor et al., 1999). 
Family functioning and neurocognitive late effects in pediatric brain tumors.  
In one of the only studies to examine the impact of family functioning on 
neurocognitive functioning among pediatric cancer patients, Carlson-Green and 
colleagues investigated the ability of family measures to predict the cognitive functioning 
of 63 children being treated for brain tumors (Carlson-Green et al., 1995). They used 
hierarchical multiple regression to determine whether or not family variables improved 
prediction of child outcomes over and above illness variables and covariates. Illness 
variables included measures of neurological symptoms and treatment severity. Family 
predictors included the total scale score from the Coping Health Inventory for Parents 
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(CHIP) as a measure of maternal coping resources, the total family stress score from the 
Family Inventory of Life Events (FILE) as a measure of family stressors, and the 
Cohesion and Control scales from the Family Environment Scale (FES) as measures of 
the family environment. Cognitive outcome variables included the Composite Standard 
Score from the Stanford-Binet Intelligence Scale: Fourth Edition as a measure of 
intelligence and the average standard score across reading, spelling, and arithmetic on the 
Wide Range Achievement Test – Revised (WRAT-R) as a measure of achievement. The 
covariates included in the model were time since diagnosis, SES, age at diagnosis, and 
parental marital status. In terms of cognitive outcomes, they found that family variables 
did explain a significant amount of variance in child intellectual outcome, with the most 
parsimonious model including both family (maternal coping resources) and illness 
(treatment severity) measures, as well as covariate measures (time since diagnosis, SES, 
and marital status). Family variables did not account for any additional variance above 
illness factors in predicting child achievement outcomes.  
Ach and colleagues examined the relationship between family functioning and 
academic achievement among pediatric brain tumor survivors (Ach et al., 2012). They 
administered the Wide Range Achievement Test – Third Edition (WRAT-3), a 
demographic data form, and the FES to pediatric brain tumor survivors between the ages 
of 8 and 15 who were 1 to 5 years posttreatment as well as classmate controls who were 
matched for age, gender, and race. They found that survivors from families with lower 
levels of support and higher levels of conflict demonstrated deficits in achievement 
relative to the classmate-controls across the domains of reading, spelling, and arithmetic, 
even after controlling for age at diagnosis, time since treatment, and type of treatment. 
The authors speculated that families with higher levels of support and lower levels of 
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conflict may devote more time and attention to helping survivors develop academic 
skills, allowing them to overcome neurocognitive late effects from treatment. 
A recent study examined the relationship between family functioning and 
neurocognitive functioning among young-adult aged survivors of pediatric brain tumor, 
as well as the role of family functioning in mediating the association between 
neurocognitive functioning and health-related quality of life (HRQOL) among this 
population (Hocking et al., 2015). Neurocognitive functioning was assessed using the 
Wechsler Adult Intelligence Scaled – Fourth Edition (WAIS-IV) Working Memory Index 
as a measure of auditory working memory, the WAIS-IV Processing Speed Index as a 
measure of processing speed, the California Verbal Learning Test – Second Edition Short 
Form (CVLT-II SF) long delay recall z-score as a measure of auditory verbal memory, 
and the Delis-Kaplan Executive Function System (D-KEFS) Trail Making Test switching 
task scaled score and Tower Test scaled achievement score as measures of executive 
functioning. They assessed survivor- and mother-reported family functioning using the 
Family Assessment Device General Functioning Scale (FAD GFS) and mother-reported 
family functioning using the PedsQL Family Impact Module (PedsQL FIM) Family 
Functioning scale score. Mothers of survivors completed the Pediatric Oncology Quality 
of Life Scale (POQOLS) as a proxy-report measure of survivor HRQOL.  
Correlational analyses indicated that worse processing speed, working memory, 
verbal memory, and executive functioning were significantly associated with worse 
survivor- and mother-reported family functioning. Further, bootstrapping analyses 
indicated that neurocognitive variables had an indirect effect on survivor HRQOL 
through mother-reported family functioning as measured by the PedsQL FIM. However, 
mother-reported family functioning on the FAD GFS did not support the indirect effects 
of the neurocognitive variables on survivor HRQOL. Survivor-reported FAD GFS scores 
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were not included in bootstrapping analyses, as they were not found to be related to 
HRQOL in correlational analyses. Results of this study indicate that survivors of 
pediatric brain tumor with greater neurocognitive late effects report greater difficulties 
with family functioning, as do the mothers of these survivors. This study provides 
support for the connection between family functioning and neurocognitive functioning 
among survivors of pediatric cancer and supports the rationale for the importance of the 
family context when considering neurocognitive late effects of pediatric cancer treatment.   
Summary.  
In summary, research from the fields of pediatric traumatic brain injury and 
pediatric brain tumors has shown that psychosocial variables such as family functioning 
moderate neurocognitive outcomes among these populations (Ach et al., 2013; Carlson-
Green et al., 1995; Max et al., 1999; Nadebaum et al., 2007; Taylor et al., 1999; Yeates et 
al., 1997). Specifically, positive family functioning has been found to serve as a 
protective factor against the development of neurocognitive deficits in areas of 
neurocognitive functioning typically affected by TBI and brain tumors. This phenomenon 
has not yet been studied among survivors of pediatric ALL. 
Statement of the Problem 
Some variables that seem to moderate neurocognitive outcome among survivors 
of pediatric ALL treated with chemotherapy-only have been identified, including gender, 
age at diagnosis, time since diagnosis, and socioeconomic status (Brouwers, 2005; Buizer 
et al., 2009; Moleski, 2000; Mulhern & Palmer, 2003; Patel & Carlson-Green, 2005; 
Peterson et al., 2008; Stehbens et al., 1994; Waber et al., 2012; Winick, 2011). However, 
much less is known about potential psychosocial moderators such as family functioning 
(Anderson & Kunin-Batson, 2009; Patel & Carlson-Green, 2005). Evidence from the 
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pediatric traumatic brain injury and pediatric brain tumor populations suggests that 
positive family functioning serves as a protective factor for neurocognitive outcomes of 
children who survive these conditions (Ach et al., 2013; Carlson-Green et al., 1995; Max 
et al., 1999; Nadebaum et al., 2007; Taylor et al., 1999; Yeates et al., 1997). No known 
research has been completed to investigate whether positive family functioning similarly 
moderates the effects of CNS-directed chemotherapy on the neurocognitive functioning 
of survivors of pediatric ALL. Identification of all possible protective factors for 
neurocognitive outcomes among survivors of pediatric ALL is necessary in order to 
design, research, and implement effective interventions in an effort to decrease the 
prevalence of neurocognitive late effects among this population. 
Statement of Purpose 
The purpose of this study was to examine the effect of family functioning upon 
neurocognitive outcome among survivors of pediatric ALL treated with chemotherapy. 
Specifically, the study sought to determine if positive family functioning serves as a 
protective factor against the neurocognitive deficits commonly seen in this population. 
Based upon a multidimensional model of attention and Anderson’s model of executive 
function (EF), four subcomponents of attention and four subcomponents of EF were 
examined (Anderson, 2002). The attention subcomponents were: selective, divided, 
sustained, and shifting. The EF subcomponents were: cognitive flexibility (working 
memory), goal setting (planning), attentional control (inhibition), and information 
processing (processing speed). In addition, caregiver report of the child’s attention and 
EF was examined as well. It was hypothesized that family functioning would add to such 
moderating factors as age at diagnosis, gender, time since diagnosis, and SES in 
predicting neurocognitive outcome in the domains listed above. 
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Research Questions, Hypotheses, and Rationale 
Research question 1. 
Does positive family functioning protect against deficits in attention among 
survivors of pediatric ALL, specifically in the subdomains of selective attention, divided 
attention, sustained attention, and shifting attention, and as reported by caregivers?  
Hypothesis 1a. 
Family functioning is expected to moderate the impact of group membership 
(survivor vs. healthy control) on performance on a task of selective attention. 
Furthermore, differences in family functioning will account for a significant amount of 
the variance in performance on a task of selective attention for survivors of pediatric ALL 
but not for healthy controls. 
Hypothesis 1b. 
Family functioning is expected to moderate the impact of group membership 
(survivor vs. healthy control) on performance on a task of divided attention. Furthermore, 
differences in family functioning will account for a significant amount of the variance in 
performance on a task of divided attention for survivors of pediatric ALL but not for 
healthy controls. 
Hypothesis 1c. 
Family functioning is expected to moderate the impact of group membership 
(survivor vs. healthy control) on performance on a task of sustained attention. 
Furthermore, differences in family functioning will account for a significant amount of 
the variance in performance on a task of sustained attention for survivors of pediatric 
ALL but not for healthy controls. 
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Hypothesis 1d. 
Family functioning is expected to moderate the impact of group membership 
(survivor vs. healthy control) on performance on a task of shifting attention. Furthermore, 
differences in family functioning will account for a significant amount of the variance in 
performance on a task of shifting attention for survivors of pediatric ALL but not for 
healthy controls.  
Hypothesis 1e. 
Family functioning is expected to moderate the impact of group membership 
(survivor vs. healthy control) on scores on caregiver ratings of attention. Furthermore, 
differences in family functioning will account for a significant amount of the variance in 
scores on caregiver ratings of inattention for survivors of pediatric ALL but not for 
healthy controls.  
Rationale. 
Survivors of pediatric ALL treated with chemotherapy have been found to have 
deficits in selective, divided, sustained, and shifting attention and in caregiver ratings of 
attention (Anderson & Kunin-Batson, 2009; Ashford et al., 2010; Bisen-Hersh et al., 
2011; Butler & Copeland, 2002; Carey et al., 2008; Harila et al., 2009; Kingma et al., 
2002; Lesnik et al, 1998; Reddick et al., 2006). Family functioning has been found to 
moderate neurocognitive outcome in survivors of pediatric traumatic brain injury and 
brain tumor in domains sensitive to insult in those populations (Carlson-Green et al., 
1995; Max et al., 1999; Nadebaum et al., 2007; Taylor et al., 1999; Yeates et al., 1997). It 
is expected that family functioning will similarly moderate neurocognitive outcomes in 
the ALL population in attention, a domain sensitive to insult in this population. 
Furthermore, it is expected that positive family functioning will serve as a protective 
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factor against the development of attention problems among survivors of pediatric ALL. 
It is thought that higher functioning families may be better able to manage survivors’ 
neurocognitive late effects, for example, by providing opportunities for the survivor to 
practice and strengthen the attentional skills that have been negatively impacted by the 
chemotherapy treatment. In alignment with Rose and colleagues’ conceptualization of 
protective factors as operating only in instances of adversity, it is expected that children 
in the healthy control group, who have not been exposed to adversity in the form of CNS 
prophylaxis, will not demonstrate the same relationship between family functioning and 
performance on measures of attention (Rose, Holmbeck, Coakley, & Franks, 2004). 
Research question 2. 
Does positive family functioning protect against deficits in executive functioning 
among survivors of pediatric ALL, specifically in the subdomains (areas) of cognitive 
flexibility (working memory), goal setting (planning), attentional control (inhibition), 
information processing (processing speed) and as reported by caregivers? 
Hypothesis 2a.  
Family functioning is expected to moderate the impact of group membership 
(survivor vs. healthy control) on performance on a task of cognitive flexibility (working 
memory). Furthermore, differences in family functioning will account for a significant 
amount of the variance in performance on a task of cognitive flexibility (working 
memory) for survivors of pediatric ALL but not for healthy controls. 
Hypothesis 2b.  
Family functioning is expected to moderate the impact of group membership 
(survivor vs. healthy control) on performance on a task of goal setting (planning). 
Furthermore, differences in family functioning will account for a significant amount of 
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the variance in performance on a task of goal setting (planning) for survivors of pediatric 
ALL but not for healthy controls.  
Hypothesis 2c.  
Family functioning is expected to moderate the impact of group membership 
(survivor vs. healthy control) on performance on a task of attentional control (inhibition). 
Furthermore, differences in family functioning will account for a significant amount of 
the variance in performance on a task of attentional control (inhibition) for survivors of 
pediatric ALL but not for healthy controls.  
Hypothesis 2d.  
Family functioning is expected to moderate the impact of group membership 
(survivor vs. healthy control) on performance on a task of information processing 
(processing speed). Furthermore, differences in family functioning will account for a 
significant amount of the variance in performance on a task of information processing 
(processing speed) for survivors of pediatric ALL but not for healthy controls. 
Hypothesis 2e.  
Family functioning is expected to moderate the impact of group membership 
(survivor vs. healthy control) on scores on caregiver ratings of an aspect of executive 
functioning (behavioral regulation). Furthermore, differences in family functioning will 
account for a significant amount of the variance in scores on caregiver ratings of 
behavioral regulation for survivors of pediatric ALL but not for healthy controls. 
Hypothesis 2f.  
Family functioning is expected to moderate the impact of group membership 
(survivor vs. healthy control) on scores on caregiver ratings of another aspect of 
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executive functioning (metacognition). Furthermore, differences in family functioning 
will account for a significant amount of variance in scores on caregiver ratings of 
metacognition for survivors of pediatric ALL but not for healthy controls. 
Rationale.  
Survivors of pediatric ALL treated with chemotherapy have been found to have 
deficits in executive functioning, including working memory, inhibition, processing 
speed, and planning, and on caregiver ratings of executive functioning (Ashford et al., 
2010; Buizer et al., 2009; Harila et al., 2009; Jansen et al., 2008; Kingma et al., 2002; 
Lesnik et al., 1998; Waber et al., 1995). Family functioning has been found to moderate 
neurocognitive outcome in survivors of pediatric traumatic brain injury in the domain of 
executive functioning (Nadebaum et al., 2007). It is expected that a similar moderating 
effect of family functioning on executive functioning will exist among the ALL 
population. Moreover, it is expected that positive family functioning will serve as a 
protective factor against the development of deficits in executive functioning among 
survivors of pediatric ALL. As such, it is expected that children in the healthy control 
group, who have not been exposed to adversity in the form of CNS prophylaxis, will not 
demonstrate the same relationship between family functioning and performance on 
measures of attention (Rose et al., 2004). 
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Chapter 3: Method 
Participants 
Participants were 20 children and adolescents who had completed chemotherapy-
only treatment for ALL and 20 healthy control participants, as well as one parent or 
guardian for each youth participant, equaling a total of 40 dyads of children and their 
caregivers (N = 40 caregiver/child dyads). All youth participants were within the ages of 
8 and 16.  
For the experimental group in this study, the following inclusion criteria applied: 
(i) aged 8 years 0 months through 15 years 11 months throughout the length of the study, 
(ii) two years post-treatment and designated as a survivor of pediatric ALL by the 
Survivorship Center at the Children’s Blood and Cancer Center (CBCC) at Dell 
Children’s Medical Center (DCMC), and (iii) English-speaking. English language was 
required because most of the standardized measures used in this study were only in 
English and were not validated in other languages. Individuals meeting school criteria as 
having a visual or auditory impairment or attention difficulties such as attention-
deficit/hyperactivity disorder (ADHD) prior to their cancer diagnosis were excluded from 
the study. Additionally, individuals who underwent a bone marrow transplant or cranial 
radiation therapy, had a recurrence of cancer, or who had impaired global cognitive 
functioning (e.g. intellectual disability) were not included in this investigation. 
For the control group, the following inclusion criteria applied: (iii) aged 8 years 0 
months through 15 years 11 months throughout the length of the study and (iv) English-
speaking. Individuals meeting school criteria as having a visual or auditory impairment or 
attention difficulties such as attention-deficit/hyperactivity disorder (ADHD) and those 
with impaired global cognitive functioning (e.g., intellectual disability) were not included 
in this study.  
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The mean age for the overall sample was 11.36 (SD = 2.32, Range = 8.01-15.83). 
The mean age for the experimental group was 12.11 (SD = 2.47, Range = 8.36-15.83), 
while the mean age for the control group was 10.62 (SD = 1.93, Range = 8.01-13.72). 
There was a significant difference in the mean ages of the two groups, such that mean age 
for the experimental group was significantly higher than the mean age for the control 
group (t [38, 2]= -2.128, p = .04). In the experimental group, the mean age at diagnosis 
was 4.22 (SD = 2.44, Range = 1.32-10.01) and the mean time since treatment was 5.27 
years (SD = 2.09, Range = 2.62-10.32). Additional demographic characteristics for the 
sample appear in the next chapter. 
Instrumentation 
Youth participants were administered measures of attention and executive 
functioning, and parent/guardians completed questionnaires about their child’s attention 
and executive functioning and their family’s functioning.  
Attention measures. 
Test of Everyday Attention – Children’s Version (TEA-Ch). The Test of Everyday 
Attention for Children (TEA-Ch; Manly, Robertson, Anderson, & Nimmo-Smith, 1999) 
is a children’s adaptation of the adult Test of Everyday Attention (TEA). It has been used 
in research with males with Fragile X syndrome, girls with Turner’s syndrome, and 
children with head injury, ADHD, and learning disabilities (Baron, 2004). The full TEA-
Ch is comprised of 9 subtests and a full administration takes approximately 1 hour. 
However, there is also a four-subtest screener version that takes 20-25 minutes to 
administer and assesses each of the four dimensions of attention (selective, divided, 
sustained, and shifting). The normative sample for the TEA-Ch included 293 Australian 
children and adolescents between the ages of 6 years, 7 months and 15 years, 11 months 
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and included equal numbers of males and females. The sample was divided into six age 
bands, with 29 to 58 children in each age band. Reported test-retest reliabilities for the 
TEA-Ch range from .57 to .87, with percentage agreement values ranging from 71% to 
76% (Manly et al, 1999). A structural equation modeling study involving the normative 
sample resulted in a three-factor model of sustained attention, attentional 
control/switching, and selective attention (Manly et al., 2001). 
The four-subtest screener version of the TEA-Ch was used in this study to assess 
the four subdomains of attention described previously. The specific subtests that were 
administered are: Sky Search, Score!, Creature Counting, and Sky Search DT. Sky 
Search is a measure of selective attention that requires the subject to filter information in 
order to detect relevant information while rejecting or inhibiting distracting information 
(Baron, 2004; Manly et al., 1999). The reported test-retest correlation coefficient from the 
normative sample for this subtest was 0.75. In the normative sample, scores on Sky 
Search demonstrated low levels of correlation with scores on subtests of an IQ test (p > 
.01, p < .001 required for statistical significance when full correction for multiple 
comparison was used), suggesting discriminant validity (Manly et al., 2001). Sky Search 
correlated with a different measure of selective attention (Stroop task, p < .001). There 
are three scores available for this subtest: an accuracy score, a timing score, and an 
overall attention score. For the purposes of this study, the attention score was used to 
measure selective attention.  
Score! is a measure of sustained attention that requires the subject to count tones 
played on an audio recording and report the correct number of tones at the end of each 
round (Baron, 2004; Manly et al., 1999). The reported percentage agreement from the 
normative sample for this subtest was 76.2%. Scores on this measure from the normative 
sample demonstrated low levels of correlation with scores on subtests of an IQ test (p > 
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.05; Manly et al., 2001). Creature Counting is a measure of shifting attention that requires 
the subject to count stimuli according to visual cues indicating for them to count either 
upwards or downwards (Baron, 2004; Manly et al., 1999). There are two scores available 
for this subtest: an accuracy score and a timing score. The accuracy score was used as a 
measure of shifting attention. The reported test-retest correlation coefficient from the 
normative sample for this measure was 0.71. When corrections for multiple correlations 
were performed, Creature Counting accuracy scores from the normative sample were not 
significantly correlated with scores on IQ measures (p > .001; Manly et al., 2001). Sky 
Search DT is a measure of divided attention that requires the subject to circle certain 
stimuli while also keeping count of auditory tones (Baron, 2004; Manly et al., 1999). The 
reported test-retest correlation coefficient from the normative sample for this subtest was 
0.81. Scores on Sky Search DT within the normative sample were not significantly 
correlated with scores on IQ measures (p > .01; Manly et al., 2001). 
Behavior Assessment System for Children – Second Edition (BASC-2). The 
Behavior Assessment System for Children – Second Edition (BASC-2; Reynolds & 
Kamphaus, 2004) is a comprehensive set of rating scales and forms that assess behavioral 
and emotional functioning of children and adolescents and includes teacher, parent, and 
self-report versions. There are various forms of each of the three versions for use with 
different age groups, ranging from 2 years old through college age. For this study, the 
child (ages 6 to 11) and adolescent (ages 12 to 21) forms of the Parent Rating Scales 
(PRS) were used. These scales contain a number of items (134-160) that describe specific 
patterns of behavior and are rated on a four-point frequency scale ranging from “never” 
to “almost always.” The child and adolescent forms of the BASC-2 PRS were each 
standardized on a sample of 1,800 individuals representative of the U.S. population in 
terms of socioeconomic status, race/ethnicity, and geographic region according to figures 
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from the March 2001 Current Population Survey. For the purposes of this study, the 
“Attention Problems” subscale from the PRS was used in assessing parental report of 
children’s attentional abilities. Reported coefficient alpha reliabilities from the normative 
sample for the attention problems scale on the child and adolescent forms of the PRS 
range from .85 to .88. Adjusted test-retest reliability coefficients for this scale are 0.81 for 
the adolescent form and 0.85 for the child form. 
Executive functioning measures. 
Delis-Kaplan Executive Function System (D-KEFS). The Delis-Kaplan Executive 
Function System (D-KEFS; Delis, Kaplan, & Kramer, 2001) is a standardized battery of 
tests that measure a variety of executive functions in people age 8 through 89 years. The 
D-KEFS was standardized on a nationally representative sample of 1750 people ages 8-
89 years. The sample was stratified in regards to age, sex, race/ethnicity, years of 
education, and geographic region using figures from the 2000 U.S. Census. For this 
study, the following two subtests of the D-KEFS were administered: the D-KEFS Tower 
Test and the D-KEFS Color-Word Interference Test. The D-KEFS Tower Test is a 
measure of planning (Baron, 2004; Delis et al., 2001). A number of scores are available 
for the Tower Test; for this study, the Total Achievement scaled score was used as a 
measure of planning. Reported internal consistency values for this measure for children 
ages 8-16 ranged from 0.43 to 0.84. The reported test-retest reliability coefficient for this 
age group was 0.51. The D-KEFS Color-Word Interference Test is a measure of 
inhibition (Baron, 2004; Delis et al., 2001). Again, a number of scores are available for 
the Color-Word Interference Test. The Trial 3: Inhibition time scaled score was used as a 
measure of inhibition. The reported test-retest reliability coefficient for this measure for 
children ages 8-16 was 0.90. 
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Wechsler Intelligence Scale for Children – Fourth Edition (WISC-IV). The 
Wechsler Intelligence Scale for Children – Fourth Edition (WISC-IV; Wechsler, 2003) is 
a widely used measure of cognitive ability. It is comprised of fifteen subtests, ten in the 
core battery and five that are supplemental. It is designed for children age 6:0 through 
16:11 and takes 65 to 80 minutes to administer in full. The WISC-IV yields a measure of 
global cognitive ability, the Full Scale IQ (FSIQ), as well as four composite scores: the 
Verbal Comprehension Index (VCI), the Perceptual Reasoning Index (PRI), the Working 
Memory Index (WMI), and the Processing Speed Index (PSI). The WISC-IV was 
standardized on a nationally representative sample of 2,200 children, stratified according 
to March 2000 U.S. Census data along the variables of age, sex, race/ethnicity, parent 
education level, and geographic region. 
For the purposes of this study, four subtests of the WISC-IV were administered to 
participants. These are the Digit Span and Letter-Number Sequencing subtests, which 
together comprise the WMI, and the Symbol Search and Coding subtests, which together 
comprise the PSI. The WMI was used as a measure of working memory and the PSI was 
used as a measure of processing speed. Digit Span consists of two parts, Digit Span 
Forward (DSF) and Digit Span Backward (DSB). On DSF, the subject is required to 
repeat verbatim numbers presented to them orally. On DSB, the subject has to repeat 
numbers in the reverse order of that in which they are presented. Scores on these two 
components are combined to produce a total Digit Span scaled score. The reported 
overall average reliability coefficient from the normative sample for this subtest was 
0.87. Letter-Number Sequencing requires the subject to listen to strings of mixed 
numbers and letters and to repeat the string with numbers first, in numerical order, 
followed by letters in alphabetical order. The reported overall average reliability 
coefficient from the normative sample for this subtest was 0.90. Symbol Search requires 
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the subject to visually scan a group of stimuli and indicate whether or not a target 
stimulus is present. The reported overall average reliability coefficient from the 
normative sample for this subtest was 0.79. Coding requires the subject to copy symbols 
paired with shapes or numbers within a given time limit. The reported overall average 
reliability coefficient from the normative sample for this subtest was 0.85. 
Behavior Rating Inventory of Executive Function (BRIEF). The Behavior Rating 
Inventory of Executive Function (BRIEF; Gioia, Isquith, Guy, & Kenworthy, 2000) 
consists of two forms, a parent questionnaire and a teacher questionnaire. Each form 
consists of 86 items scored on a 3-point scale (Never, Sometimes, Often). It takes 
approximately 10 to 15 minutes to complete and can be used with children ages 5 to 18 
years. The BRIEF assess eight subdomains of executive function: inhibition, shifting, and 
emotional control, which together comprise a broader composite score called the 
Behavioral Regulation Index (BRI), and initiation, working memory, 
planning/organizing, organization of materials, and monitoring, which together comprise 
the Metacognition Index (MI) composite. The BRI and MI are then combined to produce 
the overall Global Executive Composite (GEC) score. For this study, the BRI from the 
parent form of the BRIEF was used as a measure of behavioral regulation as reported by 
parents and the MI from the parent form of the BRIEF was used as a measure of 
metacognition as reported by parents. The parent form of the BRIEF was standardized on 
a sample of 1,419 parents from urban, suburban, and rural areas of Maryland. The sample 
was representative of 1999 U.S. Census data in regards to gender, socioeconomic status, 
ethnicity, age, and geographical population density. The reported Cronbach’s  for the 
BRI on the Parent Form of the BRIEF is .94 and the reported test-retest reliability for the 
BRI is .84. The reported Cronbach’s  for the MI on the Parent Form of the BRIEF is .96 
and the reported test-retest reliability for the MI is .88.  
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Family functioning measure. 
Family Assessment Device (FAD). Family functioning was measured using the 
Family Assessment Device (FAD), a well-established self-report measure of family 
functioning based upon the McMaster Model of Family Functioning (MMFF). It consists 
of six scales representing the six dimensions of family functioning included in the 
MMFF, as well as a General Functioning Scale (GFS) that provides a measure of overall 
family functioning based upon the other six scales. The FAD consists of 60 items about 
families and asks the rater to indicate how much each item describe their family’s 
functioning on a 4-point Likert scale that ranges from strongly agree to strongly disagree. 
The FAD takes approximately 20 minutes to complete and can be administered to any 
family member over the age of 12. Higher scores on the scales of the FAD indicate 
higher levels of family dysfunction. It was administered to one adult from each family 
participating in the study. For the purposes of this study, the FAD GFS was used as a 
measure of overall family functioning. Kabacoff and colleagues conducted a study of the 
psychometric properties of the FAD among nonclinical (n = 627), psychiatric (n = 1,138) 
and medical (n = 298) samples (Kabacoff, Miller, Bishop, Epstein, & Keitner, 1990). 
Cronbach alphas for the GFS among these samples were .83, .84, and .86, respectively.   
Socioeconomic status. 
Socioeconomic status (SES) was determined for each patient using the median 
household income for the zip code in which they resided at the time of the study (U.S. 
Census Bureau, 2009-2013 5-Year American Community). These were then grouped into 
two groups: lower than the national median household income and higher than the 
median household income (Berkowitz, Traore, Singer, & Atlas, 2015).  
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Procedure 
Approval by human subjects committee. 
This study complied with ethical standards set forth by the American 
Psychological Association and the Institutional Review Board of the University of Texas 
at Austin. All research materials were approved prior to data collection by the 
Departmental Review Committee within the Department of Educational Psychology and 
by the Institutional Review Board (IRB) of The University of Texas at Austin. Each 
parent/guardian signed an IRB-approved consent form for their own participation as well 
as an IRB-approved form giving permission for their child to participate. Each youth 
participant signed a form of assent. The consent form can be found in Appendix A, the 
parent permission form can be found in Appendix B, and the youth assent form can be 
found in Appendix C.  
In addition, IRB approval was obtained to access an archival neuropsychological 
dataset of childhood cancer survivors who participated in a larger, ongoing study of 
cognitive remediation and cognitive skills training funded by the Hyundai Hope on 
Wheels Foundation.   
Recruitment of participants. 
Participants for the experimental group were recruited through the Survivorship 
Center at the CBCC at DCMC and the Texas Child Study Center (TCSC) Embedded 
Clinic within the CBCC. Children who had been designated by their treatment team at the 
CBCC as survivors of pediatric ALL and who met the inclusion criteria were invited to 
participate in the study. Recruitment of experimental participants occurred in one of two 
ways. First of all, at the end of a regularly scheduled medical clinic or embedded clinic 
visit, a clinic staff member gave prospective youth and parent/guardian participants a 
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flyer that described the study and eligibility criteria for inclusion. Potential 
parent/guardian participants notified the clinic staff worker if they were willing to be 
contacted by the primary investigator to learn more. The clinic worker then obtained 
verbal consent to release parent/guardian and child name and contact information to the 
primary investigator. Secondly, potential experimental group participants who were not 
scheduled for a medical or embedded clinic visit during the recruitment period of the 
study were contacted by the primary investigator via phone and invited to participate. In 
total, 24 individuals were identified through the CBCC that met study criteria and were 
subsequently given flyers or contacted by the primary investigator. Five of these 
individuals ultimately declined to participate, five were non-responsive to the 
investigator’s contact, three agreed to participate and scheduled appointments but then 
cancelled and were unable to be rescheduled, and one was excluded because he was 
overdue for a full neuropsychological evaluation. In addition, archival 
neuropsychological data for 10 childhood cancer survivors was obtained from the larger 
study mentioned above. Therefore, the total number of experimental group participants in 
the study was 20 caregiver/child dyads. 
Control participants were recruited through community advertisements. IRB-
approved advertisements were distributed to neighborhood, church, and school-related 
listserves. The advertisements contained contact information for the primary investigator 
and people interested in participating were asked to contact the primary investigator. In 
total, 23 individuals contacted the primary investigator. Three individuals ultimately 
declined to participate. Therefore, the total number of control group participants in the 
study was 20 caregiver/child dyads.  
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Consent. 
Participation in the study was voluntary and participants were able to discontinue 
participation at any time, for any reason. Parent/guardian participants received a copy of 
the consent form and had the chance to discuss any concerns with the researcher. Youth 
participants were given a copy of the assent form and an opportunity to discuss any 
concerns with the researcher. 
Data collection. 
Children who assented to participate in the study, whose parents/guardians gave 
consent for participation, and who met inclusion criteria were participants. Once 
informed consent and assent were obtained, the parent or guardian of the child scheduled 
an appointment with the principal investigator for the child to participate in a 
neuropsychological evaluation. Children in the survivorship group who were due for their 
initial neuropsychological evaluation upon entering survivorship or those who were due 
for a neuropsychological re-evaluation took part in the full neuropsychological evaluation 
given as part of their routine clinical care. The measures used as part of the current study 
were administered as part of these full neuropsychological evaluations.  Control 
participants and those survivors not due for evaluation or re-evaluation were administered 
a short neuropsychological battery comprised only of the measures being used as part of 
this investigation.  
Evaluations of experimental group participants took place in a quiet, private room 
either at the CBCC in the Specially for Children building at DCMC in Austin, Texas (n = 
14) or at the participant’s home (n = 6). Control participants’ evaluations took place in a 
quiet, private room either in the Sanchez Building at the University of Texas at Austin (n 
= 4) or at the participant’s home (n = 16). Parents of participants in both groups were 
provided with a quiet, private room in which to complete their measures. The children 
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engaged in a one-on-one neuropsychological evaluation with the principal investigator 
for approximately 60 minutes (research-only battery) or 330 minutes (full battery) while 
their parent/guardian completed parent forms (BRIEF, BASC, FAD). The children were 
allowed to take breaks as needed during the testing session. 
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Chapter 4: Results 
The purpose of this study was to examine the relations between family 
functioning and concurrent neurocognitive functioning among survivors of ALL treated 
with chemotherapy as opposed to a group of healthy controls. All statistical analyses 
were performed using SPSS (version 23.0). 
Preliminary Data Analysis 
Descriptive statistics.  
Demographic characteristics of the sample are presented in Table 1. Means, 
standard deviations, and ranges for the FAD GFS and all outcome variables are reported 
in Table 2. As part of initial data cleaning, two outliers were identified. These will be 
described in more detail below. Means, standard deviations, and ranges for variables of 
interest with outliers removed are reported in Table 3. Demographic characteristics of the 
sample without the outliers are presented in Table 4. A correlation coefficient matrix was 
completed to determine correlations between FAD GFS and all variables of interest, 
including group membership, gender, SES, age at diagnosis, time since treatment, and all 
outcome variables. The correlation matrix of all variables with outliers included is 
displayed in Table 5. The correlation matrix of all variables without outliers is in Table 6.  
Table 1.  
Sample Demographic Characteristics.  
  Clinical Group Control Group Total Group 
  Count % Count % Count % 
SES Lower SES 7 35.0% 4 20.0% 11 27.5% 
Higher SES 13 65.0% 16 80.0% 29 72.5% 
Gender Male 12 60.0% 8 40.0% 20 50.0% 
Female 8 40.0% 12 60.0% 20 50.0% 
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Table 2. 
Sample Performance on Outcome Measures 
 Clinical Group (n = 20) Control Group (n = 20) Total Sample (N = 40) 
 M (SD) Range M (SD) Range M (SD) Range 
Sky Searcha 8.95 (3.00) 2-16 9.90 (1.97) 7-13 9.42 (2.55) 2-16 
Sky Search DTa 6.10 (3.97) 1-12 8.20 (3.78) 1-19 7.15 (3.97) 1-19 
Score!a 8.00 (3.39) 1-14 10.25 (3.01) 3-15 9.13 (3.36) 1-15 
Creature Countinga 8.20 (3.22) 3-14 10.55 (2.33) 6-14 9.37 (3.02) 3-14 
Attention Problemsb 54.65 (10.49) 35-73 46.00 (7.95) 35-61 50.33 (10.18) 35-73 
Working Memory Indexc 93.45 (15.22) 68-129 103.90 (10.62) 88-126 98.67 (13.99) 68-129 
Towera 10.00 (2.13) 7-14 10.65 (2.13) 8-16 10.33 (2.13) 7-16 
Inhibitiona 9.90 (3.54) 1-15 10.25 (2.69) 4-14 10.07 (3.11) 1-15 
Processing Speed Indexc 91.75 (15.94) 59-115 104.20 (10.77) 85-121 97.98 (14.83) 59-121 
Behavioral Regulation Indexb 52.20 (8.85) 37-76 45.35 (6.24) 35-59 48.78 (8.32) 35-76 
Metacognition Indexb 57.05 (10.99) 37-77 47.50 (8.99) 35-67 52.27 (11.03) 35-77 
FAD GFSd 1.86 (0.58) 1.00-3.42 1.49 (0.27) 1.00-1.92 1.67 (0.48) 1.00-3.42 
a Sky Search, Score!, Creature Counting, Sky Search DT, Inhibition, and Tower: scores are scaled scores, with a mean of 10 
and a standard deviation of 3. Higher scores indicate better performance. b Attention Problems, Behavioral Regulation Index, 
and Metacognition Index: scores are T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate more 
difficulties in that domain. c Working Memory Index, Processing Speed Index: scores are standard scores, with a mean of 100 
and a standard deviation of 15. Higher scores indicate better performance. d Family Assessment Device (FAD) General 
Functioning Scale (GFS): higher scores indicate more difficulties with family functioning. 
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Table 3. 
Sample Performance on Outcome Measures without Outliers 
 Clinical Group (n = 18) Control Group (n = 20) Total Sample (N = 38) 
 M (SD) Range M (SD) Range M (SD) Range 
Sky Searcha 8.50 (2.62) 2-13 9.90 (1.97) 7-13 9.24 (2.38) 2-13 
Sky Search DTa 6.06 (4.17) 1-12 8.20 (3.78) 1-19 7.18 (4.06) 1-19 
Score!a 8.22 (3.49) 1-14 10.25 (3.01) 3-15 9.29 (3.36) 1-15 
Creature Countinga 8.28 (3.39) 3-14 10.55 (2.33) 6-14 9.47 (3.07) 3-14 
Attention Problemsb 52.78 (9.26) 35-70 46.00 (7.95) 35-61 49.21 (9.14) 35-70 
Working Memory Indexc 94.06 (15.97) 68-129 103.90 (10.62) 88-126 99.24 (14.14) 68-129 
Towera 10.11 (2.22) 7-14 10.65 (2.13) 8-16 10.39 (2.16) 7-16 
Inhibitiona 10.17 (3.54) 1-15 10.25 (2.69) 4-14 10.21 (3.08) 1-15 
Processing Speed Indexc 92.56 (16.33) 59-115 104.20 (10.77) 85-121 98.68 (14.72) 59-121 
Behavioral Regulation Indexb 51.33 (7.04) 37-62 45.35 (6.24) 35-59 48.18 (7.20) 35-62 
Metacognition Indexb 55.11 (9.72) 37-73 47.50 (8.99) 35-67 51.11 (9.99) 35-73 
FAD GFSd 1.77 (.47) 1.00-2.75 1.49 (0.27) 1.00-1.92 1.62 (.40) 1.00-2.75 
a Sky Search, Score!, Creature Counting, Sky Search DT, Inhibition, and Tower: scores are scaled scores, with a mean of 10 
and a standard deviation of 3. Higher scores indicate better performance. b Attention Problems, Behavioral Regulation Index, 
and Metacognition Index: scores are T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate more 
difficulties in that domain. c Working Memory Index, Processing Speed Index: scores are standard scores, with a mean of 100 
and a standard deviation of 15. Higher scores indicate better performance. d Family Assessment Device (FAD) General 
Functioning Scale (GFS): higher scores indicate more difficulties with family functioning. 
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Table 4.  
Sample Demographic Characteristics without Outliers  
  Clinical Group Control Group Total Group 
  Count % Count % Count % 
SES Lower SES 7 38.9% 4 20.0% 11 28.9% 
Higher SES 11 61.1% 16 80.0% 27 71.1% 
Gender Male 10 55.6% 8 40.0% 18 47.4% 
Female 8 44.4% 12 60.0% 20 52.6% 
Assumptions for statistics used in main analyses.  
The data were examined for violation of assumptions required for multiple 
regression statistical procedures. Data were checked for outliers. As mentioned above, 
two outliers were identified. One participant’s score on the Behavioral Regulation Index 
was 3.27 standard deviations above the mean. A different participant’s score on the FAD 
GFS was 3.64 standard deviations above the mean. Analyses were conducted with and 
without these participants included and results for each are presented below. Analyses 
were also conducted with the outliers transformed (Behavioral Regulation Index was 
transformed with a square root transformation and FAD GFS was transformed with a 
log10 transformation). The results of the analyses using the transformed variables were 
consistent with the results of the analyses using the variables without transformation. The 
results using the variables without transformations are presented below.  
Normal distribution of residuals was confirmed using a p-p plot of observed and 
expected values. Residual scatterplots revealed that the assumptions of normality, 
linearity, and homoscedasticity were all satisfied. The independence of residuals was 
confirmed using the Durbin-Watson test. Data also met the assumption of 
multicollinearity, as confirmed with collinearity statistics (i.e., Tolerance and VIF) that 
were all within accepted limits. 
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Table 5. 
Correlations Among Variables of Interest in Sample 
 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 
1. Group 
Membership 
-                 
2. Gender -.200 -                
3. SES -.168 -.056 -               
4. Age at 
Dx 
.a .284 -.136 -              
5. Time 
Since Tx 
.a -.141 .180 -.427 -             
6. Sky 
Search 
-.189 -.050 .482** -.404 .493* -            
7. Score! -.339* .158 .259 .279 -.393 -.150 -           
8. Creature 
Counting 
-.394* .075 .397* .553* -.176 .032 .627** -          
9. Sky 
Search DT 
-.268 .000 .423** .197 -.121 .032 .469** .566** -         
10. Atten 
Problems 
.430** -.306 .243 -.076 .402 .058 -.244 -.021 .105 -        
11. WMI -.378* -.139 .216 .198 -.203 .122 .428** .538** .487** -.214 -       
12. PSI -.425** .189 .439** -.096 -.110 .496** .420** .495** .438** -.401* .680** -      
13. Inhib. -.057 -.024 .197 .244 -.213 .174 .254 .333* .371* -.209 .365* .541** -     
14. Tower -.155 .059 .015 .465* -.178 -.092 -.027 .364* .252 -.089 .113 .110 .287 -    
15. BRI .417** -.277 -.065 -.172 .129 -.153 -.389* -.364* -.062 .644** -.252 -
.432** 
-.156 -.154 -   
16. MI .438** -.273 .211 -.126 .534* .116 -.372* -.155 .036 .879** -.179 -.368* -.235 -.091 .735** -  
17. FAD GF .389* -.214 .194 -.131 .318 .142 -.038 -.067 .039 .631** -.228 -.182 .010 -.238 .316* .571** - 
Note: *p < .05, **p < .01, a. cannot be computed because at least one of the variables is constant and this variable is only 
relevant for the clinical sample. 
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Table 6. 
Correlations Among Variables of Interest in Sample Without Outliers 
 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 
1. Group 
Membership 
-                 
2. Gender -.156 -                
3. SES -.208 -.024 -               
4. Age at 
Dx 
.a .239 -.086 -              
5. Time 
Since Tx 
.a .011 .060 -.382 -             
6. Sky 
Search 
-.298 .028 .485** -.359 .236 -            
7. Score! -.305 .115 .301 .251 -.397 -.110 -           
8. Creature 
Counting 
-.375* .044 .426** .555* -.188 .077 .616** -          
9. Sky 
Search DT 
-.267 -.009 .435** .207 -.136 .074 .481** .573** -         
10. Atten 
Problems 
.375* -.229 .201 .053 .172 -.114 -.161 .058 .139 -        
11. WMI -.352* -.188 .248 .177 -.172 .202 .407* .526** .490** -.149 -       
12. PSI -.400* .150 .489** -.130 -.099 .600** .387* .480** .460** -.347* .675** -      
13. Inhib. -.014 -.073 .235 .219 -.196 .215 .214 .313 .395* -.130 .349* .508** -     
14. Tower -.126 .027- .036 .447 -.115 -.050 -.061 .350* .250 -.022 .090 .083 .271 -    
15. BRI .420** .250 -.130 -.176 .202 -.181 -.355* -.363* -.104 .648** -.237 -.371* -.020 -.130 -   
16. MI .386* -.193 .166 -.012 .386 -.028 -.311 -.098 .056 .844** -.110 -.307 -.160 -.027 .761** -  
17. FAD GF .362* -.138 .162 -.017 -.083 -.147 .046 -.019 .111 .598** -.185 -.179 .039 -.215 .494** .528** - 
Note: * p < .05, **p < .01, a. cannot be computed because at least one of the variables is constant and this variable is only 
relevant for the clinical sample. 
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Main Analyses  
Hierarchical multiple regression analyses were conducted to examine the relations 
between family functioning and multiple measures of neurocognitive functioning. First, a 
test for interaction effects was performed to see if the magnitude of the effect of group 
membership (survivor vs. healthy control) on neurocognitive functioning varies as a 
function of family functioning. The p-value associated with the change in R2 was 
examined to see if family functioning moderated the effect of group membership on 
neurocognitive functioning. A change in R2 associated with an alpha of less than .05 was 
considered significant.  
Hypothesis 1a.  
Family functioning was expected to moderate the impact of group membership 
(survivor vs. healthy control) on performance on a task of selective attention. 
Furthermore, family functioning was expected to explain a significant amount of variance 
in performance on a task of selective attention, above and beyond that accounted for by 
demographic and treatment-related variables in the ALL group. In the control group, 
family functioning was not expected to account for a significant amount of additional 
variance in performance on a task of selective attention beyond that accounted for by 
demographic variables.  
In order to test for an interaction between group and family functioning on 
selective attention, a hierarchical regression analysis was performed. Results are 
presented in Table 7. Selective attention (the attention scaled score on Sky Search) was 
regressed on Group (survivor or healthy control) and family functioning 
(FAD_GF_Centered) using simultaneous multiple regression. These two variables 
accounted for 9.0% of the variance in selective attention on Sky Search (F [2, 37] = 
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1.840, p = .173). Neither group membership (b = -.288, t [38] = -1.689, p = .100) nor 
family functioning (b = .254, t [38] = 1.494, p = .144) by themselves had a significant 
effect on selective attention.  
The interaction term (Group_FAD_GF_Centered) was added to the equation in 
the second step of the hierarchical regression. The addition of the interaction term did not 
lead to a statistically significant increase in R2 (ΔR2 = .024, F [1, 36] = .996, p = .325). 
Thus, this regression analysis indicated that family functioning did not moderate the 
impact of group membership on performance on a task of selective attention with outliers 
included in the analysis.  
Table 7. 
Selective Attention (With Outliers) 
 B SE B β R2 ΔR2 
Step 1    .090 .090 
     Constant 10.092 .573    
     Group membership -1.448 .857 -.288   
     Family functioning 1.350 .903 .254   
Step 2    .115 .024 
     Constant 9.815 .637    
     Group membership -.596 2.149 -.112   
     Family functioning -1.266 .877 -.251   
     Group X Family functioning 2.363 2.368 .387   
Note. N = 40; * p < .05, ** p < .01, *** p < .001 
The analysis was conducted again with the outliers removed. Results are 
presented in Table 8. In step one, group membership and family functioning accounted 
for 9.1% of the variance in selective attention (F [2, 35] = 1.745, p = .190). Neither group 
membership (b = -.282, t [36] = -1.630, p = .112) nor family functioning (b = -.045, t [36] 
= -.260, p = .796) by themselves had a significant effect on selective attention. In step 
two, the addition of the interaction term did not lead to a statistically significant increase 
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in R2 (ΔR2 = .001, F [1, 34] = .035, p = .852). Therefore, family functioning did not 
moderate the impact of group membership on performance on a task of selective attention 
with or without the outliers removed from analyses. Because the interaction term was not 
statistically significant the planned follow-up analysis testing the regression coefficients 
separately by group was not conducted. 
Table 8. 
Selective Attention (Without Outliers) 
 B SE B β R2 ΔR2 
Step 1    .091 .091 
     Constant 9.862 .541    
     Group membership -1.324 .812 -.282   
     Family functioning -.269 1.035 -.045   
Step 2    .092 .001 
     Constant 9.815 .602    
     Group membership -1.294 .838 -.276   
     Family functioning -.596 2.032 -.100   
     Group X Family functioning .445 2.373 .061   
Note. N = 38; * p < .05, ** p < .01, *** p < .001 
Hypothesis 1b.  
Family functioning was expected to moderate the impact of group membership 
(survivor vs. healthy control) on performance on a task of divided attention. Furthermore, 
family functioning was expected to explain a significant amount of variance in 
performance on a task of divided attention, above and beyond that accounted for by 
demographic and treatment-related variables in the ALL group. In the control group, 
family functioning was not expected to account for a significant amount of additional 
variance in performance on a task of divided attention beyond that accounted for by 
demographic variables. 
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A hierarchical regression analysis was performed in order to test for an interaction 
between group and family functioning on divided attention. Results are presented in 
Table 9. Divided attention (the scaled score on Sky Search DT) was regressed on Group 
(survivor or healthy control) and family functioning (FAD_GF_Centered) using 
simultaneous multiple regression. These two variables accounted for 9.6% of the variance 
in divided attention on Sky Search DT (F [2, 37] = 1.964, p = .155). Neither group 
membership (b = -.334, t [38] = -1.966, p = .057) nor family functioning (b = .169, t [38] 
= .997, p = .325) by themselves had a significant effect on divided attention.  
The interaction term (Group_FAD_GF_Centered) was added to the equation in 
the second step of the hierarchical regression. The addition of the interaction term did not 
lead to a statistically significant increase in R2 (ΔR2 < .001, F [1, 36] = .019, p = .891). 
Therefore, family functioning did not moderate the impact of group membership on 
performance on a task of divided attention with outliers included in the analysis.  
Table 9. 
Divided Attention (With Outliers) 
 B SE B β R2 ΔR2 
Step 1    .096 .096 
     Constant 8.399 .890    
     Group membership -2.616 1.331 -.334   
     Family functioning 1.398 1.402 .169   
Step 2    .096 .000 
     Constant 8.459 1.002    
     Group membership -2.656 1.379 -.339   
     Family functioning 1.821 3.380 .220   
     Group X Family functioning -.514 3.725 -.054   
Note. N = 40; * p < .05, ** p < .01, *** p < .001 
The analysis was conducted again with the outliers removed. Results are 
presented in Table 10. In step one, group membership and family functioning accounted 
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for 12.1% of the variance in divided attention (F [2, 35] = 2.412, p = .104). By itself, 
group membership had a significant effect on divided attention (b = -.354, t [36] = -2.081, 
p = .045). However, family functioning did not have a significant independent effect on 
divided attention (b = .239, t [36] = 1.406, p = .168).  In step two, the addition of the 
interaction term did not lead to a statistically significant increase in R2 (ΔR2 = .001, F [1, 
34] = .045, p = .832). Family functioning did not moderate the impact of group 
membership on performance on a task of divided attention with or without the outliers 
removed from analyses. Because the interaction term was not statistically significant the 
follow-up analysis testing the regression coefficients separately by group was not 
conducted. 
Table 10. 
Divided Attention (Without Outliers) 
 B SE B β R2 ΔR2 
Step 1    .121 .121 
     Constant 8.548 .909    
     Group membership -2.838 1.364 -.354*   
     Family functioning 2.444 1.738 .239   
Step 2    .122 .001 
     Constant 8.459 1.012    
     Group membership -2.781 1.408 -.347   
     Family functioning 1.821 3.413 .178   
     Group X Family functioning .849 3.985 .068   
Note. N = 38; * p < .05, ** p < .01, *** p < .001 
Hypothesis 1c.  
Family functioning was expected to moderate the impact of group membership 
(survivor vs. healthy control) on performance on a task of sustained attention. 
Furthermore, family functioning was expected to explain a significant amount of variance 
in performance on a task of sustained attention, above and beyond that accounted for by 
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demographic and treatment-related variables in the ALL group. In the control group, 
family functioning was not expected to account for a significant amount of additional 
variance in performance on a task of sustained attention beyond that accounted for by 
demographic variables. 
In order to test for an interaction between group and family functioning on 
sustained attention, a hierarchical regression analysis was performed. Results are 
presented in Table 11. Sustained attention (the scaled score on the Score! subtest of the 
TEA-Ch) was regressed on Group (survivor or healthy control) and family functioning 
(FAD_GF_Centered) using simultaneous multiple regression. These two variables 
accounted for 12.5% of the variance in sustained attention on Score! (F [2, 37] = 2.652, p 
= .084). By itself, group membership had a significant effect on sustained attention (b = -
382, t [38] = -2.290, p = .028). However, family functioning did not have a significant 
independent effect on sustained attention (b = .111, t [38] = .664, p = .511).   
Table 11. 
Sustained Attention (With Outliers) 
 B SE B β R2 ΔR2 
Step 1    .125 .125 
     Constant 10.360 .740    
     Group membership -2.536 1.108 -.382*   
     Family functioning .775 1.167 .111   
Step 2    .129 .004 
     Constant 10.219 .832    
     Group membership -2.443 1.146 -.368*   
     Family functioning -.220 2.808 -.031   
     Group X Family functioning 1.209 3.095 .150   
Note. N = 40; * p < .05, ** p < .01, *** p < .001 
The interaction term (Group_FAD_GF_Centered) was added to the equation in 
the second step of the hierarchical regression. The addition of the interaction term did not 
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lead to a statistically significant increase in R2 (ΔR2 = .004, F [1, 36] = .152, p = .698). 
Family functioning did not moderate the impact of group membership on performance on 
a task of sustained attention with outliers included in the analysis.  
The analysis was conducted again with the outliers removed. Results are 
presented in Table 12. In step one, group membership and family functioning accounted 
for 12.2% of the variance in sustained attention (F [2, 35] = 2.422, p = .103). By itself, 
group membership had a significant effect on sustained attention (b = -.371, t [36] = -
2.181, p = .036). However, family functioning did not have a significant independent 
effect on sustained attention (b = .181, t [36] = 1.063, p = .295). In step two, the addition 
of the interaction term did not lead to a statistically significant increase in R2 (ΔR2 = .013, 
F [1, 34] = .530, p = .472). Therefore, family functioning did not moderate the impact of 
group membership on performance on a task of sustained attention with or without 
outliers removed. Because the interaction term was not statistically significant the follow-
up analysis testing the regression coefficients separately by group was not conducted. 
Table 12. 
Sustained Attention (Without Outliers) 
 B SE B β R2 ΔR2 
Step 1    .122 .122 
     Constant 10.468 .753    
     Group membership -2.462 1.129 -.371*   
     Family functioning 1.528 1.438 .181   
Step 2    .135 .013 
     Constant 10.219 .831    
     Group membership -2.302 1.157 -3.47   
     Family functioning -.220 2.805 -.026   
     Group X Family functioning 2.384 3.275 .231   
Note. N = 38; * p < .05, ** p < .01, *** p < .001 
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Hypothesis 1d.  
Family functioning was expected to moderate the impact of group membership 
(survivor vs. healthy control) on performance on a task of switching attention. 
Furthermore, family functioning was expected to explain a significant amount of variance 
in performance on a task of switching attention, above and beyond that accounted for by 
demographic and treatment-related variables in the ALL group. In the control group, 
family functioning was not expected to account for a significant amount of additional 
variance in performance on a task of switching attention beyond that accounted for by 
demographic variables. 
In order to test for an interaction between group and family functioning on 
switching attention, a hierarchical regression analysis was performed. Results are 
presented in Table 13. Switching attention (the accuracy score on the Creature Counting 
subtest on the TEA-Ch) was regressed on group membership (survivor or healthy control) 
and family functioning (FAD_GF_Centered) using simultaneous multiple regression.  
These two variables accounted for 16.4% of the variance in switching attention on 
Table 13.  
Switching Attention (With Outliers) 
 B SE B β R2 ΔR2 
Step 1    .164* .164* 
     Constant 10.641 .650    
     Group membership -2.585 .973 -.434*   
     Family functioning .636 1.025 .101   
Step 2    .170 .006 
     Constant 10.804 .730    
     Group membership -2.692 1.005 -.452*   
     Family functioning 1.782 2.462 .284   
     Group X Family functioning -1.392 2.714 -.193   
Note. N = 40; * p < .05, ** p < .01, *** p < .001 
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Creature Counting (F [2, 37] = 3.632, p = .036). By itself, group membership had a 
significant effect on switching attention (b = -.434, t [38] = -2.658, p = .012), such that 
the control group scored higher than the clinical group. However, family functioning did 
not have a significant independent effect on switching attention (b = .101, t [38] = .621, p 
= .539).   
The interaction term (Group_FAD_GF_Centered) was added to the equation in 
the second step of the hierarchical regression. The addition of the interaction term did not 
lead to a statistically significant increase in R2 (ΔR2 = .006, F [1, 36] = .263, p = .611). 
Family functioning did not moderate the impact of group membership on performance on 
a task of switching attention with outliers included in the analysis.  
The analysis was conducted again with the outliers removed. Results are 
presented in Table 14. In step one, group membership and family functioning accounted 
for 15.6% of the variance in switching attention (F [2, 35] = 3.247, p = .051). By itself, 
group membership had a significant effect on switching attention (b = -.424, t [36] = -
2.545, p = .015). However, family functioning did not have a significant independent 
effect on switching attention (b = .135, t [36] = .808, p = .425). In step two, the addition  
Table 14. 
Switching Attention (Without Outliers) 
 B SE B β R2 ΔR2 
Step 1    .156 .156 
     Constant 10.698 .672    
     Group membership -2.567 1.008 -.424*   
     Family functioning 1.038 1.285 .135   
Step 2    .159 .003 
     Constant 10.804 .747    
     Group membership -2.635 1.040 -.435*   
     Family functioning 1.782 2.521 .231   
     Group X Family functioning -1.014 2.944 -.108   
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Note. N = 38; * p < .05, ** p < .01, *** p < .001 
 
of the interaction term did not lead to a statistically significant increase in R2 (ΔR2 = .003, 
F [1, 34] = .119, p = .733). Thus, family functioning did not moderate the impact of 
group membership on performance on a task of switching attention with or without 
outliers removed. Because the interaction term was not statistically significant the follow-
up analysis testing the regression coefficients separately by group was not conducted. 
Hypothesis 1e.  
Family functioning was expected to moderate the impact of group membership 
(survivor vs. healthy control) on scores on caregiver ratings of attention. Furthermore, 
family functioning was expected to explain a significant amount of variance in scores on 
caregiver ratings of attention, above and beyond that accounted for by demographic and 
treatment-related variables in the ALL group. In the control group, family functioning 
was not expected to account for a significant amount of additional variance in scores on 
caregiver ratings of attention beyond that accounted for by demographic variables. 
In order to test for an interaction between group and family functioning on 
caregiver ratings of attention, a hierarchical regression analysis was performed. Results 
are presented in Table 15. Caregiver ratings of attention (the Attention Problems T-score 
on the Parent Form of the BASC) was regressed on Group (survivor or healthy control) 
and family functioning (FAD_GF_Centered) using simultaneous multiple regression. 
These two variables accounted for 43.9% of the variance in caregiver ratings of attention 
on the BASC (F [2, 37] = 14.463, p < .001). By itself, group membership did not have a 
significant effect on caregiver ratings of attention (b = .218, t [38] = 1.628, p = .112). 
However, family functioning did have a significant independent effect on caregiver 
ratings of attention (b = .547, t [38] = 4.089, p < .001).   
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The interaction term (Group_FAD_GF_Centered) was added to the equation in 
the second step of the hierarchical regression. The addition of the interaction term did not 
lead to a statistically significant increase in R2 (ΔR2 = .006, F [1, 36] = .377, p = .543). 
Thus, this regression analysis indicated that family functioning did not moderate the 
impact of group membership on performance on caregiver ratings of attention with 
outliers included in the analysis.  
Table 15. 
Caregiver Ratings of Attention (With Outliers) 
 B SE B β R2 ΔR2 
Step 1    .439*** .439*** 
     Constant 47.650 1.797    
     Group membership 4.375 2.687 .218   
     Family functioning 11.577 2.831 .547***   
Step 2    .445 .006 
     Constant 47.111 2.013    
     Group membership 4.730 2.771 .235   
     Family functioning 7.793 6.793 .368   
     Group X Family functioning 4.596 7.486 .189   
Note. N = 40; * p < .05, ** p < .01, *** p < .001 
The analysis was conducted again with the outliers removed. Results are 
presented in Table 16. In step one, group membership and family functioning accounted 
for 38.7% of the variance in parent ratings of attention (F [2, 35] = 11.047, p < .001). By 
itself, group membership did not have a significant effect on parent ratings of attention (b 
= .183, t [36] = 1.286, p = .207). However, family functioning did have a significant 
independent effect on parent ratings of attention (b = .532, t [36] = 3.749, p = .001). In 
step two, the addition of the interaction term did not lead to a statistically significant 
increase in R2 (ΔR2 = .012, F [1, 34] = .671, p = .419). The regression analysis indicated 
that family functioning did not moderate the impact of group membership on 
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performance on parent ratings of attention with or without outliers removed. Because the 
interaction term was not statistically significant the follow-up analysis testing the 
regression coefficients separately by group was not conducted. 
Table 16. 
Caregiver Ratings of Attention (Without Outliers) 
 B SE B β R2 ΔR2 
Step 1    .387 .387 
     Constant 47.746 1.710    
     Group membership 3.299 2.565 .183   
     Family functioning 12.255 3.269 .532***   
Step 2    .399 .012 
     Constant 47.111 1.886    
     Group membership 3.705 2.624 .205   
     Family functioning 7.793 6.361 .338   
     Group X Family functioning 6.083 7.428 .216   
Note. N = 38; * p < .05, ** p < .01, *** p < .001 
Hypothesis 2a.  
Family functioning was expected to moderate the impact of group membership 
(survivor vs. healthy control) on performance on a task of cognitive flexibility (working 
memory). Furthermore, family functioning was expected to explain a significant amount 
of variance in performance on a task of cognitive flexibility (working memory), above 
and beyond that accounted for by demographic and treatment-related variables in the 
ALL group. In the control group, family functioning was not expected to account for a 
significant amount of additional variance in performance on a task of cognitive flexibility 
(working memory) beyond that accounted for by demographic variables. 
In order to test for an interaction between group and family functioning on 
cognitive flexibility (working memory), a hierarchical regression analysis was performed. 
Results are presented in Table 17. Cognitive flexibility (the Working Memory Index 
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score on the WISC-IV) was regressed on Group (survivor or healthy control) and family 
functioning (FAD_GF_Centered) using simultaneous multiple regression. These two 
variables accounted for 15.1% of the variance in cognitive flexibility (working memory) 
on the Working Memory Index (F [2, 37] = 3.282, p = .049). By itself, group 
membership had a significant effect on cognitive flexibility (b = -.341, t [38] = -2.074, p 
= .045). However, family functioning did not have a significant independent effect on 
cognitive flexibility (b = -.095, t [38] = -.578, p = .567).   
The interaction term (Group_FAD_GF_Centered) was added to the equation in 
the second step of the hierarchical regression. The addition of the interaction term did not 
lead to a statistically significant increase in R2 (ΔR2 = .001, F [1, 36] = .058, p = .812). 
Therefore, family functioning did not moderate the impact of group membership on 
performance on a task of cognitive flexibility (working memory) with outliers included in 
the analysis.  
Table 17. 
Cognitive Flexibility: Working Memory (With Outliers) 
 B SE B β R2 ΔR2 
Step 1    .151* .151* 
     Constant 103.505 3.038    
     Group membership -9.427 4.545 -.341*   
     Family functioning -2.770 4.788 -.095   
Step 2    .152 .001 
     Constant 103.148 3.420    
     Group membership -9.192 4.708 -.333   
     Family functioning -5.281 11.538 -.181   
     Group X Family functioning 3.050 12.716 .091   
Note. N = 40; * p < .05, ** p < .01, *** p < .001 
The analysis was conducted again with the outliers removed. Results are 
presented in Table 18. In step one, group membership and family functioning accounted 
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for 12.8% of the variance in cognitive flexibility (F [2, 35] = 2.566, p = .091). Neither 
group membership (b = -.329, t [36] = -1.940, p = .060) nor family functioning (b = -
.066, t [36] = -.388, p = .700) by themselves had a significant effect on cognitive 
flexibility (working memory). In step two, the addition of the interaction term did not 
lead to a statistically significant increase in R2 (ΔR2 = .002, F [1, 34] = .084, p = .774). 
Thus, this regression analysis indicated that family functioning did not moderate the 
impact of group membership on performance on a task of cognitive flexibility (working 
memory) with or without outliers removed. Because the interaction term was not 
statistically significant the follow-up analysis testing the regression coefficients 
separately by group was not conducted. 
Table 18. 
Cognitive Flexibility: Working Memory (Without Outliers) 
 B SE B β R2 ΔR2 
Step 1    .128 .128 
     Constant 103.566 3.155    
     Group membership -9.180 4.731 -.329   
     Family functioning -2.341 6.029 -.066   
Step 2    .130 .002 
     Constant 103.148 3.508    
     Group membership -8.912 4.883 -.319   
     Family functioning -5.281 11.835 -.148   
     Group X Family functioning 4.007 13.819 .092   
Note. N = 38; * p < .05, ** p < .01, *** p < .001 
Hypothesis 2b.  
Family functioning was expected to moderate the impact of group membership 
(survivor vs. healthy control) on performance on a task of goal setting (planning). 
Furthermore, family functioning was expected to explain a significant amount of variance 
in performance on a task of goal setting (planning), above and beyond that accounted for 
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by demographic and treatment-related variables in the ALL group. In the control group, 
family functioning was not expected to account for a significant amount of additional 
variance in performance on a task of goal setting (planning) beyond that accounted for by 
demographic variables. 
In order to test for an interaction between group and family functioning on goal 
setting (planning), a hierarchical regression analysis was performed. Results are 
presented in Table 19. Goal setting (the total achievement scaled score on the Tower 
subtest of the D-KEFS) was regressed on Group (survivor or healthy control) and family 
functioning (FAD_GF_Centered) using simultaneous multiple regression. These two 
variables accounted for 6.1% of the variance in goal setting (planning) on the Tower 
subtest (F [2, 37] = 1.207, p = .311). Neither group membership (b = -.073, t [38] = -.422, 
p = .675) nor family functioning (b = -.210, t [38] = -1.213, p = .233) by themselves had a 
significant effect on goal setting (planning).  
Table 19. 
Goal Setting: Planning (With Outliers) 
 B SE B β R2 ΔR2 
Step 1    .061 .061 
     Constant 10.518 .486    
     Group membership -.307 .727 -.073   
     Family functioning -.929 .766 -.210   
Step 2    .063 .002 
     Constant 10.587 .547    
     Group membership -.353 .753 -.084   
     Family functioning -.442 1.845 -.100   
     Group X Family functioning -.591 2.033 -.116   
Note. N = 40; * p < .05, ** p < .01, *** p < .001 
The interaction term (Group_FAD_GF_Centered) was added to the equation in 
the second step of the hierarchical regression. The addition of the interaction term did not 
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lead to a statistically significant increase in R2 (ΔR2 = .002, F [1, 36] = .085, p = .773). 
Family functioning did not moderate the impact of group membership on performance on 
a task of goal setting (planning) with outliers included in the analysis.  
The analysis was conducted again with the outliers removed. Results are 
presented in Table 20. In step one, group membership and family functioning accounted 
for 4.9% of the variance in goal setting (F [2, 35] = .903, p = .415). Neither group 
membership (b = -.055, t [36] = -.313, p = .756) nor family functioning (b = -.195, t [36] 
= -1.105, p = .277) by themselves had a significant effect on goal setting. In step two, the 
addition of the interaction term did not lead to a statistically significant increase in R2 
(ΔR2 = .004, F [1, 34] = .148, p = .703). Family functioning did not moderate the impact 
of group membership on performance on a task of goal setting (planning) with or without 
outliers removed. Because the interaction term was not statistically significant the follow-
up analysis testing the regression coefficients separately by group was not conducted. 
Table 20. 
Goal Setting: Planning (Without Outliers) 
 B SE B β R2 ΔR2 
Step 1    .049 .049 
     Constant 10.498 .504    
     Group membership -.237 .756 -.055   
     Family functioning -1.064 .963 -.195   
Step 2    .053 .004 
     Constant 10.587 .560    
     Group membership -.293 .779 -.069   
     Family functioning -.442 1.889 -.081   
     Group X Family functioning -.848 2.205 -.127   
Note. N = 38; * p < .05, ** p < .01, *** p < .001 
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Hypothesis 2c.  
Family functioning was expected to moderate the impact of group membership 
(survivor vs. healthy control) on performance on a task of attentional control (inhibition). 
Furthermore, family functioning was expected to explain a significant amount of variance 
in performance on a task of attentional control (inhibition), above and beyond that 
accounted for by demographic and treatment-related variables in the ALL group. In the 
control group, family functioning was not expected to account for a significant amount of 
additional variance in performance on a task of attentional control (inhibition) beyond 
that accounted for by demographic variables. 
In order to test for an interaction between group and family functioning on 
attentional control (inhibition), a hierarchical regression analysis was performed. Results 
are presented in Table 21. Attentional control (the Trial 3: Inhibition time scaled score on 
the D-KEFS Color-Word Interference Test) was regressed on Group (survivor or healthy 
control) and family functioning (FAD_GF_Centered) using simultaneous multiple 
regression. These two variables accounted for 0.4% of the variance in attentional control 
(inhibition) on Trial 3 of the D-KEFS Color-Word Interference Test (F [2, 37] = .083, p = 
.920). Neither group membership (b = -.072, t [38] = -.403, p = .689) nor family 
functioning (b = .038, t [38] = .214, p = .832) by themselves had a significant effect on 
attentional control (inhibition).  
The interaction term (Group_FAD_GF_Centered) was added to the equation in 
the second step of the hierarchical regression. The addition of the interaction term did not 
lead to a statistically significant increase in R2 (ΔR2 = .007, F [1, 36] = .272, p = .605). 
Thus, this regression analysis indicated that family functioning did not moderate the 
impact of group membership on performance on a task of attentional control (inhibition) 
with outliers included in the analysis.  
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Table 21. 
Attentional Control: Inhibition (With Outliers) 
 B SE B β R2 ΔR2 
Step 1    .004 .004 
     Constant 10.285 .731    
     Group membership -.441 1.093 -.072   
     Family functioning .246 1.151 .038   
Step 2    .012 .007 
     Constant 10.098 .820    
     Group membership -.318 1.129 -.052   
     Family functioning -1.064 2.766 -.165   
     Group X Family functioning 1.591 3.049 .214   
Note. N = 40; * p < .05, ** p < .01, *** p < .001 
The analysis was conducted again with the outliers removed. Results are 
presented in Table 22. In step one, group membership and family functioning accounted 
for 0.2% of the variance in attentional control (F [2, 35] = .043, p = .958). Neither group 
membership (b = -.032, t [36] = -.178, p = .860) nor family functioning (b = .051, t [36] = 
.282, p = .780) by themselves had a significant effect on attentional control (inhibition). 
In step two, the addition of the interaction term did not lead to a statistically significant 
increase in R2 (ΔR2 = .011, F [1, 34] = .386, p = .539). Family functioning did not  
Table 22. 
Attentional Control: Inhibition (Without Outliers) 
 B SE B β R2 ΔR2 
Step 1    .002 .002 
     Constant 10.306 .734    
     Group membership -.196 1.101 -.032   
     Family functioning .395 1.403 .051   
Step 2    .014 .011 
     Constant 10.098 .813    
     Group membership -.063 1.131 -.010   
     Family functioning -1.064 2.743 -.137   
     Group X Family functioning 1.989 3.202 .210   
Note. N = 38; * p < .05, ** p < .01, *** p < .001 
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moderate the impact of group membership on performance on a task of attentional 
control (inhibition) with or without outliers removed. Because the interaction term was 
not statistically significant the follow-up analysis testing the regression coefficients 
separately by group was not conducted. 
Hypothesis 2d.  
Family functioning was expected to moderate the impact of group membership 
(survivor vs. healthy control) on performance on a task of information processing 
(processing speed). Furthermore, family functioning was expected to explain a significant 
amount of variance in performance on a task of information processing (processing 
speed), above and beyond that accounted for by demographic and treatment-related 
variables in the ALL group. In the control group, family functioning was not expected to 
account for a significant amount of additional variance in performance on a task of 
information processing (processing speed) beyond that accounted for by demographic 
variables. 
In order to test for an interaction between group and family functioning on 
information processing (processing speed), a hierarchical regression analysis was 
performed. Results are presented in Table 23. Information processing (the Processing 
Speed Index score on the WISC-IV) was regressed on Group (survivor or healthy 
control) and family functioning (FAD_GF_Centered) using simultaneous multiple 
regression. These two variables accounted for 18.1% of the variance in information 
processing (processing speed) on the Processing Speed Index (F [2, 37] = 4.088, p = 
.025). By itself, group membership had a significant effect on information processing (b 
= -.417, t [38] = -2.584, p = .014). However, family functioning did not have a significant 
independent effect on information processing (b = -.020, t [38] = -.123, p = .903).   
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The interaction term (Group_FAD_GF_Centered) was added to the equation in 
the second step of the hierarchical regression. The addition of the interaction term did not 
lead to a statistically significant increase in R2 (ΔR2 = .000, F [1, 36] = .015, p = .903). 
Family functioning did not moderate the impact of group membership on performance on 
a task of information processing (processing speed) with outliers included in the analysis.  
Table 23. 
Information Processing: Processing Speed (With Outliers) 
 B SE B β R2 ΔR2 
Step 1    .181* .181* 
     Constant 104.113 3.163    
     Group membership -12.224 4.731 -.417*   
     Family functioning -.613 4.984 -.020   
Step 2    .181 .000 
     Constant 103.922 3.562    
     Group membership -12.098 4.903 -.413*   
     Family functioning -1.954 12.018 -.063   
     Group X Family functioning 1.629 13.245 .046   
Note. N = 40; * p < .05, ** p < .01, *** p < .001 
The analysis was conducted again with the outliers removed. Results are 
presented in Table 24. In step one, group membership and family functioning accounted 
for 16.2% of the variance in information processing (F [2, 35] = 3.372, p = .046). By 
itself, group membership had a significant effect on information processing (b = -.386, t 
[36] = -2.325, p = .026). However, family functioning did not have a significant 
independent effect on information processing (b = -.039, t [36] = -.238, p = .814). In step 
two, the addition of the interaction term did not lead to a statistically significant increase 
in R2 (ΔR2 = .000, F [1, 34] = .002, p = .962). Thus, this regression analysis indicated that 
family functioning did not moderate the impact of group membership on performance on 
a task of information processing (processing speed) with or without outliers removed. 
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Because the interaction term was not statistically significant the follow-up analysis 
testing the regression coefficients separately by group was not conducted. 
Table 24. 
Information Processing: Processing Speed (Without Outliers) 
 B SE B β R2 ΔR2 
Step 1    .162* .162* 
     Constant 103.992 3.221    
     Group membership -11.229 4.830 -.386*   
     Family functioning -1.462 6.155 -.039   
Step 2    .162 .000 
     Constant 103.922 3.586    
     Group membership -11.185 4.990 -.384*   
     Family functioning -1.954 12.097 -.053   
     Group X Family functioning .670 14.124 .015   
Note. N = 38; * p < .05, ** p < .01, *** p < .001 
Hypothesis 2e.  
Family functioning was expected to moderate the impact of group membership 
(survivor vs. healthy control) on scores on caregiver ratings of an aspect of executive 
functioning (behavioral regulation). Furthermore, family functioning was expected to 
explain a significant amount of variance in scores on caregiver ratings of behavioral 
regulation, above and beyond that accounted for by demographic and treatment-related 
variables in the ALL group. In the control group, family functioning was not expected to 
account for a significant amount of additional variance in scores on caregiver ratings of 
behavioral regulation beyond that accounted for by demographic variables. 
In order to test for an interaction between group and family functioning on 
caregiver ratings of behavioral regulation, a hierarchical regression analysis was 
performed. Results are presented in Table 25. Caregiver ratings of behavioral regulation 
(the Behavioral Regulation Index score on the Parent Form of the BRIEF) was regressed 
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on Group (survivor or healthy control) and family functioning (FAD_GF_Centered) 
using simultaneous multiple regression. These two variables accounted for 20.2% of the 
variance in caregiver ratings of behavioral regulation on the Behavioral Regulation Index 
(F [2, 37] = 4.681, p = .015). By itself, group membership had a significant effect on 
caregiver ratings of behavioral regulation (b = .347, t [38] = 2.173, p = .036). However, 
family functioning did not have a significant independent effect on caregiver ratings of 
behavioral regulation (b = .181, t [38] = 1.138, p = .262).   
The interaction term (Group_FAD_GF_Centered) was added to the equation in 
the second step of the hierarchical regression. The addition of the interaction term did not 
lead to a statistically significant increase in R2 (ΔR2 = .012, F [1, 36] = .526, p = .473). 
Family functioning did not moderate the impact of group membership on caregiver 
ratings of behavioral regulation with outliers included in the analysis.  
Table 25. 
Caregiver Ratings of Behavioral Regulation (With Outliers) 
 B SE B β R2 ΔR2 
Step 1    .202* .202* 
     Constant 45.797 1.750    
     Group membership 5.690 2.618 .347*   
     Family functioning 3.140 2.758 .181   
Step 2    .213 .012 
     Constant 46.417 1.958    
     Group membership 5.283 2.694 .322   
     Family functioning 7.488 6.604 .433   
     Group X Family functioning -5.281 7.278 -.265   
Note. N = 40; * p < .05, ** p < .01, *** p < .001 
The analysis was conducted again with the outliers removed. Results are 
presented in Table 26. In step one, group membership and family functioning accounted 
for 31.1% of the variance in caregiver ratings of behavioral regulation (F [2, 35] = 7.892, 
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p < .001). By itself, group membership did not have a significant effect on caregiver 
ratings of behavioral regulation (b = .278, t [36] = 1.848, p = .073). However, family 
functioning did have a significant independent effect on caregiver ratings of behavioral 
regulation (b = .393, t [36] = 2.610, p = .013). In step two, the addition of the interaction 
term did not lead to a statistically significant increase in R2 (ΔR2 = .000, F [1, 34] = .006, 
p = .938). Therefore, family functioning did not moderate the impact of group 
membership on caregiver ratings of behavioral regulation with or without outliers 
removed. Because the interaction term was not statistically significant the follow-up 
analysis testing the regression coefficients separately by group was not conducted. 
Table 26. 
Caregiver Ratings of Behavioral Regulation (Without Outliers) 
 B SE B β R2 ΔR2 
Step 1    .311*** .311*** 
     Constant 46.366 1.429    
     Group membership 3.960 2.143 .278   
     Family functioning 7.127 2.731 .393*   
Step 2    .311 .000 
     Constant 46.417 1.591    
     Group membership 3.927 2.214 .276   
     Family functioning 7.488 5.366 .413   
     Group X Family functioning -.492 6.265 -.022   
Note. N = 38; * p < .05, ** p < .01, *** p < .001 
Hypothesis 2f.  
Family functioning was expected to moderate the impact of group membership 
(survivor vs. healthy control) on scores on caregiver ratings of another aspect of 
executive functioning (metacognition). Furthermore, family functioning was expected to 
explain a significant amount of variance in scores on caregiver ratings of metacognition, 
above and beyond that accounted for by demographic and treatment-related variables in 
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the ALL group. In the control group, family functioning was not expected to account for 
a significant amount of additional variance in scores on caregiver ratings of 
metacognition beyond that accounted for by demographic variables. 
In order to test for an interaction between group and family functioning on 
caregiver ratings of metacognition, a hierarchical regression analysis was performed. 
Results are presented in Table 27. Caregiver ratings of metacognition (the Metacognition 
Index score on the Parent Form of the BRIEF) was regressed on Group (survivor or 
healthy control) and family functioning (FAD_GF_Centered) using simultaneous 
multiple regression. These two variables accounted for 38.2% of the variance in caregiver 
ratings of metacognition on the Metacognition Index (F [2, 37] = 11.412, p < .001). By 
itself, group membership did not have a significant effect on caregiver ratings of 
metacognition (b = .255, t [38] = 1.815, p = .078). However, family functioning did have 
a significant independent effect on caregiver ratings of metacognition (b = .472, t [38] = 
3.365, p = .002).   
Table 27. 
Caregiver Ratings of Metacognition (With Outliers) 
 B SE B β R2 ΔR2 
Step 1    .382*** .382*** 
     Constant 49.044 2.043    
     Group membership 5.548 3.057 .255   
     Family functioning 10.837 3.221 .472**   
Step 2    .386 .004 
     Constant 48.533 2.294    
     Group membership 5.885 3.157 .270   
     Family functioning 7.249 7.738 .316   
     Group X Family functioning 4.358 8.529 .165   
Note. N = 40; * p < .05, ** p < .01, *** p < .001 
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The interaction term (Group_FAD_GF_Centered) was added to the equation in 
the second step of the hierarchical regression. The addition of the interaction term did not 
lead to a statistically significant increase in R2 (ΔR2 = .004, F [1, 36] = .261, p = .612). 
Thus, this regression analysis indicated that family functioning did not moderate the 
impact of group membership on caregiver ratings of metacognition with outliers included 
in the analysis.  
The analysis was conducted again with the outliers removed. Results are 
presented in Table 28. In step one, group membership and family functioning accounted 
for 32.3% of the variance in caregiver ratings of metacognition (F [2, 35] = 8.330, p = 
.001). By itself, group membership did not have a significant effect on caregiver ratings 
of metacognition (b = .224, t [36] = 1.499, p = .143). However, family functioning did 
have a significant independent effect on caregiver ratings of metacognition (b = .447, t 
[36] = 2.997, p = .005). In step two, the addition of the interaction term did not lead to a 
statistically significant increase in R2 (ΔR2 = .008, F [1, 34] = .406, p = .528). Therefore, 
this regression analysis indicated that family functioning did not moderate the impact of 
group membership on caregiver ratings of metacognition with or without outliers  
Table 28. 
Caregiver Ratings of Metacognition (Without Outliers) 
 B SE B β R2 ΔR2 
Step 1    .323*** .323*** 
     Constant 49.103 1.964    
     Group membership 4.417 2.946 .224   
     Family functioning 11.251 3.754 .447**   
Step 2    .330 .008 
     Constant 48.533 2.174    
     Group membership 4.782 3.026 .242   
     Family functioning 7.249 7.335 .288   
     Group X Family functioning 5.455 8.564 .177   
Note. N = 38; * p < .05, ** p < .01, *** p < .001 
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removed. Because the interaction term was not statistically significant the follow-up 
analysis testing the regression coefficients separately by group was not conducted. 
Summary of results of main analyses.  
A summary of the results of the main analyses is presented in Table 29. Tests for 
interaction effects revealed that the magnitude of the effect of group membership 
(survivor vs. healthy control) on multiple measures of neurocognitive functioning does 
not vary as a function of family functioning, with or without outliers included. Therefore, 
family functioning did not moderate the impact of group membership on performance on 
any of the measures of neurocognitive functioning. When outliers were included in the 
analysis, family functioning had significant independent effects on caregiver ratings of 
attention and on caregiver ratings of metacognition. With outliers included, group 
membership had significant independent effects on sustained attention, switching 
attention, cognitive flexibility (working memory), information processing (processing 
speed), and caregiver ratings of behavioral regulation. When outliers were removed from 
analyses, family functioning had significant independent effects on caregiver ratings of 
attention, caregiver ratings of behavioral regulation, and caregiver ratings of 
metacognition. Group membership had significant independent effects on divided 
attention, sustained attention, switching attention, and information processing (processing 
speed) with outliers removed.  
Supplementary Analyses 
As a follow up of the significant independent effects that were found, supplementary 
analyses were conducted. To investigate whether family functioning explains a 
significant amount of variance in scores on measures of neurocognitive functioning 
above and beyond that accounted for by demographic variables in the sample as a whole 
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and demographic and treatment-related variables in the ALL group, hierarchical multiple 
regression analyses were performed. Using a sequential regression, the control variables 
were entered first. For the sample as a whole, this included gender and SES. For the ALL 
group alone, this included gender, SES, age at diagnosis, and time since diagnosis. These 
were followed by family functioning as a predictor variable for the neurocognitive 
outcome measures.  
With outliers included, the domains of neurocognitive functioning that were 
examined were caregiver ratings of attention and caregiver ratings of metacognition, as 
these were the domains in which there were significant independent effects for family 
functioning. Likewise, with outliers excluded, the domains of neurocognitive functioning 
that were examined were caregiver ratings of attention, caregiver ratings of behavioral 
regulation, and caregiver ratings of metacognition, as these were the domains in which 
there were significant independent effects for family functioning. The p-value associated 
with the change in R2 was examined to determine if family functioning explains a 
significant amount of variance in neurocognitive outcome, even after controlling for 
demographic or demographic and treatment-related variables. A change in R2 associated 
with an alpha of less than .05 was considered significant. 
To further investigate the significant independent effects for group membership 
that were found, independent samples t-tests were performed to see if the two groups 
differed significantly in neurocognitive functioning. With outliers included, the domains 
of neurocognitive functioning investigated were sustained attention, switching attention, 
cognitive flexibility (working memory), information processing (processing speed), and 
caregiver ratings of behavioral regulation, as these were the domains in which there were 
significant effects for group membership. With outliers excluded, the domains 
investigated were divided attention, sustained attention, switching attention, and  
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Table 29. 
Significant Results of Main Analyses of Outcome Measures 
Analysis With Outliers Without Outliers 
Hypothesis 1a: Selective Attention  Neither Neither 
Hypothesis 1b: Divided Attention  Neither Group Membership 
Hypothesis 1c: Sustained Attention  Group Membership Group Membership 
Hypothesis 1d: Switching Attention  Group Membership Group Membership 
Hypothesis 1e: Caregiver Ratings of Attention  Family Functioning  Family Functioning 
Hypothesis 2a: Cognitive Flexibility (Working Memory) Group Membership Neither 
Hypothesis 2b: Goal Setting (Planning) Neither Neither 
Hypothesis 2c: Attentional Control (Inhibition) Neither Neither 
Hypothesis 2d: Information Processing (Processing Speed) Group Membership Group Membership 
Hypothesis 2e: Caregiver Ratings of Behavioral Regulation Group Membership Family Functioning 
Hypothesis 2f: Caregiver Ratings of Metacognition Family Functioning Family Functioning 
Note: Group Membership and Family Functioning were used as predictors in all analyses 
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information processing (processing speed), as these were the domains in which there 
were significant effects for group membership. 
Family functioning with outliers included. 
Caregiver ratings of attention.  
In order to determine whether family functioning accounts for a significant 
amount of variance in caregiver ratings of attention above and beyond demographic 
variables in the sample as a whole with outliers included, a hierarchical multiple 
regression analysis was performed. Results are presented in Table 30. Gender and SES 
were entered in step 1. These two variables accounted for 14.5% of the variance in 
caregiver ratings of attention (F [2, 37] = 3.129, p = .056). Neither gender (b = -.293, t 
[38] = -1.926, p = .062) nor SES (b = .226, t [38] = 1.486, p = .146) by themselves had a 
significant effect on caregiver ratings of attention. In step 2, family functioning was 
entered. The addition of family functioning led to a statistically significant increase in R2 
(ΔR2 = .299, F [1, 36] = 19.333, p < .001). 
Table 30. 
Caregiver Ratings of Attention in the Whole Sample (With Outliers) 
 B SE B β R2 ΔR2 
Step 1    .145 .145 
     Constant 49.579 3.359    
     Gender -5.895 3.061 -.293   
     SES 5.094 3.428 .226   
Step 2    .444*** .299*** 
     Constant 49.601 2.746    
     Gender -3.560 2.559 -.177   
     SES 2.753 2.853 .122   
     Family functioning 12.065 2.744 .570***   
Note. N = 40; * p < .05, ** p < .01, *** p < .001 
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In order to determine whether family functioning accounts for a significant 
amount of variance in caregiver ratings of attention above and beyond demographic and 
treatment variables in the clinical group with outliers included, a hierarchical multiple 
regression analysis was performed. Results are presented in Table 31. Gender, SES, age 
at diagnosis, and time since treatment were entered in step 2. These four variables 
accounted for 50.0% of the variance in caregiver ratings of attention (F [4, 15] = 3.745, p 
= .026). By itself, SES had a significant effect on caregiver ratings of attention (b = .448, 
t [18] = 2.408, p = .029). By themselves, gender (b = -.381, t [18] = -2.001, p = .064), age 
at diagnosis (b = .253, t [18] = 1.211, p = .245), and time since treatment (b = .376, t [18] 
= 1.841, p = .085) did not have significant independent effects on caregiver ratings of 
attention. In the second step, family functioning was added. The addition of family 
functioning did not lead to a statistically significant increase in R2 (ΔR2 = .113, F [1, 14] 
= 4.062, p = .063).  
Table 31. 
Caregiver Ratings of Attention in the Clinical Group (With Outliers) 
 B SE B β R2 ΔR2 
Step 1    .500* .500* 
     Constant 37.051 8.202    
     Gender -7.958 3.978 -.381   
     SES 9.608 3.990 .448*   
     Age at Diagnosis 1.091 .900 .253   
     Time Since Treatment 1.885 1.024 .376   
Step 2    .612 .113 
     Constant 40.438 7.661    
     Gender -5.5608 3.808 -.269   
     SES 5.813 4.095 .271   
     Age at Diagnosis .893 .826 .207   
     Time Since Treatment 1.365 .968 .272   
     Family functioning 7.556 3.749 .414   
Note. N = 20; * p < .05, ** p < .01, *** p < .001 
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Results of these supplemental analyses indicate that family functioning accounts 
for a significant amount of variance in caregiver ratings of attention above and beyond 
demographic variables in the sample as a whole with outliers included. Within the 
clinical group alone, family functioning did not account for a significant amount of 
variance in caregiver ratings of attention above and beyond that accounted for by 
demographic and treatment variables when outliers were included. Rather, SES was the 
best predictor of caregiver ratings of attention within the clinical group with outliers 
included.   
Caregiver ratings of metacognition.  
In order to determine whether family functioning accounts for a significant 
amount of variance in caregiver ratings of metacognition above and beyond demographic 
variables in the sample as a whole with outliers included, a hierarchical multiple 
regression analysis was performed. Results are presented in Table 32. Gender and SES 
were entered in step 1. These two variables accounted for 11.3% of the variance in  
Table 32. 
Caregiver Ratings of Metacognition in the Whole Sample (With Outliers) 
 B SE B β R2 ΔR2 
Step 1    .113 .113 
     Constant 51.660 3.706    
     Gender -5.711 3.378 -.262   
     SES 4.786 3.782 .196   
Step 2    .360** .247** 
     Constant 51.682 3.191    
     Gender -3.409 2.973 -.157   
     SES 2.479 3.315 .102   
     Family functioning 11.890 3.188 .518**   
Note. N = 40; * p < .05, ** p < .01, *** p < .001 
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caregiver ratings of metacognition (F [2, 37] = 2.357, p = .109). Neither gender (b = -
.262, t [38] = -1.691, p = .099) nor SES (b = .196, t [38] = 1.265, p = .214) by themselves 
had a significant effect on caregiver ratings of metacognition. In step 2, family 
functioning was entered. The addition of family functioning led to a statistically 
significant increase in R2 (ΔR2 = .247, F [1, 36] = 13.911, p = .001). 
In order to determine whether family functioning accounts for a significant 
amount of variance in caregiver ratings of metacognition above and beyond demographic 
and treatment variables in the clinical group with outliers included, a hierarchical 
multiple regression analysis was performed. Results are presented in Table 33. Gender, 
SES, age at diagnosis, and time since treatment were entered in step 2. These four 
variables accounted for 63.6% of the variance in caregiver ratings of metacognition (F [4, 
15] = 6.552, p = .003). By themselves, gender (b = -.429, t [18] = -2.641, p = .019), SES  
Table 33. 
Caregiver Ratings of Metacognition in the Clinical Group (With Outliers)  
 B SE B β R2 ΔR2 
Step 1    .636** .636** 
     Constant 35.274 7.327    
     Gender -9.385 3.554 -.429*   
     SES 9.405 3.565 .419*   
     Age at Diagnosis 1.226 .804 .272   
     Time Since Treatment 2.702 .914 .514*   
Step 2    .674 .038 
     Gender 37.338 7.356    
     SES -7.952 3.656 -.364*   
     Age at Diagnosis 7.092 3.932 .316   
     Time Since Treatment 1.106 .793 .245   
     Gender 2.385 .929 .454*   
     Family functioning 4.604 3.599 .241   
Note. N = 20; * p < .05, ** p < .01, *** p < .001 
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(b = .419, t [18] = 2.639, p = .019), and time since treatment (b = .514, t [18] = 2.955, p = 
.010) had a significant effect on caregiver ratings of metacognition. By itself, age at 
diagnosis did not have a significant independent effect on caregiver ratings of 
metacognition (b = .272, t [18] = 1.525, p = .148). In the second step, family functioning 
was added. The addition of family functioning did not lead to a statistically significant 
increase in R2 (ΔR2 = .038, F [1, 14] = 1.636, p = .222). 
Results of these supplementary analyses indicate that family functioning accounts 
for a significant amount of variance in caregiver ratings of executive functioning 
(metacognition), above and beyond demographic variables, in the sample as a whole 
when outliers are included. Within the clinical group alone, family functioning did not 
account for a significant amount of variance in caregiver ratings of executive functioning 
(metacognition) above and beyond that accounted for by demographic and treatment 
variables with outliers included. Rather, gender, SES, and time since treatment were the 
best predictors of caregiver ratings of executive functioning (metacognition) within the 
clinical group when outliers were included.   
Family functioning without outliers included. 
Caregiver ratings of attention.  
In order to determine whether family functioning accounts for a significant 
amount of variance in caregiver ratings of attention above and beyond demographic 
variables in the sample as a whole with outliers removed (N = 38), a hierarchical multiple 
regression analysis was performed. Results are presented in Table 34. Gender and SES 
were entered in step 1. These two variables accounted for 9.1% of the variance in 
caregiver ratings of attention (F [2, 35] = 1.749, p = .189). Neither gender (b = -.224, t 
[36] = -1.391, p = .173) nor SES (b = .196, t [36] = 1.215, p = .232) by themselves had a 
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significant effect on caregiver ratings of attention. In step 2, family functioning was 
entered. The addition of family functioning led to a statistically significant increase in R2 
(ΔR2 = .391, F [1, 34] = 16.754, p < .001). 
Table 34. 
Caregiver Ratings of Attention in the Whole Sample (Without Outliers) 
 B SE B β R2 ΔR2 
Step 1    .091 .091 
     Constant 48.574 3.135    
     Gender -4.052 2.913 -.224   
     SES 3.898 3.207 .196   
Step 2    .391*** .300*** 
     Constant 49.216 2.608    
     Gender -2.690 2.442 -.149   
     SES 2.130 2.698 .107   
     Family Functioning 12.902 3.152 .560***   
Note. N = 38; * p < .05, ** p < .01, *** p < .001 
In order to determine whether family functioning accounts for a significant 
amount of variance in caregiver ratings of attention above and beyond demographic and 
treatment variables in the clinical group with outliers removed (n = 18), a hierarchical 
multiple regression analysis was performed. Results are presented in Table 35. Gender, 
SES, age at diagnosis, and time since treatment were entered in step 2. These four 
variables accounted for 37.5% of the variance in caregiver ratings of attention (F [4, 13] 
= 1.951, p = .162). By themselves, gender (b = -.370, t [16] = -1.626, p = .128), SES (b = 
.467, t [16] = 2.120, p = .054), age at diagnosis (b = .279, t [16] = 1.131, p = .278), and 
time since treatment (b = .255, t [16] = 1.066, p = .306) did not have a significant effect 
on caregiver ratings of attention. In the second step, family functioning was added. The 
addition of family functioning led to a statistically significant increase in R2 (ΔR2 = .251, 
F [1, 12] = 8.028, p = .015). This is a large effect according to Cohen (1988). 
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Table 35. 
Caregiver Ratings of Attention in the Clinical Sample (Without Outliers) 
 B SE B β R2 ΔR2 
Step 1    .375 .375 
     Constant 39.389 8.990    
     Gender -6.696 4.119 -.370   
     SES 8.622 4.068 .467   
     Age at Diagnosis 1.029 .910 .279   
     Time Since Treatment 1.341 1.259 .255   
Step 2    .626* .251* 
     Constant 38.958 7.244    
     Gender -3.950 3.457 -.218   
     SES 3.145 3.805 .170   
     Age at Diagnosis .914 .734 .248   
     Time Since Treatment 1.625 1.019 .308   
     Family Functioning 11.857 4.185 .599*   
Note. N = 18; * p < .05, ** p < .01, *** p < .001 
Results of these supplemental analyses indicate that family functioning accounted 
for a significant amount of variance in caregiver ratings of attention, above and beyond 
demographic variables, in the sample as a whole when outliers were removed. Within the 
clinical group alone, family functioning accounted for a significant amount of variance in 
caregiver ratings of attention above and beyond that accounted for by demographic and 
treatment variables when outliers were removed.  
Caregiver ratings of behavioral regulation.  
In order to determine whether family functioning accounts for a significant 
amount of variance in caregiver ratings of behavioral regulation above and beyond 
demographic variables in the sample as a whole with outliers removed, a hierarchical 
multiple regression analysis was performed. Results are presented in Table 36. Gender 
and SES were entered in step 1. These two variables accounted for 8.1% of the variance 
in caregiver ratings of behavioral regulation (F [2, 35] = 1.543, p = .228). Neither gender 
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(b = -.253, t [36] = -1.562, p = .127) nor SES (b = -.137, t [36] = -.843, p = .405) by 
themselves had a significant effect on parent ratings of behavioral regulation. In step 2, 
family functioning was entered. The addition of family functioning led to a statistically 
significant increase in R2 (ΔR2 = .323, F [1, 34] = 12.130, p = .001). 
Table 36. 
Caregiver Ratings of Behavioral Regulation in the Whole Sample (Without Outliers) 
 B SE B β R2 ΔR2 
Step 1    .081 .081 
     Constant 51.602 2.483    
     Gender -3.603 2.307 -.253   
     SES -2.141 2.540 -.137   
Step 2    .323** .323** 
     Constant 52.056 2.167    
     Gender -2.640 2.029 -.185   
     SES -3.390 2.242 -.216   
     Family Functioning 9.122 2.619 .503**   
Note. N = 38; * p < .05, ** p < .01, *** p < .001 
In order to determine whether family functioning accounts for a significant 
amount of variance in caregiver ratings of behavioral regulation above and beyond 
demographic and treatment variables in the clinical group with outliers removed, a 
hierarchical multiple regression analysis was performed. Results are presented in Table 
37. Gender, SES, age at diagnosis, and time since treatment were entered in step 2. These 
four variables accounted for 11.5% of the variance in caregiver ratings of behavioral 
regulation (F [4, 13] = .424, p = .789). By themselves, gender (b = -.219, t [16] = -.808, p 
= .434), SES (b = .147, t [16] = .559, p = .586), age at diagnosis (b = -.043, t [16] = -.147, 
p = .885), and time since treatment (b = .179, t [16] = .629, p = .541) did not have a 
significant effect on caregiver ratings of behavioral regulation. In the second step, family 
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functioning was added. The addition of family functioning did not lead to a statistically 
significant increase in R2 (ΔR2 = .184, F [1, 36] = 3.156, p = .101). 
Table 37. 
Caregiver Ratings of Behavioral Regulation in the Clinical Sample (Without Outliers) 
 B SE B β R2 ΔR2 
Step 1    .115 .115 
     Constant 48.439 8.131    
     Gender -3.011 3.725 -.219   
     SES 2.057 3.679 .147   
     Age at Diagnosis -.121 .823 -.043   
     Time Since Treatment .716 1.139 .179   
Step 2    .300 .184 
     Constant 48.158 7.532    
     Gender -1.220 3.594 -.089   
     SES -1.514 3.956 -.108   
     Age at Diagnosis -.196 .763 -.070   
     Time Since Treatment .900 1.060 .225   
     Family Functioning 7.730 4.351 .514   
Note. N = 18; * p < .05, ** p < .01, *** p < .001 
Results of these supplementary analyses indicate that family functioning 
accounted for a significant amount of variance in caregiver ratings of executive 
functioning (behavioral regulation), above and beyond demographic variables, in the 
sample as a whole when outliers were removed. Within the clinical group alone, family 
functioning did not account for a significant amount of variance in caregiver ratings of 
executive functioning (behavioral regulation) above and beyond that accounted for by 
demographic and treatment variables when outliers were removed.  
Caregiver ratings of metacognition.  
In order to determine whether family functioning accounts for a significant 
amount of variance in caregiver ratings of metacognition above and beyond demographic 
variables in the sample as a whole with outliers removed, a hierarchical multiple 
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regression analysis was performed. Results are presented in Table 38. Gender and SES 
were entered in step 1. These two variables accounted for 6.3% of the variance in 
caregiver ratings of metacognition (F [2, 35] = 1.181, p = .319). Neither gender (b = -
.189, t [36] = -1.156, p = .256) nor SES (b = .161, t [36] = .985, p = .332) by themselves 
had a significant effect on caregiver ratings of metacognition. In step 2, family 
functioning was entered. The addition of family functioning led to a statistically 
significant increase in R2 (ΔR2 = .300, F [1, 34] = 11.515, p = .002).  
Table 38. 
Caregiver Ratings of Metacognition in the Whole Sample (Without Outliers) 
 B SE B β R2 ΔR2 
Step 1    .063 .063 
     Constant 50.582 3.477    
     Gender -3.733 3.230 -.189   
     SES 3.502 3.557 .161   
Step 2    .300** .237** 
     Constant 51.205 3.054    
     Gender -2.410 2.860 -.122   
     SES 1.786 3.160 .082   
     Family Functioning 12.527 3.692 .498**   
Note. N = 38; * p < .05, ** p < .01, *** p < .001 
In order to determine whether family functioning accounts for a significant 
amount of variance in caregiver ratings of metacognition above and beyond demographic 
and treatment variables in the clinical group with outliers removed, a hierarchical 
multiple regression analysis was performed. Results are presented in Table 39. Gender, 
SES, age at diagnosis, and time since treatment were entered in step 2. These four 
variables accounted for 55.4% of the variance in caregiver ratings of metacognition (F [4, 
13] = 4.039, p = .024). By themselves, gender (b = -.460, t [16] = -2.392, p = .033), SES 
(b = .454, t [16] = 2.439, p = .030), and time since treatment (b = .487, t [16] = 2.416, p = 
 110 
.031) had a significant effect on caregiver ratings of metacognition. By itself, age at 
diagnosis did not have a significant independent effect on caregiver ratings of 
metacognition (b = .324, t [16] = 1.554, p = .144). In the second step, family functioning 
was added. The addition of family functioning led to a statistically significant increase in 
R2 (ΔR2 = .160, F [1, 12] = 6.718, p = .024). This is a medium to large effect according to 
Cohen (1988). 
Table 39. 
Caregiver Ratings of Metacognition in the Clinical Sample (Without Outliers) 
 B SE B β R2 ΔR2 
Step 1    .554* .554* 
     Constant 34.894 7.972    
     Gender -8.738 3.652 -.460*   
     SES 8.798 3.607 .454*   
     Age at Diagnosis 1.254 .807 .324   
     Time Since Treatment 2.697 1.116 .487*   
Step 2    .714* .160* 
     Constant 34.532 6.645    
     Gender -6.433 3.171 -.338   
     SES 4.202 3.490 .217   
     Age at Diagnosis 1.157 .673 .299   
     Time Since Treatment 2.935 .935 .530**   
     Family Functioning 9.949 3.838 .479*   
Note. N = 18; * p < .05, ** p < .01, *** p < .001 
Results of these supplemental analyses indicate that family functioning accounted 
for a significant amount of variance in caregiver ratings of executive functioning 
(metacognition), above and beyond demographic variables, in the sample as a whole 
when outliers were removed. Within the clinical group alone, family functioning 
accounted for a significant amount of variance in caregiver ratings of executive 
functioning (metacognition) above and beyond that accounted for by demographic and 
treatment variables when outliers were removed.  
 111 
Summary of family functioning supplemental analyses.  
A summary of the family functioning supplemental analyses is presented in Table 
40. As a follow-up of the significant independent effects for family functioning that were 
found in the original analyses, supplementary analyses were conducted. For the sample as 
a whole, with outliers included, family functioning explained a significant amount of 
variance in scores on measures of caregiver ratings of attention and executive functioning 
(metacognition), above and beyond that accounted for by demographic variables (gender 
and SES). Without outliers included, family functioning explained a significant amount 
of variance in scores on measures of caregiver ratings of attention and executive 
functioning (behavioral regulation and metacognition), above and beyond that accounted 
for by demographic variables in the sample as a whole.  
For the clinical group alone, with outliers included, family functioning did not 
explain a significant amount of variance in scores on measures of caregiver ratings of 
attention and executive functioning (metacognition), above and beyond that accounted 
for by demographic variables and treatment variables (age at diagnosis and time since 
treatment). Without outliers included, for the clinical group alone, family functioning 
explained a significant amount of variance in scores on measures of caregiver ratings of 
attention and metacognition, above and beyond that accounted for by demographic 
variables and treatment variables, but did not explain a significant amount of variance in 
scores on measures of caregiver ratings of behavioral regulation above and beyond that 
accounted for by demographic and treatment variables.  
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Table 40.  
Summary of Family Functioning Supplemental Analyses 
Analysis With Outliers Without Outliers 
 Whole Sample Clinical Group Whole Sample Clinical Group 
Caregiver Ratings of Attention  Significant Not significant Significant Significant 
Caregiver Ratings of Behavioral 
Regulation 
- - Significant Not significant 
Caregiver Ratings of Metacognition Significant Not significant Significant Significant 
Note: With the sample as a whole, there were two demographic variables (gender and SES) entered before family functioning. 
With the clinical group alone, there were two demographic variables (gender and SES) and two treatment-related variables 
(age at diagnosis and time since treatment) entered before family functioning. 
 113 
Group membership supplemental analyses. 
Assumptions of t-tests.  
Given that group membership had a significant independent effect on several of 
the neurocognitive outcome measures, independent samples t-tests were used to test the 
significance of apparent group differences in the relevant neurocognitive domains. This 
was done in order to determine if the two groups’ scores were significantly different 
without controlling for family functioning. Prior to analysis, the assumptions for t-tests 
were examined. Normal sampling distribution was examined using the Kolmogorov-
Smirnov test. With outliers included, cognitive flexibility (working memory; D [20] = 
.240, p = .004) and sustained attention (D [20] = .216, p = .015) were significantly non-
normal. With outliers removed, cognitive flexibility (working memory) in the clinical 
group (D [18] = .203, p = .048) and divided attention in the control (D [20] = .217, p = 
.015) and clinical (D [18] = .205, p = .045) groups were significantly non-normal. All 
other variables of interest were normally distributed in the sample. 
Homogeneity of variance was examined using Levine’s test. With outliers 
included, the variances were equal for the two groups for sustained attention (F [1, 39] = 
.412, p = .525), switching attention (F [1,39] = 2.371, p = .132), cognitive flexibility 
(working memory; F [1, 39] = 1.984, p = .167), information processing (processing 
speed; F [1, 39] = 3.470, p = .070), and caregiver ratings of behavioral regulation (F [1, 
39] = 1.089, p = .303). With outliers removed, variances were equal for the two groups 
for divided attention (F [1, 36] = 2.876, p = .099), sustained attention (F [1, 36] = .691, p 
= .411), switching attention (F [1, 36] = 4.051, p = .052), and cognitive flexibility 
(working memory; F [1, 36] = 2.815, p = .102). For information processing (processing 
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speed) the variances were significantly different in the two groups, (F [1, 36] = 4.266, p = 
.046). 
With outliers included.  
With outliers included, the neurocognitive domains examined were sustained 
attention, switching attention, cognitive flexibility (working memory), information 
processing (processing speed), and caregiver ratings of behavioral regulation. Results are 
presented in Table 41. Participants in the control group performed statistically 
significantly better than participants in the clinical group on tests of sustained attention, t 
(38) = 2.222, p = .032; switching attention, t (38) = 2.644, p = .012; cognitive flexibility 
(working memory), t (38) = 2.518, p = .016; information processing (processing speed), t 
(38) = 2.894, p = .006; and caregiver ratings of behavioral regulation, t (38) = -2.829, p = 
.007. 
Table 41.  
Group Differences (With Outliers) 
 M SD t df p 
Sustained Attention   2.222 38 .032 
    Control 10.25 3.007    
    Clinical 8.00 3.387    
Switching Attention   2.644 38 .012 
    Control 10.55 2.328    
    Clinical 8.20 3.222    
Cognitive Flexibility (Working Memory)   2.518 38 .016 
    Control 103.90 10.622    
    Clinical 93.45 15.219    
Information Processing (Processing Speed)   2.894 38 .006 
    Control 104.20 10.768    
    Clinical 91.75 15.940    
Caregiver Ratings of Behavioral Regulation   -2.829 38 .007 
    Control 45.35 6.235    
    Clinical 52.20 8.853    
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With outliers removed.  
With outliers excluded, the domains investigated were divided attention, sustained 
attention, switching attention, cognitive flexibility (working memory), and information 
processing (processing speed). Results are presented in Table 42. Participants in the 
control group performed statistically significantly better than participants in the clinical 
group on tests of switching attention, t (36) = 2.429, p = .020; cognitive flexibility 
(working memory), t (36) = 2.259, p = .030; and information processing (processing 
speed), t (28.949) = 2.565, p = .016. Participants in the control group also performed 
better than participants in the clinical group on tests of sustained attention, t (36) = 1.924, 
p = .062, and divided attention, t (36) = 1.664, p = .105, but these differences were not 
statistically significant.  
Table 42. 
Group Differences (Without Outliers) 
 M SD t df p 
Divided Attention   1.664 36 .105 
    Control 8.20 3.778    
    Clinical 6.06 4.165    
Sustained Attention   1.924 36 .062 
    Control 10.25 3.007    
    Clinical 8.22 3.490    
Switching Attention   2.429 36 .020 
    Control 10.55 2.328    
    Clinical 8.28 3.392    
Cognitive Flexibility (Working Memory)   2.259 36 .030 
    Control 103.90 10.622    
    Clinical 94.06 15.969    
Information Processing (Processing Speed)   2.565 28.949 .016 
    Control 104.20 10.768    
    Clinical 92.56 16.325    
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Summary of group membership supplemental analyses.  
A summary of the group membership supplemental analyses is presented in Table 
43. As a follow up of the significant independent effects for group membership that were 
found in the original analyses, supplementary analyses were conducted. With outliers 
included, the control group performed significantly better than the clinical group on 
measures of sustained attention, switching attention, cognitive flexibility (working 
memory), information processing (processing speed), and caregiver ratings of behavioral 
regulation. Without outliers included, the control group performed significantly better 
than the clinical group on measures of switching attention, cognitive flexibility (working 
memory), and information processing (processing speed). The control group also 
performed better than the clinical group on measures of divided attention and sustained 
attention, but the difference was not statistically significant.  
Table 43. 
Summary of Group Membership Supplemental Analyses 
Analysis With Outliers Without Outliers 
Hypothesis 1a: Selective Attention  Not included Not included 
Hypothesis 1b: Divided Attention  Not included Control > Clinical 
Hypothesis 1c: Sustained Attention  Control > Clinical* Control > Clinical 
Hypothesis 1d: Switching Attention  Control > Clinical* Control > Clinical* 
Hypothesis 1e: Caregiver Ratings of 
Attention  
Not included Not included 
Hypothesis 2a: Cognitive Flexibility 
(Working Memory) 
Control > Clinical* Control > Clinical* 
Hypothesis 2b: Goal Setting (Planning) Not included Not included 
Hypothesis 2c: Attentional Control 
(Inhibition) 
Not included Not included 
Hypothesis 2d: Information Processing 
(Processing Speed) 
Control > Clinical** Control > Clinical* 
Hypothesis 2e: Caregiver Ratings of 
Behavioral Regulation 
Control > Clinical** Not included 
Hypothesis 2f: Caregiver Ratings of 
Metacognition 
Not included Not included 
Note: * p < .05, ** p < .01, *** p < .001  
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Chapter 5: Discussion 
This study investigated the effect of family functioning upon neurocognitive 
outcome among survivors of pediatric ALL treated with chemotherapy, specifically in the 
domains of attention and executive functioning, compared with a group of healthy control 
children. It was expected that for the ALL group, but not for the comparison group, 
family functioning would explain a significant amount of variance in neurocognitive 
outcome, even after controlling for demographic and treatment-related variables. These 
hypotheses were generated based on previous research among pediatric traumatic brain 
injury and pediatric brain tumor populations that found that positive family functioning 
serves as a protective factor for neurocognitive outcomes of children who survive these 
conditions. 
Summary of Results 
The investigator had two primary research questions: (1) Does positive family 
functioning protect against deficits in attention among survivors of pediatric ALL, 
specifically in the subdomains of selective attention, divided attention, sustained 
attention, and shifting attention, and as reported by caregivers? (2) Does positive family 
functioning protect against deficits in executive functioning among survivors of pediatric 
ALL, specifically in the subdomains (areas) of cognitive flexibility (working memory), 
goal setting (planning), attentional control (inhibition), information processing 
(processing speed) and as reported by caregivers (behavioral regulation and 
metacognition)? It was hypothesized that family functioning would be associated with 
these domains of neurocognitive functioning among survivors of pediatric ALL but not 
among healthy control children. Contrary to expectations, the relationship between family 
functioning and neurocognitive functioning did not differ by group (survivor vs. healthy 
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control) for any of the domains listed above. That is, the negative effects of cancer 
treatment upon neurocognitive functioning were not any more severe among children 
from families with greater levels of family dysfunction than those children from families 
with better family functioning.  
Supplemental analyses indicated that, across the sample as whole (survivors and 
healthy controls), family functioning was associated with caregiver ratings of attention 
and metacognition. Without outliers included, it was also associated with caregiver 
ratings of behavioral regulation. That is, children (both survivors and healthy control 
children) whose caregivers endorsed higher levels of family dysfunction (difficulty 
engaging in the interactional patterns necessary for the achievement of family goals) also 
rated their children as having more difficulty maintaining necessary levels of attention; 
shifting their cognitive set and modulating their emotions and behavior via appropriate 
inhibitory control; and initiating, planning, organizing, self-monitoring, and sustaining 
working memory.   
Family functioning was not found to be associated with performance-based 
measures of attention or executive functioning for survivors or healthy control 
participants. That is, for the sample as a whole, family functioning was not associated 
with performance on measures of selective attention, divided attention, sustained 
attention, shifting attention, cognitive flexibility/working memory, goal setting/planning, 
attentional control/inhibition, or information processing/processing speed. Children from 
families with higher levels of family dysfunction did not perform any worse in these 
domains than children from families with better family functioning.  
Supplemental analyses also revealed that group membership (survivor vs. healthy 
control) was associated with neurocognitive functioning in the domains of sustained 
attention, switching attention, cognitive flexibility/working memory, information 
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processing/processing speed, divided attention (without outliers only), and caregiver 
rated behavioral regulation (with outliers only) domains. That is, children in the healthy 
control group performed significantly better than children in the survivor group on tests 
of switching attention, cognitive flexibility/working memory, and information 
processing/processing speed. With outliers included, the control group also performed 
significantly better than the clinical group on measures of sustained attention and 
caregiver rated behavioral regulation.   
No Interaction Effects 
Contrary to what was expected, family functioning did not have a differential 
effect on neurocognitive functioning for survivors of pediatric ALL as compared to 
healthy children. It had been hypothesized, based on previous literature in the pediatric 
TBI population that compared children who survived a TBI with children who survived 
an orthopedic injury, that such a differential effect would be found (Max et al., 1999; 
Nadebaum et al., 2007; Taylor et al., 1999; Yeates et al., 1997). It is thought that perhaps 
the neurological impairment suffered by children who sustain a TBI makes them more 
vulnerable to family influence than their peers who have not sustained such neurological 
damage (Taylor et al., 1999). Likewise, it was hypothesized that pediatric ALL survivors 
would be more vulnerable to the effects of family functioning upon neurocognitive 
functioning than children who had not experienced cancer treatment. The current study 
was the first known study to investigate the relationship between family functioning and 
neurocognitive functioning among the ALL population. 
A potential explanation for the lack of a differential effect of family functioning 
upon neurocognitive functioning among survivors of ALL treated with chemotherapy 
alone as compared to healthy children may be that this subset of ALL survivors do not 
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suffer sufficient neurological impairment from their treatment to make them more 
vulnerable to family influence than their peers who have not received cancer treatment. 
Indeed, current treatment protocols that utilize chemotherapy alone were developed in 
large part to reduce the neurotoxic effects of previous treatment protocols that utilized 
CRT (van der Plas et al., 2015). Although research has found significant differences on 
neuroimaging, particularly in white matter, among survivors of ALL treated with 
chemotherapy alone as compared with healthy children, these differences are more subtle 
than the neurological deficits found among survivors of pediatric TBI or BT (Kunin-
Batson et al., 2014; van der Plas et al., 2015). Survivors of pediatric ALL treated with 
chemotherapy have been found to have lesions in deep white matter, reduced white 
matter volume, and alterations in white matter tract development (van der Plas et al., 
2015). However, gray matter appears to be relatively spared in this population (van der 
Plas et al., 2015). Survivors of pediatric brain tumor also experience damage to white 
matter but to a greater extent than ALL survivors (i.e., greater white matter volume loss; 
Reddick et al., 2014). The neuropathology of TBI often includes damage to white matter 
and gray matter, increased cerebrospinal fluid volume, and decreased whole brain volume 
(Bigler et al., 2013). This damage may further progress over time (Yeates 2009).  The 
more severe neurological impacts experienced by survivors of pediatric brain tumor and 
TBI, as compared to survivors of pediatric ALL, may be what make these populations 
more vulnerable to family functioning than the ALL population.  
Another potential explanation is that children who suffer a TBI or undergo a brain 
tumor resection sometimes experience difficulties in functioning independently due to 
deficits in motor, self-care, or language skills (Giordana & Clara, 2006; Yeates, 2009). 
These difficulties make them more dependent upon their caregivers for completing 
activities of daily living (Taylor et al., 1999). Such functional impairments, which are 
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less prevalent among survivors of ALL treated with chemotherapy alone, and the 
dependence upon caregivers that they create, may contribute to making these populations 
more vulnerable to family influences than the ALL population.    
Another possible explanation for the lack of a differential effect may be that the 
FAD GFS might not be sensitive to the particular issues faced by families of childhood 
ALL survivors. Some researchers in this field have suggested using measures of family 
functioning designed particularly for families of youth with chronic health conditions 
(Hocking et al., 2015). Perhaps using a measure that is more sensitive to the particular 
issues faced by families of childhood ALL survivors would have captured a differential 
effect of family functioning on neurocognitive functioning among survivors compared 
with healthy controls.  
Alternatively, there are methodological differences in the current study that may 
have contributed to the lack of expected findings. For one, the sample size of the current 
study was smaller than most of the studies examining family functioning and 
neurocognitive functioning among pediatric TBI and pediatric brain tumor populations 
(Carlson-Green et al., 1995; Max et al., 1999; Nadebaum et al., 2007; Taylor et al., 1999; 
Yeates et al., 1997). It may be that the current study was under-powered to find a 
significant interaction effect between family functioning and group membership in 
accounting for differences in neurocognitive functioning.  
The one former study with a similar sample size (24 participants in the severe TBI 
group, 24 in the moderate TBI group, and 24 in the OI group) utilized a “psychosocial 
disadvantage factor” comprised of family functioning and family psychiatric history in 
predicting difference in IQ and memory, as opposed to family functioning alone (Max et 
al., 1999). Similarly, in one of the studies examining family functioning among pediatric 
brain tumor survivors, family factors (specifically, maternal coping resources) as opposed 
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to family functioning per se were significantly associated with neurocognitive outcomes 
in survivors (Carlson-Green et al., 1995).  
Some of the previous studies used different measures of family functioning than 
that used in the current study, which could also explain differences in results. Max et al. 
(1999) used the Mc-SIFF, a clinical research interview based on the MMFF, as opposed 
to a caregiver-report measure. Nadebaum et al. (2007) used the Family Functioning 
Questionnaire, which assesses three domains of family functioning (i.e., conflict, 
intimacy, and democratic parenting style). Carlson-Green and colleagues (1995) and Ach 
and colleagues (2013) used the Family Environment Scale, which assesses three domains 
of the social environment within the family (i.e., supportiveness, conflict, and control).  
Caregiver Ratings vs. Performance-Based Measures of Attention and Executive 
Functioning 
Although the expected interaction effects were not found, some significant 
independent effects for family functioning were found. Family functioning was 
significantly associated with caregiver ratings of attention and executive functioning for 
both survivors and healthy controls. That is, among the whole sample, caregivers who 
viewed their family as having difficulties with family functioning were more likely to 
view their child as having difficulties with attention and executive functioning. Family 
functioning was not significantly associated with performance-based measures of 
attention/executive functioning for either group (survivor or healthy control).  
The fact that caregiver ratings of family functioning were significantly related to 
caregiver ratings of attention/executive functioning, but not to performance-based 
measures of attention/executive functioning, may reflect single source bias, as the same 
person (the caregiver) was rating the family’s functioning and rating the child’s 
attention/executive functioning (Hocking et al., 2015). This is consistent with literature 
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that has found that, among both community and clinical samples, parent ratings of family 
functioning are highly correlated with parent ratings of children’s behavioral and 
emotional functioning (Kinsman, Wildman, & Smucker, 1999). It has been suggested that 
perhaps parent report of child or family problems serve as proxies for parent psychosocial 
distress.  
Group Differences in Attention and Executive Functioning 
As expected based upon the literature on neurocognitive late effects among 
survivors of pediatric ALL, children with a history of ALL performed worse than healthy 
peers on measures of sustained attention (Reddick et al., 2006), working memory 
(Ashford et al., 2010; Carey et al., 2008; Iyer et al., 2015; Kingma et al., 2002; Lesnik et 
al., 1998; Waber et al., 1995), and processing speed (Iyer et al., 2015; Jansen, 2008). 
Working memory and processing speed in particular have most consistently been found 
to be impaired within this population as compared to healthy controls.  
On average, children in the survivorship group also performed worse than 
children in the healthy control group on the other domains of attention (selective, divided, 
switching) and executive functioning (planning, inhibition) assessed in this study, but 
these differences were not significant. It may be that the small sample size of the study 
limited the power to find significant group differences within these domains. However, 
there have been more mixed findings in the literature regarding whether or not these 
domains are affected in this population (Iyer et al., 2015).  
Summary of Integration of Results 
This study was the first known study to examine the relationship between family 
functioning and neurocognitive functioning among survivors of pediatric ALL treated 
with chemotherapy alone. Contrary to what has been found within the pediatric TBI and 
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pediatric brain tumor populations, results of this study indicate that family functioning 
does not moderate neurocognitive functioning among this population. That is, differences 
in neurocognitive functioning between survivors and healthy controls were no more 
pronounced among those from families reporting higher degrees of dysfunction than 
those from families reported more optimal family functioning.  
For both groups of children in this study, survivors and healthy controls, those 
from families rated by caregivers as having higher degrees of family dysfunction were 
rated by their caregivers as having more difficulties with attention and executive 
functioning. This is not unexpected given that high rates of correlation have been found 
between caregiver ratings of family functioning and caregiver ratings of children’s 
functioning in both clinical and non-clinical samples.  
This study contributes to the literature on neurocognitive late effects among 
survivors of pediatric ALL treated with chemotherapy alone. Survivors in the current 
sample performed significantly worse than healthy peers on measures of sustained 
attention, working memory, and processing speed. Working memory and processing 
speed have been consistently found to be areas of relative weakness for this population. 
While attention overall has been one of the domains most commonly found to be affected 
among this population, there have been fewer studies looking at specific subdomains of 
attention, particularly sustained attention. Thus, this study helps increase our 
understanding of the specific subdomains of attention that may be most impacted among 
this population.    
Limitations 
There are several limitations that should be mentioned in this study. First of all, 
there was generally a lack of variability in family functioning, particularly if outliers were 
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removed. This may be due at least in part to a form of selection bias, in that perhaps the 
people who volunteer for research studies (particularly those about family functioning) 
are from families that have higher levels of functioning. It is possible that the restricted 
range of family functioning may have impacted the results of this study. Additionally, the 
families and patients who participated in this study may not be representative of the 
larger population of childhood ALL survivors and their families. Furthermore, the sample 
size in this study was small and there may not have been sufficient power to detect 
significant effects. Also, given that this study was cross sectional as opposed to 
longitudinal, it is not possible to determine directional or causal associations between the 
variables. 
Another limitation of this study is the potential for single-rater bias, given that 
caregivers filled out rating forms of their child’s attention and executive functioning as 
well as the family functioning measure. Additionally, there was only a single rating of 
family functioning for each participant. Best practice would have been to have multiple 
members of the family rate the family’s functioning, and/or to include a clinician rating 
based on interview or observation of a family task. Similarly, there was only one rating of 
children’s attention and executive functioning. Best practice would be to have more than 
one informant, such as obtaining a teacher or second caregiver perspective as well.  
Recommendations for Future Research 
The findings of this study and the aforementioned limitations suggest many 
possible directions for future research. First of all, obtaining a larger sample size would 
assist with ensuring there is sufficient power to detect possible interaction effects. 
Utilizing a longitudinal design, as opposed to cross sectional, would allow for 
examination of the directionality of the association between family functioning and 
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neurocognitive functioning. Furthermore, obtaining additional perspectives on 
participants’ attention and executive functioning, such as through teacher ratings, could 
be of value.  
Future studies could obtain a more robust assessment of family functioning by 
collecting ratings from multiple members of each family (i.e., multiple caregivers, child) 
or by utilizing clinician-rated measures of family functioning. In addition, future studies 
could examine specific aspects of family functioning (i.e., roles, behavior control, 
problem solving, etc.) as opposed to utilizing global measures of family functioning as 
was used in this study, to see if specific domains of family functioning are particularly 
associated with neurocognitive functioning. Alternatively, it might be worth utilizing a 
measure of family functioning that is more specific to families of children with chronic 
health conditions. Finally, utilizing a mixed-methods approach and including a qualitative 
component would allow for a richer understanding of family functioning among this 
population.  
Implications for Clinical Practice 
Although the current study is correlational in nature and thus no directionality can 
be inferred, results suggest a relationship between family dysfunction and difficulties 
with children’s attention/executive functioning as reported by caregivers. As such, 
elevated caregiver ratings of a survivor’s attention or executive functioning, particularly 
in the absence of low scores on performance-based measures of attention or executive 
functioning, could be a signal for the clinician to consider the caregiver’s perception of 
the family’s functioning and could suggest the need to assess for the need for additional 
supports for the caregiver and family. In such cases, family intervention may be 
warranted. Within the multidisciplinary clinic or hospital setting, social work could assist 
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with providing services to families identified as having difficulties with family 
functioning. 
This study’s findings that family functioning does not moderate neurocognitive 
functioning among survivors of ALL treated with chemotherapy could be good news for 
the families of these survivors. Very often, parents of childhood ALL survivors 
experience anxiety and guilt about whether anything they have done is contributing to 
their child’s functioning. The results of this study could provide some relief to these 
families, letting them know that they are not to blame if their child is experiencing 
difficulties with attention or executive functioning.  
Finally, this study found evidence for the existence of neurocognitive late effects 
among survivors of pediatric ALL treated with chemotherapy alone. As such, it provides 
support for the need for ongoing monitoring of neurocognitive functioning among this 
population. Furthermore, this study investigated specific subdomains of attention and 
executive functioning and found some to be more affected in this population than others. 
This suggests that it is important to assess these particular subdomains, as opposed to 
simply assessing for attention or executive functioning more globally, as knowledge of 
the specific subdomains affected may help target interventions and potentially make them 
more effective. Such information could be invaluable for teachers and others working 
with survivors experiencing difficulties with attention and executive functioning.  
Conclusion 
Contrary to expectations, family functioning did not have a differential 
association with neurocognitive functioning among survivors of pediatric ALL as 
compared with healthy control children. For survivors and healthy children, family 
functioning was significantly associated with caregiver ratings of children’s attention and 
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executive functioning. Family functioning was not associated with performance-based 
measures of attention or executive functioning for survivors or healthy control children. 
This was the first known study to examine the relation between family functioning and 
neurocognitive functioning among survivors of pediatric ALL and the results suggest 
many avenues for future study.  
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Appendix A: Consent Form 
 
Consent for Participation in Research 
 
Title: Family Functioning as a Moderator of Neurocognitive Outcome Among Survivors of 
Pediatric Acute Lymphoblastic Leukemia 
 
Introduction 
The purpose of this form is to provide you information that may affect your decision as to 
whether or not to participate in this research study.  The person performing the research will 
answer any of your questions.  Read the information below and ask any questions you might 
have before deciding whether or not to take part. If you decide to be involved in this study, 
this form will be used to record your consent. 
 
Purpose of the Study 
You have been asked to participate in a research study about the effect of family functioning 
upon neurocognitive outcome among survivors of pediatric ALL treated with chemotherapy.  
The purpose of this study is to determine if positive family functioning serves as a protective 
factor against the neurocognitive deficits commonly seen in this population.    
 
What will you be asked to do? 
If you agree to participate in this study, you will be asked to complete questionnaires about 
your child’s emotional and behavioral functioning and your family’s functioning. 
 
Your child will be asked to participate in neuropsychological tasks to measure attention and 
executive functioning. 
 
This study will take 90 minutes and will include approximately 60 study participants.   
 
What are the risks involved in this study? 
Minimal risk in participating in this study includes emotional distress from completing 
measures. If this occurs, emotional support will be provided by a licensed psychologist.  
 
Another possible risk that all participants may incur by participating in this study is a loss of 
confidentiality if study measures were to be lost. This risk will be addressed by: (i) use of 
subject numbers only to label any study materials and (ii) storage of all completed measures 
in a designated locked cabinet separate from the roster that links subject numbers with names 
of participants. 
 
Any incident that occurs that in any way compromises the rights or welfare of the participants 
will be reported by the principal investigator to the Institutional Review Board within five 
days of its occurrence as an unanticipated event, per board policy. 
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What are the possible benefits of this study? 
You will receive no direct benefit from participating in this study; however, you may enjoy 
positive emotions associated with your contribution to informing the field of research in 
psychology as applied to medical populations.   
 
Do you have to participate? 
No, your participation is voluntary. You may decide not to participate at all or, if you start the 
study, you may withdraw at any time. Withdrawal or refusing to participate will not affect 
your relationship with The University of Texas at Austin in anyway.  
 
If you would like to participate please sign below. You will receive a copy of this form. 
  
Will there be any compensation? 
Your child will receive a $5 gift certificate from Target as compensation for your 
participation in this study.  Payments will occur after completion of neuropsychological tasks 
and questionnaires. You will be responsible for any taxes assessed on the compensation. If 
you or your child decide to withdraw from the study, your child will still receive the 
compensation.  
 
How will your privacy and confidentiality be protected if you participate in this research 
study? 
Your privacy and the confidentiality of your data will be protected by randomly assigning 
you a number (ranging from 001 to 100) at the outset of the study. All completed forms will 
be de-identified.  A roster of individual names and their corresponding participant numbers 
will be maintained in a separate, locked filing cabinet from the participant forms. Your 
privacy will be protected by providing a private place for you to complete questionnaires and 
neuropsychological tasks.    
 
If it becomes necessary for the Institutional Review Board to review the study records, 
information that can be linked to you will be protected to the extent permitted by law. Your 
research records will not be released without your consent unless required by law or a court 
order. The data resulting from your participation may be made available to other researchers 
in the future for research purposes not detailed within this consent form. In these cases, the 
data will contain no identifying information that could associate it with you, or with your 
participation in any study. 
 
Participants will be given notice at least twenty-four hours prior to a researcher’s arrival at 
their homes or other non-public places where they will be tested. Researchers will not show 
up unannounced. If the researcher(s) observe or otherwise learn of child or elder abuse while 
visiting your home, confidentiality will be broken: state law requires the reporting of abuse to 
relevant agencies. If I should observe or otherwise learn of child or elder abuse while visiting 
the participant’s home, confidentiality will be broken. The researcher will report the abuse to 
relevant agencies (Child Protective Services or the Texas Department of Family and 
Protective Services) as required by law. 
 
 
 
 132 
Whom to contact with questions about the study?   
Prior, during or after your participation you can contact the researcher Thea Norris at (405) 742-
4389 or send an email to thea.norris@utexas.edu for any questions or if you feel that you have 
been harmed.   
 
This study has been reviewed and approved by The University Institutional Review Board and the 
study number is 2014-04-0112.  
 
Whom to contact with questions concerning your rights as a research participant? 
For questions about your rights or any dissatisfaction with any part of this study, you can contact, 
anonymously if you wish, the Institutional Review Board by phone at (512) 471-8871 or email at 
orsc@uts.cc.utexas.edu.  
 
Participation 
 If you agree to participate please sign below. 
 
Signature   
You have been informed about this study’s purpose, procedures, possible benefits and risks, and 
you have received a copy of this form. You have been given the opportunity to ask questions 
before you sign, and you have been told that you can ask other questions at any time. You 
voluntarily agree to participate in this study.  By signing this form, you are not waiving any of 
your legal rights. 
 
 
_________________________________ 
Printed Name  
 
_________________________________    _________________ 
Signature Date 
 
As a representative of this study, I have explained the purpose, procedures, benefits, and the risks 
involved in this research study. 
 
_________________________________      
Print Name of Person obtaining consent      
 
 
_________________________________    _________________  
Signature of Person obtaining consent     Date 
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Appendix B: Permission Form 
 
Parental Permission for Children Participation in Research 
 
Title: Family Functioning as a Moderator of Neurocognitive Outcome Among 
Survivors of Pediatric Acute Lymphoblastic Leukemia 
 
Introduction 
The purpose of this form is to provide you (as the parent of a prospective research 
study participant) information that may affect your decision as to whether or not to let 
your child participate in this research study.  The person performing the research will 
describe the study to you and answer all your questions.  Read the information below 
and ask any questions you might have before deciding whether or not to give your 
permission for your child to take part. If you decide to let your child be involved in 
this study, this form will be used to record your permission. 
 
Purpose of the Study 
If you agree, your child will be asked to participate in a research study about the 
effect of family functioning upon neurocognitive outcome among survivors of 
pediatric ALL treated with chemotherapy.  The purpose of this study is to determine 
if positive family functioning serves as a protective factor against the neurocognitive 
deficits commonly seen in this population.    
 
What is my child going to be asked to do? 
If you allow your child to participate in this study, they will be asked participate in 
neuropsychological tasks to measure attention and executive functioning.  This study 
will take 90 minutes and will include approximately 60 study participants. 
  
What are the risks involved in this study? 
Minimal risk in participating in this study includes emotional distress from 
completing measures. If this occurs, emotional support will be provided by a licensed 
psychologist.  
 
Another possible risk that all participants may incur by participating in this study is a 
loss of confidentiality if study measures were to be lost. This risk will be addressed 
by: (i) use of subject numbers only to label any study materials and (ii) storage of all 
completed measures in a designated locked cabinet separate from the roster that links 
subject numbers with names of participants. 
 
Any incident that occurs that in any way compromises the rights or welfare of the 
participants will be reported by the principal investigator to the Institutional Review 
Board within five days of its occurrence as an unanticipated event, per board policy.  
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What are the possible benefits of this study? 
Your child will receive no direct benefit from participating in this study; however, 
they may enjoy positive emotions associated with your contribution to informing the 
field of research in psychology as applied to medical populations.   
 
Does my child have to participate? 
No, your child’s participation in this study is voluntary. Your child may decline to 
participate or to withdraw from participation at any time.  Withdrawal or refusing to 
participate will not affect their relationship with The University of Texas at Austin in 
anyway. You can agree to allow your child to be in the study now and change your 
mind later without any penalty.   
 
What if my child does not want to participate? 
In addition to your permission, your child must agree to participate in the study.  If 
you child does not want to participate they will not be included in the study and there 
will be no penalty.  If your child initially agrees to be in the study they can change 
their mind later without any penalty.  
 
Will there be any compensation? 
Your child will receive a $5 gift certificate from Target as compensation for their 
participation in this study.  Payments will occur after completion of 
neuropsychological tasks and questionnaires. You will be responsible for any taxes 
assessed on the compensation. If your child decides to withdraw from the study, they 
will still receive the compensation.  
 
How will your child’s privacy and confidentiality be protected if s/he participates in 
this research study? 
Your child’s privacy and the confidentiality of his/her data will be protected by by 
randomly assigning them a number (ranging from 001 to 100) at the outset of the 
study. All completed forms will be de-identified.  A roster of individual names and 
their corresponding participant numbers will be maintained in a separate, locked 
filing cabinet from the participant forms. Their privacy will be protected by providing 
a private place for them to complete neuropsychological tasks.    
 
If it becomes necessary for the Institutional Review Board to review the study 
records, information that can be linked to your child will be protected to the extent 
permitted by law. Your child’s research records will not be released without your 
consent unless required by law or a court order. The data resulting from your child’s 
participation may be made available to other researchers in the future for research 
purposes not detailed within this consent form. In these cases, the data will contain no 
identifying information that could associate it with your child, or with your child’s 
participation in any study. 
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Participants will be given notice at least twenty-four hours prior to a researcher’s 
arrival at their homes or other non-public places where they will be tested. 
Researchers will not show up unannounced. If the researcher(s) observe or otherwise 
learn of child or elder abuse while visiting your home, confidentiality will be broken: 
state law requires the reporting of abuse to relevant agencies. If I should observe or 
otherwise learn of child or elder abuse while visiting the participant’s home, 
confidentiality will be broken. The researcher will report the abuse to relevant 
agencies (Child Protective Services or the Texas Department of Family and 
Protective Services) as required by law. 
 
Whom to contact with questions about the study?   
Prior, during or after your participation you can contact the researcher Thea Norris at 
(405) 742-4389 or send an email to thea.norris@utexas.edu for any questions or if you 
feel that you have been harmed.   
 
This study has been reviewed and approved by The University Institutional Review 
Board and the study number is 2014-04-0112.  
 
Whom to contact with questions concerning your rights as a research participant? 
For questions about your rights or any dissatisfaction with any part of this study, you can 
contact, anonymously if you wish, the Institutional Review Board by phone at (512) 471-
8871 or email at orsc@uts.cc.utexas.edu.  
 
Signature   
You are making a decision about allowing your child to participate in this study. Your 
signature below indicates that you have read the information provided above and have 
decided to allow them to participate in the study. If you later decide that you wish to 
withdraw your permission for your child to participate in the study you may discontinue his 
or her participation at any time.  You will be given a copy of this document. 
 
 
 
 
_________________________________ 
Printed Name of Child 
 
_________________________________    _________________ 
Signature of Parent(s) or Legal Guardian Date 
 
_________________________________    _________________  
Signature of Investigator      Date 
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Appendix C: Assent Form 
 
Assent for Participation in Research 
 
Title: Family Functioning as a Moderator of Neurocognitive Outcome Among 
Survivors of Pediatric Acute Lymphoblastic Leukemia  
 
Introduction 
You have been asked to be in a research study about families and how people pay 
attention and think.   This study was explained to your parent and they said that you 
could be in it if you want to.  We are doing this study to learn about ways to help 
children who have survived cancer think and learn better. 
 
What am I going to be asked to do? 
If you agree to be in this study, you will be asked to do some attention tasks.  This 
study will take 90 minutes and there will be 60 other people in this study.  
 
What are the risks involved in this study? 
Minimal risk in participating in this study includes emotional distress from 
completing measures. If this occurs, emotional support will be provided by a licensed 
psychologist.  
 
Another possible risk that all participants may incur by participating in this study is a 
loss of confidentiality if study measures were to be lost. This risk will be addressed 
by: (i) use of subject numbers only to label any study materials and (ii) storage of all 
completed measures in a designated locked cabinet separate from the roster that links 
subject numbers with names of participants. 
 
Any incident that occurs that in any way compromises the rights or welfare of the 
participants will be reported by the principal investigator to the Institutional Review 
Board within five days of its occurrence as an unanticipated event, per board policy. 
 
If I should observe or otherwise learn of child or elder abuse while visiting the 
participant’s home, confidentiality will be broken. The researcher will report the 
abuse to relevant agencies (Child Protective Services or the Texas Department of 
Family and Protective Services) as required by law. 
 
Do I have to participate? 
No, participation is voluntary.  You should only be in the study if you want to.  You 
can even decide you want to be in the study now, and change your mind later.  No 
one will be upset. 
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If you would like to participate sign below and give this form back to the researcher.  
You will receive a copy of this form so if you want to you can look at it later. 
 
Will I get anything to participate? 
You will receive a $5 gift certificate from Target for participating in this study.  
Payments will occur after you have completed your attention tasks. If you decide to 
withdraw from the study, you will still receive the payment.  
 
Who will know about my participation in this research study? 
The records of this study will be kept private.  Your responses may be used for a 
future study by these researchers or other researchers. 
 
Whom to contact with questions about the study?   
Prior, during or after your participation contact the researcher Thea Norris at (405) 742-
4389 or send an email to thea.norris@utexas.edu for any questions or if you feel that you 
have been harmed.  
 
Signature 
 
Writing your name on this page means that the page was read by or to you and that you 
agree to be in the study.  If you have any questions before, after or during the study, ask 
the person in charge.  If you decide to quit the study, all you have to do is tell the person 
in charge. 
 
 
 
________________________________   ____________________ 
 Signature of Participant Date 
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